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CHAPTER 1 BACKGROUND AND SIGNIFICANCE 
1.1 Neuroblastoma 
The second most common cause of death in children from ages 1-14 in the 
United States is cancer (Jemal, A. et al., 2008).  8-10% of all pediatric cancers are 
neuroblastoma, however it accounts for about 15% of all cancer deaths in children 
(Cotran, R. S. et al., 1994; Howman-Giles, R. et al., 2007).  There are 400-650 new 
diagnoses in the United States each year ("What Are the Key Statistics About 
Neuroblastoma?," 2009; Young Jr, J. L. et al., 1986).  Neuroblastoma is most common 
in infants and toddlers.  In approximately half of all cases, children begin to show 
symptoms before age 2, and 90% of cases present by 5 years old (Howman-Giles, R. et 
al., 2007).   
Neuroblastoma develops in neural cells of the sympathetic nervous system 
("What is Neuroblastoma," 2009) which are derived from the neural crest, an 
embryologic structure (Jessen, K. R. Mirsky, R., 2005).  The malignant immature 
developing neural cells are called neuroblasts (neural = nerve, blast = immature).   
The sympathetic nervous system is part of the autonomic nervous system, 
meaning that it is controlled automatically, or without conscious input.  The sympathetic 
nervous system runs throughout the body, and consists of nerve cells (neurons) and 
glial cells.  Glial cells support neural cells by performing several important functions, 
including myelinating nerve axons, releasing neurotransmitters, and forming connective 
tissue to hold neurons in place.  Detailed reviews of the origin, formation, and function 
of glial cells of the peripheral nervous system are available from many sources (Jessen, 
K. R. Mirsky, R., 2005).  
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Just over 1/3 of neuroblastomas are found in the medulla of the adrenal gland, 
which contains sympathetic nervous system glial cells derived from the neural crest 
("What is Neuroblastoma," 2009).  Another 1/3 of neuroblastomas are found in the 
sympathetic ganglia and sympathetic chain elsewhere in the abdomen, and the rest can 
be found in the sympathetic ganglia of the chest, neck, and pelvis (Orkin, S. H. et al., 
2009). 
1.1.1 Neuroblastoma Diagnosis 
Symptoms of neuroblastoma vary based on where the tumor is located.  When 
the tumor is found in the abdomen, symptoms include an abdominal mass which may 
be accompanied by pain or fullness.  Other symptoms such as swelling or hypertension 
can be caused by compression of local vessels.  When neuroblastoma metastasizes, 
frequent symptoms are bone and joint pain, fever, failure to thrive,  bruising, low white 
blood cell levels, and proptosis (eye dislocation) or periorbital ecchymoses (raccoon 
eyes) which can both be caused by metastasis to the periorbital bones.  Another 
symptom of neuroblastoma is increased levels of catecholamine byproducts in the urine 
caused by increased release of neurotransmitters by glial cells.  Opsoclonus-myoclonus 
syndrome and vasoactive intestinal peptide syndrome are two paraneoplastic 
syndromes which are associated with neuroblastoma (Orkin, S. H. et al., 2009). 
While a suspected diagnosis of neuroblastoma can be made based on a patient’s 
symptoms, the only way to make a definite diagnosis is to perform a biopsy and 
examine the tumor cells using histology or other pathology methods.  To look at the 
histology, the pathologist cuts a thin slice of tissue (~10 microns) and mounts it on a 
clear glass slide.  The tissue is then stained with hematoxylin and eosin (H&E).  
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Hematoxylin binds to nucleic acids within the cell nucleus and stains them blue.  
Likewise, eosin stains the cytoplasm pink.  Once the stained tissue sample dries, the 
pathologist can view it under a microscope to examine the cellular behavior within the 
tumor.  Remaining portions of the tumor are saved and may be used for other pathology 
tests, if a conclusive diagnosis cannot be made with histology alone, or if more detailed 
diagnostic information is required. 
The histology and aggressiveness of neuroblastoma varies from tumor to tumor.  
Representative histology images of neuroblastoma are shown in Figures 2.1 and 4.2.  
Some neuroblastomas are fully encapsulated, while others invade the surrounding 
tissue.  The most common histological appearance contains sheets of small, embryonic-
appearing cells that have dark blue nuclei, little cytoplasm, and indistinct cell walls 
(Cotran, R. S. et al., 1994).  This histologic appearance is similar to a class of childhood 
tumors called small round blue cell tumors.  This group of tumors includes 
neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and non-Hodgkin lymphoma.  
Tumors with this histology often require further testing including immunohistochemistry 
(Finegold, M. J. et al., 1983; Gregorio, A. et al., 2008), cytogenetics including 
fluorescence in situ hybridization (Taylor, C. et al., 1993), and polymerase chain 
reactions (PCR) (Chen, Q.-R. et al., 2007), or complementary DNA microarrays (Khan, 
J. et al., 2001) to confirm the diagnosis. 
 The second typical histology of neuroblastoma shows some differentiation.  
While the tumor is still predominantly composed of immature neuroblast cells, there are 
also some larger, differentiated cells.  Cell differentiation can be identified by the larger 
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cell size, larger nuclei and nucleolus, and higher amounts of cytoplasm (Cotran, R. S. et 
al., 1994).  
Ganglioneuroma is composed of similar cells to neuroblastoma, however its 
histologic appearance contains all differentiated cells which look like mature neurons or 
ganglion cells (Cotran, R. S. et al., 1994) instead of immature neuroblasts.  In this case, 
the tumor is benign.  In some cases, malignant neuroblastoma cells can mature to 
ganglioneuroma cells. 
Ganglioneuroblastoma is a condition between ganglioneuroma and 
neuroblastoma ("What is Neuroblastoma," 2009).  It contains a mixture of benign 
mature ganglion cells and malignant immature neuroblasts.  Because it still contains 
malignant cells, ganglioneuroblastoma is treated like neuroblastoma.  For the purposes 
of this document, ganglioneuroblastomas will simply be referred to as neuroblastomas. 
Following a positive diagnosis of neuroblastoma, the pathologist assigns several 
sub-classifications.  The tumor is given a stage from I-IV based on the spread of the 
tumor through the lymphatic system and the rest of the body.  A favorable or 
unfavorable assignment is also assigned based on the histology and the patient’s age, 
according to a methodology called the Shimada classification.  Tumor favorability is 
used to determine the patient’s prognosis, as well as to predict the optimal treatment 
plan for each patient.  The histologic factors included in identifying the favorability 
include the degree of maturation of the tumor cells, the presence or absence of stromal 
cells (connective tissue), and the ratio of cells undergoing mitosis or karyorrhexis.  
Section 5.1 explains tumor favorability based on the Shimada classification and other 
prognostic markers of neuroblastoma in depth.  
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Additionally, the pathologist may test the genetic profile of the tumor to see if it 
displays genetic features which are associated with a positive or poor prognosis.  These 
sub-classifications are further described in Chapters 5 and 7. 
1.1.2 Screening for Neuroblastoma  
Neuroblastoma has no major risk factors.  Some studies show only 1-2% of 
cases are hereditary ("What are the Risk Factors for Neuroblastoma?," 2009), but other 
sources say as many as 20% of cases may be due to hereditary factors (Cotran, R. S. 
et al., 1994).  Neuroblastomas may be caused by neuroblast cells which do not fully 
mature during fetal development due to some type of genetic mutation ("Do We Know 
What Causes Neuroblastoma?," 2009).  The MYCN oncogene is over expressed in 
many neuroblastomas, and the TrkA tumor suppressor gene is under expressed in 
many neuroblastomas.  There are no known causes for the genetic changes which 
occur in neuroblastoma. 
Non-invasive or minimally invasive screening methods have had high success 
rates in detecting other types of cancer. These screening techniques tend to have lower 
sensitivity and high specificity.  Truth tables are often used to calculate sensitivity and 
specificity, as shown in Table 1.1.  Sensitivity is defined as the number of true positives 
divided by the sum of true positives and false negatives, while specificity is defined as 
the number of true negatives divided by the sum of true negatives and false positives. 
 
 
Actual Diagnosis 
Positive Negative 
Predicted 
Diagnosis 
Positive True Positive False Positive 
Negative False Negative True Negative 
Table 1.1: Truth table for calculation of sensitivity and specificity 
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High specificity is important so that there are no false negatives (the test misses 
a true cancer case).  Sensitivity relates to the number of true positives detected, so 
lower sensitivity means that not all cancer cases are detected with the given test.  An 
added benefit of screening tests is that they can reduce the mortality rate of the cancer 
for which they are screening (Mandel, J. S. et al., 1993), although this is not always the 
case (Olsen, O. Gøtzsche, P. C., 2001).  Examples of widely accepted screening tests 
are: 
• The papanicolaou cervical smear test (PAP smear) is used to detect cervical 
cancer with 30-87% sensitivity and 86-100% specificity (Nanda, K. et al., 2000). 
• Mammography is used to detect breast cancer with approximately 75% 
sensitivity and approximately 88% specificity (Houssami, N. et al., 2003). 
• Fecal occult blood testing to detect colon cancer or other disease of the anus had 
12-82% sensitivity and 95% specificity in one study (Nakama, H. et al., 1997), but 
results have been significantly lower in other studies (Winawer, S. J., 2007).  
Annual screening instead of sporadic screening can increase detection rates. 
 
More than 35 years ago, researchers in Japan noticed that there was an increase 
in the catecholamines homovanillic acid (HVA) and vanillymandelic acid (VMA) in the 
urine of patients with neuroblastoma.  Figure 1.1 briefly describes the conversion of 
tyrosine to epinephrine and norepinephrine (Vuguin, P. M., 2009). Epinephrine and 
norepinephrine are then converted to VMA and HVA.  Typically, the release of 
norepinephrine and epinephrine is governed by the sympathetic nervous system.  In the 
case of neuroblastoma, ganglia within the tumor can synthesize catecholamines, and 
release can be triggered by physical or chemical triggers outside of the sympathetic 
nervous system.  
Figure 1.1: Conversion from tyrosine to norepinephrine and epinephrine
 
Since neuroblastoma is most common in young children, s
developed to test the level of VMA and HVA 
et al., 1991; Treuner, J. Schilling, F. H., 1995)
internationally, but never in the Unit
These urine screening tests were shown to accurately identify neuroblastoma at 
much higher rates than it was previously identified.  
screening tests were not actually beneficial, however, because the majority of 
neuroblastomas identified were a special type of neuroblastoma described as ‘Stage 
4S’ (described below) which would not require treatment 
Found Early?," 2009).   
1.1.3 Neuroblastoma Treatment and Outcomes
Neuroblastoma has two unusual outcomes which make it stand out from other 
types of cancer.  Under 
spontaneous regression, and patients can go into complete remission with little or no 
Tyrosine
Dihydroxy
phenylalanine
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creening tests were 
in urine samples of newborns 
.  These tests were implemented 
ed States. 
Long-term studies show
("Can Neuroblastoma be 
 
specific circumstances, neuroblastomas can undergo 
-
Dopamine
Norepinephrine
(Sawada, T. 
ed that 
Epinephrine
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medical intervention ("What is Neuroblastoma," 2009).  This is called stage 4S 
neuroblastoma. 
In other cases, the immature cancer cells can develop into mature ganglion or 
nerve sheath cells, and the neuroblastoma as a whole develops into a ganglioneuroma.  
This is also significant because ganglioneuroma is a benign condition and poses 
significantly fewer risks to the patient, whereas neuroblastoma is a malignant condition.  
Typically, however, neuroblastoma must be treated.   
1.2 Raman Spectroscopy 
1.2.1 Raman Scattering 
The following series of equations can be used to describe the relationship 
between energy, wavelength, frequency, and wavenumber in radiating light.   
E = h ν 
λ = c / ν 
σ = ν / c = 1 / λ  
The energy (E) is equal to Planck’s constant (h  6.626 × 10-34 m2 kg / s) multiplied 
by the frequency (ν) of the light.  The wavelength of the light is equal to the speed of 
light (c  3* 108 m/s) divided by the frequency.  Finally, the wavenumber (σ) is equal to 
the frequency divided by the speed of light, or the inverse of the wavelength. 
Typically, when light is incident on a molecule, it interacts only with the electron 
cloud surrounding the molecule, and there is only a tiny energy interaction between the 
electrons and the incident light.  This interaction is very unstable.  The molecule quickly 
returns back to its original state, and the light is scattered at its original wavelength and 
frequency.  This is elastic scattering known as Rayleigh scattering (Smith, E. Dent, G., 
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2005).  In rare cases, however, the photon (unit of light energy) interacts with the 
nucleus, causing a shift in the vibration of the nucleus.   
Infrared spectroscopy is a vibrational spectroscopy technique complimentary to 
Raman spectroscopy.  It measures the change in the dipole moment of a molecule.  
Molecules which have no net dipole moment, however, cannot be measured using 
infrared spectroscopy.  Figure 1.2 illustrates this concept.  The left hand molecule is 
infrared-active because the net dipole moment can be changed while the right hand 
molecule is infrared-inactive because there is no net dipole moment.  Therefore, there 
can be no shift in the dipole moment. 
Complimentary to infrared spectroscopy, Raman spectroscopy measures the 
resulting change in polarizability caused by interaction of the incident light with the 
nucleus.  Polarizability is the tendency of the electron cloud to distort caused by the shift 
in the dipole moments.  While Infrared spectroscopy cannot detect the presence of the 
right-hand molecule in Figure 1.2, note that the same molecule could be measured 
using Raman spectroscopy, as shown in Figure 1.3. 
 
Figure 1.2: Infrared-active and inactive molecules 
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There are two types of vibrational scattering.  In Stokes scattering, some of the 
energy of the incident photon is absorbed by the molecule.  Due to conservation of 
energy, the loss in energy of the scattered photon from the incident photon is equal and 
opposite to the energy change of the shift in the dipole moment.   
 
Figure 1.3: Changes in polarizability caused by shifting dipole moments. 
 
Anti-Stokes scattering occurs when the molecule is already in an excited 
vibrational state.  In this case, the scattered photon absorbs some of the energy from 
the molecule as it returns to its ground state.  The scattered photon, then, has a higher 
energy and shorter wavelength than the incident photon.  Note that Stokes and anti-
Stokes scattering result in a wavelength shift due to the change in energy of the test 
molecule, whereas Rayleigh scattering has no shift in wavelength because there is no 
vibrational change within the molecule.  Figure 1.4 shows the energy diagram for 
Rayleigh, Stokes, and anti-Stokes scattering. 
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Figure 1.4: Anti-Stokes, Stokes, and Rayleigh scattering. 
 
Typically, most of the molecules within a test sample will be at the ground state, 
rather than an excited state.  Therefore, Stokes scattering is far more common than 
anti-Stokes scattering.  For that reason, most Raman instrumentation is only setup to 
measure Stokes scattering.  Even measurement of Stokes scattering posed a large 
challenge for decades, however, because only about 1 in 107 incident photons trigger 
the Raman effect.  Current systems use single-wavelength lasers as excitation sources, 
sensitive charge coupled devices to count the scattered photons, and advanced 
computer processing to analyze data.  The combination of these advances make 
Raman spectroscopy a reasonable tool for biological applications. 
For a given particle, it is possible to theoretically predict the change in 
polarizability (α).   
α = p /  
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Polarizability is defined as the ratio between the dipole (p – calculated in general 
as the integral of the charges multiplied by the distance) of the molecule and the electric 
field of the incident light (.  The electric field of the incident light is defined as 
   cos	 2  ν t 
where ν is the frequency of the light, t is time, and E0 is the initial electric field.  
The polarizability is defined as  
     cos	2    
where νvib is the vibrational frequency of the incident molecule.  These two terms 
can be multiplied to calculate the dipole (Colthup, N. B. et al., 1990): 
p = 

cos2   	    cos2   	  ! 
1.2.2 The Raman Spectrum 
Quantum mechanics states that a molecule can only vibrate a specific number of 
ways.  Linear molecules containing N atoms have 3N-5 modes, and nonlinear 
molecules have 3N-6 vibration modes.  Based on the change in energy of the 
vibrational frequency, the wavelength of the scattered photon can be calculated.  For a 
given molecule, the exact Raman shift in wavenumbers can be calculated using the 
formula 
ω = 
#
$%&'(%)
 
#
$*&+))(,('
 
A Raman spectrum is the plot of the wavenumbers on the x-axis versus the count 
on the y-axis.  The y-axis represents how many Raman shifts were measured.  Because 
each molecule has a unique set of possible vibrations, a single molecule can be 
identified based on the wavelength shifts of the incident light (wavenumber).  When a 
sample is composed of different types of molecules, there will be peaks at several 
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wavenumbers.  The relative height of the peaks represents the relative ratios of each 
molecule within the sample. 
Using known biochemicals to establish known peaks, Raman spectroscopy can 
provide information about the underlying biochemistry of a sample.  Each chemical has 
a characteristic Raman peak or combination of Raman peaks.  Some chemicals have 
overlapping peak regions.  Analysis of Raman peaks becomes more and more 
complicated as more and more chemicals are added to a sample (Socrates, G., 2001).  
Raman peaks for a given chemical may shift slightly based on the characteristics of the 
other chemicals it is surrounded by (Socrates, G., 2001). 
1.2.3 Raman Spectrometer 
Because the Raman effect is so small (approximately 1 in 107), specialized 
instrumentation is required to obtain efficient Raman measurements.  Figure 1.5 shows 
a simplified schematic of a Raman spectrometer.  A laser source is used to provide high 
power light at a specific wavelength with a highly focused beam.  The beam is focused 
on the sample through the microscope lens.  The lens then collects the scattered light.  
It passes through a notch filter which removes all the Rayleigh scattered light of the 
same wavelength.  It is then focused on a grating which separates all the wavelengths 
of light, and then focused on a charge coupled device detector (CCD).  The CCD counts 
the number of photons at each wavelength and sends the information to the computer.  
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Figure 1.5: Raman spectrometer schematic 
 
All experiments described here were performed using a Renishaw In-Via Raman 
spectrometer using a 500 mw 785 nm GaAs laser excitation source and 1200/mm 
grating.  The system resolution is 3 cm-1. 
1.2.4 Analysis Methods Used in Raman Diagnostics 
1.2.4.1 Preprocessing 
Following Raman measurement, a two-column text file is created by the 
measurement software.  The first column contains the wavenumbers measured, and the 
second column contains the number of photons counted at each wavenumber.  Before 
any processing can be done, however, files must be pre-processed to standardize the 
spectra. 
 In-house automated pre-processing software is used to remove cosmic rays, 
noise and tissue fluorescence, and then normalize data on a scale from 0 to 1 (Cao, A. 
et al., 2007).  Wavelet filtering is used to remove noise and smooth the data. 
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For fluorescence removal, the software matches a polynomial background to 
local minima along the spectra.  The software was programmed to identify which order 
of polynomial best fit each spectrum based on its fluorescence pattern.  Figure 1.6 
shows two example spectra plotted before and after preprocessing.  Note that the 
underlying fluorescence pattern is different between the two spectra, and the 
background subtraction was adjusted accordingly for each. 
 
Figure 1.6: Examples of Raman spectra before and after preprocessing. 
 
Data is stored on a secure online server until processing.  An in-house database 
stores information about the files, including the date collected and measurement 
parameters, as well as the diagnosis and notes made by the pathologists.  This 
database was described extensively in previous work (Weber, R. E., 2007). 
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1.2.4.2 Data Analysis 
Several options exist for analyzing and classifying Raman spectra, including 
neural networks (de Paula, A. Sathaiah, S., 2005; Gniadecka, M. et al., 2004; Weber, R. 
E., 2007), principal component analysis (Frausto-Reyes, C. et al., 2005; Guicheteau, J. 
et al., 2008; Kawabata, T. et al., 2008; Sato-Berru, R. et al., 2007; Ye, Z. Auner, G., 
2004a), and discriminant function analysis (Brown, K. L. et al.; Jarvis, R. Goodacre, R., 
2004; Kawabata, T. et al., 2008), amongst other methods (Krafft, C. et al., 2009; Ye, Z. 
Auner, G., 2003, 2004b).  Previous work showed good agreement between neural 
network analysis and discriminant function analysis when both were performed on the 
same dataset (Weber, R. E., 2007). 
Principal component analysis (PCA) is a technique which can be used to 
compress the data set from many variables to a manageable set of 20 or less.  PCA 
rotates the data in such a way that the new first variable (component) represents the 
maximum variability within the dataset.  The second component explains the next-most 
variability, and it is orthogonal to the first component.   The components continue in this 
pattern until all the variability is explained.  The final number of principal components is 
equal to the original number of variables; however, the only significant components will 
be at the beginning of the dataset.  A cutoff can be assigned so those only the variables 
which explain X% new variance (example: .05% of variance) are saved.  This allows the 
data to be condensed from thousands of variables to a much smaller set which often 
contains 75% of the variance or more.  In depth description of PCA is available in 
several texts (Jolliffe, I. T., 1986) (Geladi, P. Kowalski, B. R., 1986; Stevens, J. P., 
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2002; Tabachnick, B. G. Fidell, L. S., 2007), and description of PCA used for analysis of 
Raman spectra is also available (Dai, H., 2005). 
While PCA is a helpful tool for data compression, it is not an ideal diagnostic tool.  
Discriminant function analysis (DFA) is the classification technique used for all 
experiments described here.  While Raman spectroscopic data often does not meet the 
statistical requirements assumed for DFA (Klecka, W. R., 1980), it has been applied to 
several types of Raman data (Brown, K. L. et al.; Kast, R. E. et al., 2008; Pandya, A. K. 
et al., 2008; Wills, H. et al., 2009b).  PCA components can be used as input to 
discriminant function analysis, or a combination of peak data can be used as input.  A 
benefit of DFA is that the analysis results allow the user to determine which variables in 
the analysis are significant from which variables are noisy or insignificant.  Like PCA, 
DFA rotates the dataset, aligning the most variation along the first variable (canonical 
function), the second most variability along the second variable, etc.  Data points are 
plotted along the rotated variables.   
When performing analysis, a ‘gold standard’ diagnosis is assigned to each 
spectrum.  The gold standard diagnosis is assigned by the pathology staff as the 
‘known’ diagnosis based on the tissue histology and other methods when necessary.  
To ensure accuracy of the gold standard diagnosis, two or more pathologists review 
each case.  The DFA model is created based on the known gold standard diagnosis.  
For each diagnosis group, a centroid point is calculated based on the average location 
of all points within that group.  Diagnosis of new spectra, then, is based on the closest 
centroid.  Again, there are many books available which describe DFA in depth (Klecka, 
W. R., 1980; Stevens, J. P., 2002; Tabachnick, B. G. Fidell, L. S., 2007).  While DFA is 
the classification methodology used in this work, neural networks, logistic regression, or 
other methods may be used with Raman spectroscopic data
Classification results provide 
Sensitivity and specificity are calculated at the spectral level based on these results, 
using pathology diagnosis as the gold standard.  
calculated, the same results are calculated for each tissue.  Each tissue’s diagnosis is 
made based on the majority classification
the data processing methodology.
Figure 1.7: Data analysis flowchart
 
1.2.5 History of Raman Spectroscopy as a Biological Detection Tool
Raman spectroscopy was used in biological applications
identify amino acids and fatty acids, among other compounds 
was not commonly used as a laboratory practice, however, until commercial lasers, 
spectrometers, and computers became available in the 1960’s 
2001).  In 1977, Cancer Research published an article which examined the plasma 
Preprocess
Compress
(Optional) 
PCA
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a predicted diagnosis for each individual spectrum.  
Once spectra-level results are 
 of the individual spectra.  Figure 1.7 outlines 
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membranes from normal and cancerous hamster lymphocytes using Raman 
spectroscopy (Verma, S. P. et al., 1977).  This marked the beginning of the modern era 
of Raman spectroscopy for tissue diagnostics. 
In the past 20 years, Raman spectroscopy has been applied to several whole-
tissue cancer diagnostic applications, including breast (Frank, C. J., 1994; Haka, A. S. 
et al., 2002; Haka AS, V., Gardecki, Nazemi, Lyons, Hicks, Fitzmaurice, Dasari, Crowe, 
Feld, 2006; Haka, S.-P., Fitzmaurice, Crowe, Dasari, Feld, 2005; Manoharan, R. et al., 
1998; Redd, D. C. B. et al., 1993), brain (Krafft, C. et al., 2003; Wolthuis, R. et al., 
2001), cervical (Mahadevan-Jansen, A. et al., 1998a; Mahadevan-Jansen, A. et al., 
1998b; Utzinger, U. et al., 2001), thyroid (Teixeira, C. et al., 2009), pancreatic (Pandya, 
A. K. et al., 2008), bladder (Stone, N. et al., 2002), lung (Draux, F. et al., 2008; Huang, 
Z. et al., 2003b; Kaminaka, S. et al., 2001), kidney (Lieber, C. Kabeer, M.; Wills, H. et 
al., 2009b), prostate (Crow, P. et al., 2003a), esophageal (Kendall, C. et al., 2003; Li, X. 
et al., 2004; Shetty, G. et al., 2006a), and skin cancer (Fendel, S. Schrader, B., 1998; 
Gniadecka, M. et al., 1997; Hata, T. R. et al., 2000; Johansson, C. K. et al., 1999), 
amongst others.   
Once Raman spectroscopy was proven as a diagnostic technique, researchers 
began developing portable tools for Raman spectroscopic measurement in-vivo 
(Mahadevan-Jansen, A. et al., 1998b; Motz, J. T. et al., 2005; Motz, J. T. et al., 2004; 
Shim, M. G. et al., 1999; Utzinger, U. Richards-Kortum, R., 2003).  Rather than trying to 
miniaturize an entire spectrometer, however, these designs focus on development of 
fiber optic delivery and collection fibers for Raman measurement.  They still require 
attachment to a larger spectrometer which must be within the length of the fiber probe.  
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Several studies used portable fiber optic devices to measure Raman spectra from 
easily-accessible tissues, including skin (Caspers, P. J. et al., 2003; Fendel, S. 
Schrader, B., 1998) and cervical tissue (Robichaux-Viehoever, A. et al., 2007).  In 2006, 
the first in-vivo Raman measurement of breast cancer resection surgery was published 
(Haka, A. S. et al., 2006a).   
Raman spectroscopy has also been used to measure individual cancer cells in 
many applications, including breast and cervical cancer (Yazdi, Y. et al., 1999), lung 
cancer (Draux, F. et al., 2008; Verrier, S. et al., 2004), prostate cancer (Crow, P. et al., 
2005a; Harvey, T. J. et al., 2008; Taleb, A. et al., 2006), leukemia and lymphoma 
(Chan, J. W. et al., 2008; Chan, J. W. et al., 2006), cervical cancer (Matthaus, C. et al., 
2007), liver cancer (Hawi, S. et al., 1996), and bladder cancer (Harvey, T. J. et al., 
2008).  It has also been used outside of cancer research.  In cellular studies, it has been 
used to measure cell death (Huang, Y. et al., 2005; Notingher, I. et al., 2002; Verrier, S. 
et al., 2004), cell proliferation (Short, K. W. et al., 2005), identify individual bacteria cells 
(Schuster, K. et al., 2000), identify specific biochemical constituents within a cell 
(Hellerer, T. et al., 2007; Matthaus, C. et al., 2007), identify immune cell activation 
(Brown, K. L. et al., 2009a, b; Mannie, M. D. et al., 2005).  Several studies have also 
been performed to identify ideal measurement parameters for cells in culture.  Research 
showed that the ideal collection wavelength for single cell measurements was near 785 
nm (Notingher, I. et al., 2002).  Lower wavelength lasers damaged cells, even at 
reduced power levels.  It was also found that cells which were dehydrated and then 
tested exhibited significant artifact (Mariani, M. M. et al., 2009; Mourant, J. et al., 2003).  
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Cells should instead be measured while suspended in an aqueous solution.  Third, 
water does not interfere with Raman signals because it vibrates symmetrically.  
Raman spectroscopy offers several distinct advantages as a diagnostic tool.  
First, it does not require any biomarkers or tags (Gremlich, H.-U. Yan, B., 2001).  
Second, Raman signals can be measured from a broad range of molecules (Gremlich, 
H.-U. Yan, B., 2001).  This offers a distinct advantage over infrared spectroscopy 
(Gremlich, H.-U. Yan, B., 2001). 
1.3 The Problem and Proposed Solution 
1.3.1 Raman Spectroscopy as a Diagnostic Tool for Neuroblastoma 
To accurately diagnose neuroblastoma, it must be distinguished from 
histologically similar tumors or geographically close tumors.  Current pathology methods 
are slow, and can be biased by the surgeon’s skill in removing the affected area, and 
the pathologist’s skill and experience in diagnosing a relatively rare pediatric neoplasm 
such as neuroblastoma.  Methods including immunohistochemistry (Finegold, M. J. et 
al., 1983; Gregorio, A. et al., 2008), cytogenetics (Taylor, C. et al., 1993), polymerase 
chain reactions (PCR) (Chen, Q.-R. et al., 2007), electron microscopy, and karotyping 
are often required in addition to traditional tissue staining and light microscopy.   
Once neuroblastoma is diagnosed, the aggressiveness of the tumor must be 
identified.  The Shimada classification is the gold standard method for diagnosing tumor 
favorability; however, it can vary based on the pathologist and the region of tissue under 
examination.  Other factors such as the genetic profile of the tumor may also be 
examined to determine aggressiveness and plan treatment. 
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Raman spectroscopy can be exploited as a non-biased, quick, and accurate 
method for cancer diagnosis.  A portable Raman instrument can be developed for 
biopsy use, or biopsy samples can be tested using a traditional desktop Raman 
spectrometer in the pathology laboratory.  We hypothesize that Raman can accurately 
identify neuroblastoma from other neural tumors and from histologically similar small 
round blue cell tumors.  Furthermore, we hypothesize that Raman spectroscopy can 
identify subtle characteristics of tumor aggressiveness such as favorability and 
amplification of key genes.  Even if a biopsy sample were tested in the pathology lab 
after resection, a thorough diagnosis could be provided within an hour of surgery, 
instead of waiting days using current pathological methods. 
1.3.2 Raman Spectroscopy as a Surgical Tool for Neuroblastoma 
When a tumor is removed, the surgeon removes a margin of normal-appearing 
tissue outside of where he or she thinks the tumor boundaries are.  The pathologist 
quickly cuts, stains, and views frozen sections of the margin tissue to ensure there are 
no remaining tumor cells and the whole tumor is removed.  This process takes 
approximately 20 minutes, and must be repeated if tumor cells are found within the 
margin.  Throughout this process, the surgeon and the patient’s family wait, while the 
patient is kept sedated in the operating room.   
If the pathologist’s initial review shows that there are no cancer cells in the tissue 
margin, the surgeon finishes the surgery.  However, the initial review by the pathologist 
is simply a best guess.  Over several days, the pathologist performs a more thorough 
review of the tumor margin to verify that there were no tumor cells.  In the case that 
tumor cells are found, the patient must have a second surgery to remove the remaining 
cancer cells.  This is expensive and puts the patient at a higher risk.  Figure 
flow chart of the current surgical and pathology system used.
We suggest that Raman spectroscopy can be used as an alternative to the 
frozen section diagnosis in tumor section.  Engineers are developing a hand
Raman spectrometer for surgical use which can be used in open surgery, laparoscopic 
surgery, or attached to a robot arm for robotic surgery.  Unlike other 
spectroscopy probe designs, this 
spectrometer, rather than attaching a long fiber optic probe to a traditional spectrometer.  
 
Figure 1.8: Following tumor resection, a pathologist performs a quick analysis, then a 
more detailed analysis.  If tumor cells are found, more tissue must be removed.
 
Once the tumor is removed, the Raman probe can be used to scan the margin 
area for any remaining cells. When integrated with real time diagnostic and mapping 
software, this should provide an accurate 
20 minutes.    The portable Raman probe could even be attached to a surgical robot to 
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portable Raman 
design miniaturizes all the components of the 
assessment of the tumor margin in less than 
1.8 shows a 
-held 
 
 
fully automate the scanning process.
analysis of the margin following surgery, but we expect a much higher accuracy in 
diagnosing tumor margins.   
Figure 1.9 shows a schematic of our proposed methodology.
portable Raman probe can be used in a traditional open or laparoscopic surgery, or it 
can be attached to a robotic arm.  The probe will interface with 3
tumor area to scan the margin
clear margin, the surgery will end and the resected tissue will be sent to pathology for a 
full workup.  The rate of positive margins should be mu
because the Raman probe should be able to obtain more detailed biochemical 
information about the sample.
be able to identify abnormal, potentially pre
identified by pathology (Kast, R. E. et al., 2008)
 
Figure 1.9: Proposed Raman system for margin assessment should provide quicker 
results with higher accuracy 
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  A pathologist would still perform a thorough 
  
-D mapping of the 
 (Reisner, L. A. et al., 2007).  Once scanning shows a 
ch lower than the current rate
  Previous studies showed that Raman spectroscopy may 
-cancerous cells before they can be 
. 
As shown, the 
, 
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1.4 Scope of Work 
The goal of this research is to develop a detailed classification methodology for 
neuroblastoma.  The two major steps of this goal are: 
1) Use Raman spectroscopy to develop a methodology for identifying neuroblastoma 
from normal adrenal gland tissue, other neural diseases, and histologically similar 
small round blue cell tumors.    
2) Use Raman spectroscopy to identify the prognostic markers of neuroblastoma to 
provide specific diagnostic details and allow rapid development of an optimal 
treatment plan. 
The following hypotheses were developed based on this research goal: 
1) Raman spectroscopy can distinguish neuroblastoma from other tissues, including 
histologically similar small round blue cell tumors and other pathologies of the 
adrenal gland, using standard histology as the gold-standard for diagnosis. 
2) Raman spectroscopy can identify prognostic markers of the disease (tumor markers, 
histology, genetics, etc) to provide specific details about the diagnosis and optimal 
treatment plan.  
1.5 Research Plan 
This dissertation is divided into three main segments: identification of 
neuroblastoma tumor tissue, identification of prognostic markers of neuroblastoma, and 
conclusions and future work.   
1.5.1 Identification of Neuroblastoma Tumor Tissue 
Chapter 2 examines identification of neuroblastoma from normal adrenal gland 
tissues and from other peripheral nervous system tumors, including ganglioneuroma, 
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peripheral nerve sheath tumor, and pheochromocytoma.  This work was originally 
published in the Journal of Pediatric Surgery (Rabah, R. et al., 2008).   
In Chapter 3, neuroblastoma is compared to the same types of tissues; however, 
tumors from a frozen tumor bank were also included in the study.  Because 
neuroblastoma and the related tumors have such low occurrence, development of a 
robust tissue database would take many years.  If frozen tumors could be included, a 
database could be built more expediently.  This work was also originally published in the 
Journal of Pediatric Surgery (Wills, H. et al., 2009a).   
Chapter 4 compares neuroblastoma with the other common small round blue cell 
tumors, non-Hodgkin lymphoma, rhabdomyosarcoma, and Ewing sarcoma.  This work 
was accepted for publication in the June 2010 edition of the Journal of Pediatric Surgery 
(Kast, R. et al., Accepted for June 2010).   
1.5.2 Identification of Prognostic Markers 
Chapter 5 marks the beginning of the second portion of the dissertation: 
identification of prognostic factors associated with neuroblastoma.  In this chapter, 
favorable histology, unfavorable histology, and treated neuroblastoma are compared.  
This work was also included in the two Journal of Pediatric Surgery papers from 
Chapters 2 and 3 (Rabah, R. et al., 2008; Wills, H. et al., 2009b).  
Chapter 6 further expands on differentiation between favorable histology 
neuroblastoma, unfavorable histology neuroblastoma, and treated neuroblastoma, by 
including frozen, blinded tumor samples received from the Children’s Oncology Group, 
a national tumor bank.   
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Chapter 7 examines another prognostic factor associated with neuroblastoma: 
amplification of the MYCN gene.  A cell line which alters its gene expression level based 
on tetracycline treatment was used to model normal and amplified levels of MYCN.   
1.6 Novelty and Significance 
This work is novel because it is the first major study using Raman spectroscopy 
to diagnose a pediatric tumor in a human model.  Many Raman spectroscopic studies in 
the literature diagnose cancer in adult tissues, but this is the first investigation of 
neuroblastoma. 
Furthermore, most of the prognostic markers of cancer have not been examined 
in detail.  Adding this increased capability to Raman spectroscopic diagnosis will add a 
new degree of clinical relevance.  Raman spectroscopy could offer an immediate, 
objective evaluation of tumor aggressiveness, and provide immediate information 
regarding patient prognosis.  The two specific factors which will be examined are tumor 
histology and MYCN gene amplification. 
Raman spectroscopy could offer significant improvements over existing 
diagnostic techniques for neuroblastoma.  A methodology for real-time diagnosis would 
bring physicians one step closer to making immediate treatment decisions directly from 
the operating room.  When integrated into a biopsy needle or laparoscopic surgical 
probe, Raman spectroscopy could provide an immediate, accurate diagnosis.  This is 
especially significant for diagnosing small round blue cell tumors and identifying genetic 
amplification because existing diagnosis methods are expensive, subjective, or slow. 
Accurate diagnosis could prevent patients from undergoing unnecessary 
treatment.  Alternately, it could allow patients to begin treatment immediately based on 
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the real-time diagnosis.  Quick identification of prognostic markers will allow rapid, 
individualized treatment plans. 
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CHAPTER 2 IDENTIFICATION OF NEUROBLASTOMA FROM NEURAL TUMORS 
2.1 Introduction 
Because neuroblastoma is derived from the neural crest, it can arise on 
sympathetic ganglia or on the sympathetic chain anywhere in the body.  About one third 
of neuroblastomas present on the adrenal gland because it is a common site of 
migration for cells derived from the neural crest ("What is Neuroblastoma," 2009).  This 
is the most common primary neuroblastoma site (Orkin, S. H. et al., 2009). 
Other tumors which can arise on neural tissue include ganglioneuroma, 
peripheral nerve sheath tumor, and pheochromocytoma.  While peripheral nerve sheath 
tumor and pheochromocytoma have unique histologies, ganglioneuroma is closely 
related to neuroblastoma. 
2.1.1 Ganglioneuroma 
As described in the introduction, ganglioneuroma is closely related to 
neuroblastoma (Cotran, R. S. et al., 1994).  It is composed of the same types of cells of 
neuroblastoma, except they are mature.  Ganglioneuroma is a benign condition, and 
usually requires no treatment.  In some cases, it may need to be removed if it causes 
secondary symptoms 
2.1.2 Nerve Sheath Tumor and Peripheral Nerve Sheath Tumor 
A nerve sheath tumor is a neural tumor, and a peripheral nerve sheath tumor is 
simply a nerve sheath tumor which is found in the peripheral nervous system.  There 
are several types of nerve sheath tumor, including Schwannoma, neurofibroma, and 
malignant peripheral nerve sheath tumor (Cotran, R. S. et al., 1994). 
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Schwannomas come from Schwann cells, which are found in the neural crest.  
Schwannomas are most commonly found on the eighth cranial nerve, but can be found 
on the other cranial nerves, in the dorsal roots of the spinal cord (and sometimes 
extending past the vertebral foramen), or at large nerve trunks which contain both motor 
and sensory nerves (Cotran, R. S. et al., 1994).  Schwannomas grow attached to 
nerves, however, they do not invade nerves; therefore, they can typically be separated 
from the nerve with relative ease, as long as the tumor capsule does not surround the 
nerve. 
Conversely, neurofibromas infiltrate the fascicles of the nerve, making it difficult 
to fully resect the tumor mass (Cotran, R. S. et al., 1994).  Neurofibromas can be found 
on any nerve, though they tend to be found in larger, communicating areas more than 
terminal branches of the nerve.  Neurofibromas consist of Schwannian cells, fibroblasts, 
and inflammatory cells.  Since the tumor invades the actual nerve, axons can also be 
found within neurofibromas. 
Malignant peripheral nerve sheath tumors are not caused by degeneration of 
Schwannomas, but they can be caused by degeneration of plexiform neurofibromas or 
they can occur spontaneously or as a result of radiation therapy (Cotran, R. S. et al., 
1994).  They are classified as sarcomas (tumor of soft tissue) and considered very 
malignant.  Tumor recurrence and metastasis are common in malignant peripheral 
nerve sheath tumors, and there is a poor prognosis.  Malignant peripheral nerve sheath 
tumors infiltrate both the host nerve as well as other local soft tissue. 
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2.1.3 Pheochromocytoma 
Pheochromocytoma is a rare neoplasm which is found in the medulla of the 
adrenal gland in about 85% of cases and found on other paraganglia in the remaining 
15% of cases (Cotran, R. S. et al., 1994).  Less than 10% of adrenal 
pheochromocytomas are malignant, however 20-40% of non-adrenal 
pheochromocytomas are malignant.  Because benign and malignant tumors share 
nearly identical histology, the only way to verify malignancy is the presence of 
metastasis.   
Approximately 10% of pheochromocytomas come from familial syndromes, while 
the other 90% appear sporadically.  Pheochromocytoma is most common in those 
between 40 and 60 years old, however, pediatric occurrence is common in those with 
familial syndromes.  In the United States, the overall rate of pheochromocytoma is 1 in 
100,000; however, only 10-20% of those cases occur in children (Vuguin, P. M., 2009).  
Pheochromocytomas tend to occur in slightly older children than neuroblastoma, with 
the average age at diagnosis between 6 and 14 years. 
Like neuroblastoma, pheochromocytomas secrete epinephrine or 
norepinephrine, which lead to increased levels of catecholamines throughout the body 
and in the urine (Cotran, R. S. et al., 1994; Vuguin, P. M., 2009).  Catecholamine 
release is triggered by physical or chemical changes around the tumor, rather than 
neural stimulation, because pheochromocytomas are not innervated. Key symptoms of 
pheochromocytoma are hypertension, paroxysms (strong emotional outbursts), 
increased levels of urinary catecholamines, and circulatory problems caused by surging 
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levels of catecholamines, including pulmonary edema, heart attack, congestive heart 
failure, cerebral hemorrhage, and ventricular fibrillation (Cotran, R. S. et al., 1994). 
2.1.4 Research Goal 
The goal of this chapter is to determine whether Raman spectroscopy can 
distinguish between neuroblastoma, ganglioneuroma, peripheral nerve sheath tumor, 
pheochromocytoma, and normal adrenal gland. 
2.2 Materials and Methods 
2.2.1 Internal Review Board Approval 
All tissue-based studies described in this work were approved by the Wayne 
State University Internal Review Board Human Investigation Committee (IRB 
#0506002366).  Supporting documentation, including the protocol, 2009 continuation 
form for 2010, and a signed approval for the 2009 continuation are included in Appendix 
A.   
2.2.2 Data Collection 
Samples of neuroblastoma, ganglioneuroma, peripheral nerve sheath tumor, 
pheochromocytoma, and normal adrenal gland were collected fresh from the operating 
room from routine surgical procedures.  After arriving in the pathology lab, half of the 
sample was reserved for routine pathology.  The other half was used for Raman 
spectroscopy testing.  An experienced pathologist selected regions of normal tissue 
and/or tumor tissue for each sample.   
Raman testing was performed using the Renishaw Raman spectrometer using a 
20x magnification Leica objective.  At least twelve different points were measured on 
each sample, in case any single measurement was made over non-tumor area such as 
33 
 
vessels, fat, or inflammation.  Whenever a tissue was big enough and time allowed, 
more than twelve spectra were measured.  Each measurement consisted of 2 or 3 
accumulations of 10 seconds each over the range of 600-1800 cm-1.  This region is 
known as the fingerprint region.  Raman shifts for biological molecules, including 
proteins, amino acids, lipids, and carbohydrates are all found within this region, and it 
offers the most diagnostic information. 
Following Raman measurements, each sample was placed in 10% neutral 
buffered formalin to preserve the tissue structure, and later sent for routine histology 
processing.  Samples were embedded in paraffin by an experienced laboratory 
technician, and a 5 µm section was cut, mounted on a standard glass slide, and stained 
with hematoxylin-eosin.  The remaining tissue was preserved in paraffin.  In the case of 
classification disagreement between the control sample and the Raman-tested sample, 
or in disagreements between the pathologic diagnosis and Raman diagnosis, more 
hematoxylin-eosin slides were made for review from the preserved paraffin-fixed 
sample. 
All tissue slides were reviewed by two or more experienced pediatric 
pathologists, who agreed on the diagnosis of the tissue.  In cases of neuroblastoma, 
pathologists also identified whether the tumor was favorable or unfavorable based on 
the Shimada classification, or whether the tissue was treated.  Samples which displayed 
extensive damage due to trauma (such as cauterization during surgery) were excluded 
from the study.  In some cases, just a few tumor cells were present in an area of 
otherwise normal tissue.  Samples with this characteristic were included in this study, to 
gauge the sensitivity and specificity of the Raman technique. 
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2.2.3 Data Processing 
Data was processed as described in section 1.2.4.  Appendix B provides a 
detailed statement of procedure protocol for data processing.  After pre-processing, 
each spectrum was visually examined.  Spectra which showed clear measurement 
errors, including spectra where measurement was stopped mid-measurement, spectra 
where the glass slide was measured instead of the tumor or out of focus measurements 
were deleted from the dataset.  For each group of tissues examined, the mean 
spectrum was calculated to get an overall understanding of the differences between 
tissue groups. 
Data was averaged into intervals of 2.25 cm-1 and imported into SPSS for 
analysis.  2.25 cm-1 was selected because it was the smallest interval size which 
allowed SPSS to perform principal component analysis.  This compressed the data from 
1310 variables to 534 variables.  Within SPSS, principal component analysis was used 
to reduce the dimensionality of the binned data set of 534 variables to 20 or less.  Next, 
discriminant function analysis was used to build a classification model.  Sensitivity (true 
positives / (true positives + false negatives)) and specificity (true negatives / (true 
negatives + false positives)) based on the gold standard diagnoses were used to judge 
the classification models.   
The results of discriminant function analysis were examined at the spectral level 
and the tissue level.  Because normal and tumor tissue are both heterogeneous, a given 
Raman spectrum may be representative of a pocket of fat, inflammation, or a vessel 
rather than tumor tissue.  Therefore, it would not be unexpected to have a misclassified 
spectrum in an analysis.  For this reason, a classification rule was developed for whole 
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tissues.  Each whole tissue’s classification was determined based on the classification 
of a majority of its spectra.  For example, in a sample with 12 measured spectra, if 
seven or more spectra were classified as ‘neuroblastoma’, the whole tissue was 
diagnosed as neuroblastoma.  Likewise, if six spectra were classified as neuroblastoma, 
three as normal, and three as ganglioneuroma, the overall tissue diagnosis of 
neuroblastoma was assigned.  Usually 12 spectra were measured per sample, but that 
number could be more if tissue tested was large or less if some spectra from the tissue 
were excluded from analysis.  Spectra were only excluded from analysis if they 
displayed clear signs of measurement error, including saturation, background signal of 
glass slide, or cut-off of data mid-measurement.   
2.3 Results 
2.3.1 Data Collected 
The data consisted of 698 spectra from 31 tissue samples as shown in Table 2.1.  
Within the neuroblastoma group of tumors, there were 106 spectra from 6 tissue 
samples of unfavorable histology neuroblastoma, 114 spectra from 5 cases of favorable 
neuroblastoma, and 82 spectra from 5 treated neuroblastomas.  As mentioned in the 
materials and methods section, at least twelve points were measured for each sample; 
however some samples were quite large and allowed significantly more measurements 
with no sample degradation.   
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Diagnosis Number of Samples Number of Spectra 
Normal adrenal gland 3 78 
Neuroblastoma 16 302 
Ganglioneuroma 5 189 
Nerve Sheath Tumor 6 117 
Pheochromocytoma 1 12 
Total 31 698 
Table 2.1: Number of spectra and samples for adrenal gland, neuroblastoma, 
ganglioneuroma, nerve sheath tumor, and pheochromocytoma. 
 
2.3.2 Visual Examination of Raman Spectra 
The mean Raman spectrum of each tissue type and correlating representative 
histology images are shown in Figure 2.1.  As shown, there were clear differences in the 
histology from tissue to tissue which correlated to clear differences in the Raman 
spectra. Normal adrenal gland tissue was clearly different from each of the four types of 
tumors.  On visual inspection, normal tissues had higher peaks at 1102, 1160, and 1518 
cm-1, which correlates to a higher concentration of carotenoids in normal tissues 
(Schulz, H. et al., 2005).  These peaks are circled in the normal spectrum of Figure 2.1.  
Note that the carotenoid peaks at 1160 and 1518 cm-1 were absent from the mean 
spectra of every tumor type. 
Conversely, the tumor samples, especially ganglioneuroma and neuroblastoma 
had higher intensities at peaks which correlate to proteins, specifically 754, 853, 938, 
1002, 1300 through 1345, 1447, 1550, 1620, and 1660 cm-1. 
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Figure 2.1: Mean spectra of each tissue type with correlating histological images.  
Labeled circled peaks are areas of difference between tissue types.   
2.3.3  
2.3.4 Classification Results 
Neuroblastoma was separated from normal adrenal gland with 100% sensitivity 
(302/302 neuroblastoma spectra correctly identified) and 92.3% specificity (5/78 adrenal 
gland spectra correctly identified).  The five misclassified spectra came from two tissue 
samples.  In both cases, the misclassified spectra represented only a fraction of the 
overall spectra.  In the first sample, 3 of 22 spectra were misclassified, and in the 
second sample, 2 of 44 spectra were identified.  Using tissue level diagnosis, there was 
100% sensitivity (16/16 neuroblastoma tissues) and 100% specificity (3/3 normal 
adrenal gland tissues) in diagnosing between normal adrenal gland and neuroblastoma.  
Classification results for this analysis and the other two-group comparisons are 
summarized in Table 2.2. 
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 Normal AG v 
NB 
NB  
v GN 
Normal AG  
v GN 
NB  
V Pheo 
NB  
v NST 
 Sen Spec Sen Spec Sen Spec Sen Spec Sen Spec 
Spectral-
level  
100% 100% 96.3% 95.7% 100% 94.8% 100% 88.1% 79.5% 85.1% 
Tissue- 
level 
100% 100% 100% 100% 100% 100% 100% 100% 66.6% 87.5% 
Table 2.2: Classification sensitivity and specificity results at the spectral and tissue level 
for each 2-group analysis (AG = adrenal gland, NB = neuroblastoma, GN = 
ganglioneuroma, Pheo = pheochromocytoma, NST = nerve sheath tumor, Sen = 
sensitivity, and Spec = specificity) 
 
 
Next, the separation between neuroblastoma and ganglioneuroma was 
examined.  Neuroblastoma was correctly identified from ganglioneuroma with 96.3% 
sensitivity (291/302 neuroblastoma spectra correctly identified) and 95.7% specificity 
(181/189 ganglioneuroma spectra correctly identified).  The eleven misclassified 
neuroblastoma were split between 3 tissues (2 of 18, 3 of 14, and 6 of 36 misclassified) 
and the eight misclassified spectra of ganglioneuroma were split between three tissues 
(1/55, 1 of 19, and 6 of 59 misclassified).  Using the tissue-level classification, 
neuroblastoma and ganglioneuroma were separated with 100% sensitivity (16/16 
neuroblastoma) and 100% specificity (5/5 ganglioneuroma).  These results are 
summarized in Table 2.2. 
Ganglioneuroma was separated from normal adrenal gland with 100% sensitivity 
(189/189 ganglioneuroma spectra correctly identified) and 94.8% specificity (74/78 
adrenal gland spectra correctly identified).  The four misclassified normal spectra came 
from two different tissues (2/22 and 2/55 spectra misclassified).  The tissue level 
classification was 100% sensitivity and 100% specificity, as shown in Table 2.2. 
A three-group analysis was performed between normal adrenal gland, 
neuroblastoma, and ganglioneuroma.  The results are shown in Table 2.3.  While each 
39 
 
these tissues were easy to distinguish in a two-group model, any of the three may be 
present in a clinical example.  Overall classification was 90%, with 91% of normal 
adrenal gland correctly identified, 87.1% of neuroblastoma correctly identified, and 
94.2% of ganglioneuroma spectra correctly identified. 
 
Classification Resultsa 
  
Diagnosis Predicted Group Membership 
Total   Normal Neuroblastoma Ganglioneuroma 
Original Count Normal 71 6 1 78 
Neuroblastoma 0 263 39 302 
Ganglioneuroma 0 11 178 189 
% Normal 91.0 7.7 1.3 100.0 
Neuroblastoma .0 87.1 12.9 100.0 
Ganglioneuroma .0 5.8 94.2 100.0 
a. 90.0% of original grouped cases correctly classified. 
Table 2.3: Three-group classification results for discrimination between normal adrenal 
gland, neuroblastoma, and ganglioneuroma. 
 
Figure 2.2 shows a plot of the discriminant function scores for the analysis.  
Normal adrenal gland spectra were represented in a single group, while there was some 
overlap between the neuroblastoma and ganglioneuroma groups. 
Finally, neuroblastoma was compared to peripheral nerve sheath tumor and 
pheochromocytoma.  Summarized results are shown in Table 2.2.  Neuroblastoma and 
peripheral nerve sheath tumor were separated with 79.5% sensitivity and 85.1% 
specificity.  At the tissue level, two neuroblastoma and two nerve sheath tumors were 
misclassified.  Neuroblastoma and pheochromocytoma were distinguished with 100% 
sensitivity and 81.1% specificity at the spectral level and 100% sensitivity and specificity 
at the tissue level.  Nerve sheath tumors and maturing neuroblastomas and 
ganglioneuromas both display a collagenous Schwannian stromal component.  On 
examination of the mean Raman spectra, nerve sheath tumors had higher intensities at 
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854, 938, 1003, 1447, and 1657 cm-1.  These peaks have all been associated with 
protein and collagen components (Shim, M. G. Wilson, B. C., 1997). 
 
 
Figure 2.2:  Discriminant function results show separation between normal adrenal 
tissue and neuroblastoma and ganglioneuroma.  Results (circled) also show an overlap 
between neuroblastoma and ganglioneuroma. 
 
 
2.4 Conclusions 
This study suggests that Raman spectroscopy can be used to distinguish 
between neuroblastoma, adrenal gland, and other tumors of neural origin, including 
ganglioneuroma, peripheral nerve sheath tumor, and pheochromocytoma.  
Neuroblastoma was differentiated from each of these tissues with high sensitivity and 
specificity.  This is the first study to apply Raman spectroscopy to the diagnosis of 
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neuroblastoma, and the first study applying Raman spectroscopy to any pediatric 
cancer. 
Visual examination of the mean spectrum of each tissue provided biochemical 
support towards validating Raman spectroscopy.  In general, malignant tissues had 
higher protein content.  This is consistent with previous findings (Malini, R. et al., 2006).  
Likewise, neuroblastoma and ganglioneuroma had significantly lower intensities at 
carotenoid peaks, signifying a lower carotenoid concentration.   Again, this is consistent 
with previous findings which suggest that carotenoids can prevent the cancer process in 
colon, liver, skin, lung, and mammary gland (Hata, T. R. et al., 2000). 
In the future, a cancer biologist will be consulted for further biochemical analysis 
of experimental Raman spectra.  A biologist will be able to correlate the changing 
biochemistry with specific biologic processes.  With this knowledge, Raman can be 
exploited not just as a diagnostic tool, but also as a basic science tool. 
Data was compressed twice before performing discriminant function analysis 
(binning and principal component analysis) because existing software and hardware 
capabilities did not allow for analysis of the full spectral data.  Even this simplified 
analysis method was able to provide a highly accurate diagnosis.   
This method, however, does not provide biochemical information about the data. 
In order to confirm that the peaks which were visually identified as significant are truly 
significant, another analysis method must be used.   
When comparing two groups of tissue at a time, different pathologies could all be 
distinguished with 100% sensitivity and specificity, except neuroblastoma and nerve 
sheath tumor.  This suggests that there is a level of similarity between neuroblastoma 
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and nerve sheath tumor.  To improve this classification result, more data can be added 
to both groups.  Alternate classification methods, such as neural networks, support 
vector machines, or logistic regression can also be used to try to improve classification 
(Krafft, C. et al., 2009). 
Three-group analysis comparing normal adrenal gland, neuroblastoma, and 
ganglioneuroma provided 90% overall accuracy, however, neuroblastoma was only 
classified with 87.1% accuracy.  It is notable that neither neuroblastoma nor 
ganglioneuroma had any spectra misclassified as normal adrenal gland.  This shows a 
high sensitivity, as no false negatives were identified during the analysis.  Because 
neuroblastoma is a spectrum disorder with ganglioneuroma, it is not unusual that it 
would be slightly more difficult to distinguish between those two diseases. 
In order to further validate these results, more data must be collected and blinded 
studies must be performed.  Because these tumors are exceedingly rare, building a 
database of samples fresh from the operating room would take years.  Chapter 3 
examines the use of frozen tissues in data analysis to develop a classification database 
more expediently, and Chapter 6 describes a blinded study carried out with the 
Children’s Oncology Group to test the classification database.     
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CHAPTER 3 INCLUSION OF FROZEN TUMORS IN TISSUE STUDIES 
3.1 Introduction 
In the previous study, it was shown that Raman spectroscopy can accurately 
identify neuroblastoma from adrenal gland and other neural tumors, including 
ganglioneuroma, peripheral nerve sheath tumor, and pheochromocytoma.  Conceivably, 
one could build an extensive Raman spectra database of these tissues which could be 
used to diagnose new tumor incidences. 
While this finding is significant, there is still a dilemma in developing the Raman 
spectral database because of the low incidence of these tumors.  For example, there 
are between 400-650 cases of neuroblastoma diagnosed annually in the United States 
("What Are the Key Statistics About Neuroblastoma?," 2009; Young Jr, J. L. et al., 
1986).  To develop a database of these tumors at a single institution, even a pediatric-
specialty hospital, would take years.  Furthermore, shipping fresh samples between 
institutions poses another set of logistical dilemmas. 
Rather than focusing on only fresh from the operating room samples, this chapter 
focuses on the inclusion of frozen samples into the Raman spectral database.  It is 
known that formalin-fixed tissues are less than ideal for Raman spectroscopic 
measurement because the fixation causes cross-linking of the collagen proteins, 
thereby altering the molecular vibrations and Raman spectrum of the sample (Huang, Z. 
et al., 2003a).  This makes formalin-preserved tissues poor candidates for database 
development for identification of fresh tissues. 
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Several investigators have used frozen tissue samples in their Raman 
spectroscopic investigations (Crow, P. et al., 2005b; Haka, A. S. et al., 2005), however 
there is minimal, if any literature pertaining to the validity of frozen tissue use.      
A histologic study performed on frozen liver and heart tissues showed smaller 
cells after freezing, with larger extracellular spaces.  The changes became more 
pronounced over time.  Furthermore, specific types of tissue react differently to freezing.  
For example, skeletal muscle and skin tend to harden after the freeze-thaw cycle, 
whereas spleen and brain tissues tend to soften (Schäfer, A. T. Kaufmann, J. D., 1999).  
It is not known how such changes would affect Raman spectroscopic measurements of 
frozen tissues.   
A 1996 study recommended that the optimal preservation method for samples to 
be tested with Raman spectroscopy was freezing in optimal cutting temperature 
medium (OCT) (Shim, M. G. Wilson, B. C., 1996).  While many researchers seemed to 
follow similar guidelines, there was little attention paid to the advances in measurement 
technique and processing since the time this paper was published.  For example, the 
spectral resolution of the system described by Shim was 8 cm-1; the resolution of the 
system used for studies described in this text was 3 cm-1.   
3.1.1 Research Goal 
The goal of this chapter is to determine whether Raman spectra of frozen tissues 
are a valid replacement for measurements of fresh tissues.  This was studied in-depth in 
1996, but has not been re-examined in the literature since then, even with major 
technological advances in Raman spectroscopic measurement and analysis.  Spectra of 
peripheral nervous system tumors were collected frozen and compared to that of the 
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tumors measured fresh in Chapter 2.  To judge classification, frozen tissues were 
classified based on a fresh model, and fresh tissues were classified based on a frozen 
model. 
3.2 Materials and Methods 
3.2.1 Data Collection from Fresh Tumors 
The Raman spectra collected and described in Chapter 2 were used as the fresh 
samples for this study.  Any fresh samples which became available throughout the 
period of data collection for frozen tumors were also included in the study.  In these 
cases, the sample was divided into a piece for routine pathology and a piece for Raman 
spectroscopy, as described previously.  In this case, however, the portion reserved for 
Raman spectroscopy was further divided into a piece to test fresh and a piece to test 
frozen, if enough tissue was available.  The portion set aside to test frozen was placed 
in a labeled cryovial or eppindorf tube, and then put in the freezer for testing at a later 
date.  All fresh tissues tested were preserved in formalin and later cut and stained for 
histology review by a trained pathologist as described in Chapter 2.  
3.2.2 Data Collection from Frozen Tumors 
Prior to initiating this study, a preliminary study was performed on fresh (never 
frozen) and frozen chicken muscle, fat, and bone obtained from a butcher to determine 
the best protocol for testing frozen samples (results not published).  Information from a 
literature review was also used to develop the frozen tumor measurement protocol. 
Whenever there was excess fresh tissue available from a pathology case, it was 
placed in a cryovial with no preservatives or fixatives, labeled, and put in a -80°C 
freezer to freeze slowly.  The minimum freezing time for a sample was 24 hours; 
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however, some samples were banked by pathologists for several years, and then pulled 
for Raman testing. 
Before Raman testing, the sample was removed from the freezer.  The cryovial 
was filled with room-temperature saline and the specimen was allowed to defrost for 30 
minutes.  When the sample was thoroughly defrosted, it was removed from the vial and 
placed on a glass microscope slide for Raman testing.  At this point, the sample was 
measured with the same procedures as the fresh samples, described in section 2.2.2.  
Following measurement, the sample was placed in fixative and sent for routine 
pathology testing. 
3.2.3 Data Processing and Analysis 
Raw data was stored on a secure server, and measurement parameters were 
stored in a customized database.  Raw files were preprocessed, reviewed, binned, and 
imported into SPSS as described in Chapter 2 and Appendix B. 
Data was then split into two groups: spectra which were measured from fresh 
specimens (called ‘fresh’ hereafter), and spectra which were measured from frozen, 
defrosted specimens (called ‘frozen’ hereafter).  Principal component analysis and 
discriminant function analysis were performed on the fresh data, and then both models 
were applied to the frozen data.  This showed how well the fresh data model could 
classify the frozen data.  Next, principal component analysis and discriminant function 
analysis were performed on the frozen data, and then applied to the fresh data.  This 
showed how well the frozen data model could classify frozen data.  For each 
comparison, separate models were created. 
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Sensitivity, specificity, and accuracy were used to judge the classification 
methodologies.  They were calculated at the spectral level and at the tissue level, were 
the tissue diagnosis was made based on the majority of the individual spectra. 
3.3 Results 
62 tissues were measured for this experiment.  45 of the samples were only 
measured fresh.  Three samples came from the frozen tumor bank and were only 
measured frozen.  Fourteen samples were split and tested both fresh and frozen. 
The resulting data set consisted of 862 Raman spectra from 59 fresh tissue 
samples, and 252 Raman spectra from 17 frozen tissue samples.  Table 3.1 shows the 
exact number of spectra measured for each fresh and frozen tissue type, as well as the 
total number of specimens examined.   
 
 Fresh  Frozen  Total 
Spectra 
 Specimens Spectra Specimens Spectra  
Adrenal Gland 8 69 1 9 78 
Neuroblastoma 26 416 11 141 557 
Ganglioneuroma 14 206 2 22 228 
PNST 8 117 1 12 129 
Pheochromocytoma 3 54 2 68 122 
Total 59 862 17 252 1114 
Table 3.1: Number of fresh and frozen specimen and spectra measured for each type of 
tissue. 
 
Figure 3.1 shows the fresh and frozen mean spectrum for each tissue type.  
Notice that overall, there is close correlation between fresh and frozen.  Most peaks 
were preserved along the x-axis (wavenumber) with only minor shifts in the vertical axis 
(intensity). 
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Figure 3.1: Mean fresh (solid black line) and frozen (dotted line) spectra of normal 
adrenal gland, neuroblastoma, ganglioneuroma, nerve sheath tumor, and 
pheochromocytoma. 
 
 
 Table 3.2 compares the tissue-level classification results using frozen data tested 
on a fresh model, fresh data tested on a frozen model, and fresh-only results obtained 
in Chapter 2.  Table 3.3 shows the same results at the spectra-level. 
When frozen data was tested with the fresh model, normal adrenal gland was 
distinguished from neuroblastoma, ganglioneuroma, nerve sheath tumor, and 
pheochromocytoma with 100% sensitivity and specificity.  Likewise, neuroblastoma and 
ganglioneuroma were separated with 100% sensitivity and specificity at the tissue level.   
When fresh data was tested against the frozen model, normal adrenal gland was 
distinguished from neuroblastoma, ganglioneuroma, and pheochromocytoma with 100% 
sensitivity and specificity at the tissue level.  All normal tissues were distinguished from 
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nerve sheath tumor, but one of seven nerve sheath tumors was classified as normal 
adrenal gland tissue.  When neuroblastoma and ganglioneuroma were compared, 5 of 
14 ganglioneuroma were misclassified as neuroblastoma, and 5 of 26 neuroblastoma 
were misclassified and ganglioneuroma. 
 
 NB v 
Normal 
GN  v 
Normal 
NST v 
Normal 
Pheo v 
Normal 
NB v GN 
 Sen Spec Sen Spec Sen Spec Sen Spec Sen Spec 
Fresh Model 
Frozen Test  
100 100 100 100 100 100 100 100 100 100 
Frozen 
model 
 Fresh test 
100 100 100 100 87.5 100 100 100 80.8 64.3 
Fresh only 
(Chapter 2) 
100 100 100 100 100 100 100 100 100 100 
Table 3.2: Tissue-Level Classification Results (results shown are percentages; (AG = 
adrenal gland, NB = neuroblastoma, GN = ganglioneuroma, Pheo = 
pheochromocytoma, NST = nerve sheath tumor, Sen = sensitivity, and Spec = 
specificity) 
 
 
Frozen ganglioneuroma and nerve sheath tumor were classified from frozen 
adrenal gland with 100% sensitivity and specificity.  All 141 frozen neuroblastoma 
spectra were correctly separated from frozen adrenal gland when tested against the 
fresh model; however two of nine of the frozen adrenal gland spectra were called 
neuroblastoma.  Only one of 68 pheochromocytoma spectra was misclassified when 
compared to adrenal gland.  All adrenal gland spectra were correctly identified from 
pheochromocytoma when frozen spectra were tested with the fresh model.  When 
neuroblastoma and ganglioneuroma were compared, just 1 of 141 neuroblastoma 
spectra was misclassified.  All ganglioneuromas were correctly identified.  
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NB  
v Normal 
GN   
v Normal 
NST  
v Normal 
Pheo  
v Normal 
NB v GN 
 
Sen Spec Sen Spec Sen Spec Sen Spec Sen Spec 
Fresh Model 
Frozen Test 
100 77.8 100 100 100 100 98.5 100 100 99.3 
Frozen model 
Fresh test 
98.8 91.3 100 91.3 86.3 97.1 100 88.4 84.1 69.9 
Fresh only (Chapter 
2) 
100 92.3 100 94.8 100 94.9 100 97.4 95 96 
Table 3.3: Individual Spectra Classification Results (results shown are percentages; 
(AG = adrenal gland, NB = neuroblastoma, GN = ganglioneuroma, Pheo = 
pheochromocytoma, NST = nerve sheath tumor, Sen = sensitivity, and Spec = 
specificity) 
 
When fresh neuroblastoma was compared to normal adrenal gland based on the 
frozen model, only 5 of 416 neuroblastoma and 6 of 69 adrenal gland spectra were 
misclassified.  When ganglioneuromas were compared to adrenal gland, 6 of 69 adrenal 
gland spectra were misclassified and all ganglioneuroma spectra were correctly 
identified.  16 of 117 nerve sheath tumor and 2 of 69 adrenal gland spectra were 
misclassified when those groups were compared.  3 normal adrenal gland spectra were 
misclassified when compared to pheochromocytoma.  All pheochromocytoma spectra 
were identified correctly. 
3.4 Conclusions 
This study showed that a fresh tissue model could be used to classify frozen 
tissues, and a frozen tissue model could be used to classify fresh tissues.  Normal 
adrenal gland tissue was separated from neuroblastoma, ganglioneuroma, nerve sheath 
tumor, and pheochromocytoma, and neuroblastoma was distinguished from 
ganglioneuroma with high sensitivity and specificity at the tissue level and at the 
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spectral level.  The tissue-level and spectra-level results obtained were comparable to 
the results found in Chapter 2 using only fresh tissues. 
Likewise, there was high correlation between the mean fresh and frozen 
spectrum for each type of tissue.  There was little horizontal shift in peaks, although 
there were some differences in peak intensities.  Some of these differences appear to 
be due to normalization or background subtraction of the original data.  Fine-tuning of 
background subtraction methods may make the differences between fresh and frozen 
tissues even more subtle.  For example, the mean fresh Raman spectra of both normal 
adrenal gland and nerve sheath tumor display maximum values around 0.75, while a 
maximum value of 1 would be expected.  This could signal that there are multiple 
populations within the data where background subtraction created maximum values at 
points other than ~1320 cm-1.  Further review of the individual spectra for both fresh 
groups could show populations being normalized to different wavenumbers.  This could 
signal multiple populations within the data, or it could signal multiple background 
fluorescence signals which are not properly or uniformly subtracted using the existing 
automatic background subtraction methodology. 
In the cases of normal adrenal gland, ganglioneuroma, and nerve sheath tumor, 
less than 25 spectra were collected from frozen tissue.  With a sample size this small, 
differences from the mean fresh spectra might simply be due to measurement of a non-
tumor area, or purely from the small sample size. 
Other reasons for differences between the fresh and frozen mean spectra from 
each tissue type could be caused by physical changes to the tissue caused by freezing.  
For example, when the cell membranes rupture, it disrupts the molecular bonds within 
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the cell wall.  This will contribute to changes in the Raman signature, but it is not known 
how strong the impact will be.    
 Classification results of fresh tissue based on a frozen model were less than 
100% in some cases.  The size of the frozen tissue model was substantially smaller 
than that of the fresh tissue model (about ¼ of the total data).  Every group except 
neuroblastoma only had one or two frozen cases.  This does not offer enough variation 
to build a robust classification model.  As more samples are added to the frozen tissue 
model, classification of new, unknown tissues should improve dramatically. 
Additionally, a histological review of the frozen tissue sections offers another 
potential cause for misdiagnosis.  Within the subset of frozen neuroblastoma tissues, 
one case of neuroblastoma was actually a ganglioneuroblastoma which had distinct 
regions of mature ganglioneuroma cells with islands of immature neuroblasts.  Tissues 
were classified as neuroblastoma even if they had only a few neuroblast cells.  Although 
the tissue in question looked predominantly like a ganglioneuroma, it was still called 
neuroblastoma because of the presence of neuroblast cells.  It is possible that Raman 
measurement missed these islands of neuroblast cells.  In the future, detailed scanning 
studies will determine the optimal minimum area to be measured with each scan.    
Another tissue was a chemotherapy-treated neuroblastoma which had mostly 
mature cells with a region of immature neuroblast cells which appeared to be from a 
different clone than the mature cells.  Because 2 out of 11 (18%) of the neuroblastoma 
samples in the frozen training model displayed non-textbook histology, this could cause 
a skew to the frozen tissue model.   
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The overall results suggest that the tissue changes due to the freeze-thaw 
process may not be significant in Raman diagnosis.  While it is known that freezing 
causes cells to shrink, and may cause rupture of cells by ice crystals, it has not yet been 
specifically defined how this would alter the Raman spectrum (Schäfer, A. T. Kaufmann, 
J. D., 1999).  For the time being, it does appear that inclusion of frozen tumor samples 
in studies applied to fresh tissues is still a valid technique. 
This study implies that in might be possible to build a classification model based 
on frozen tissues from a cryopreserved tissue bank which could then be used to classify 
fresh tissues.  This would allow rapid development of a large database of tissues which 
could include both common and extremely rare tissues.  When Raman spectroscopy is 
combined with real-time software and a diagnostic model, nearly any tissue could be 
identified, potentially even from the operating room.  An immediate diagnosis would 
offer a huge advantage over the traditional frozen section diagnosis.  Frozen section 
diagnosis takes 20-30 minutes, and does not guarantee 100% accuracy.  Raman might 
offer a near-real-time alternative with accuracy at least as good as the frozen section.     
Furthermore, with proper privacy practices established, Raman spectra collected 
from a frozen tumor bank can be combined with other patient information, including 
treatment information and outcome.  It might be used to determine the optimal treatment 
method or measure the effect of chemotherapy throughout treatment.  
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CHAPTER 4 IDENTIFICATION OF NEUROBLASTOMA FROM SMALL ROUND 
BLUE CELL TUMORS 
4.1 Introduction: Small Round Blue Cell Tumors 
The purpose of the previous chapters was to identify neuroblastoma from adrenal 
gland, it’s most common origin site, and from other neural-derived tumors, including 
ganglioneuroma, nerve sheath tumor, and pheochromocytoma.  The goal of this chapter 
is to distinguish neuroblastoma from other tumors which have similar histology but 
which are not neural-derived.  In cases where neuroblastoma is found outside the 
adrenal gland, it must also be distinguished from these histologically similar tumors. 
Neuroblastoma is a small round blue cell tumor (SRBCT).  The main types of 
small round blue cell tumors are neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, 
and non-Hodgkin lymphoma (Chen, Q.-R. et al., 2007; Gregorio, A. et al., 2008).  
Differentiation between these types of tumors is difficult, especially when the clinical 
context is unusual.  Accurate diagnosis is essential with small round blue cell tumors 
because the treatment methods vary for each type of tumor (Chen, Q.-R. et al., 2007).  
Most commonly, diagnostic confusion occurs when a tumor metastasizes to a distant 
location, or when the tumor presents as a large mass in the abdomen and the exact 
origin cannot be determined (Orkin, S. H. et al., 2009). 
The mean age at diagnosis for neuroblastoma, non-Hodgkin’s lymphoma, Ewing 
sarcoma, and rhabdomyosarcoma are shown in Table 4.1 (Cotran, R. S. et al., 1994). 
 
0-4 years old 5-9 years old 
Neuroblastoma Neuroblastoma 
 Ewing’s Sarcoma 
Rhabdomyosarcoma  
 non-Hodgkin Lymphoma 
Table 4.1: Most commonly diagnosed ages for each small round blue cell tumors. 
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4.1.1 Non-Hodgkin Lymphoma 
Non-Hodgkin lymphomas are derived from lymph tissue and its cells, including 
lymphocytes, histiocytes, and their precursor cells.  Non-Hodgkin lymphoma 
encompasses several sub-types, and a variety of systems exist for their classification.  
The most widely-accepted grouping is the ‘World Health Organization Classification of 
Tumors of the Hematopoietec and Lymphoid Tissues’.  This separates tumors based on 
the parent cell (B-cell, T-cell, or natural killer cell), then further groups tumors based on 
histology, genetics, immunophenotype, and clinical presentation.  Pediatric tumors of B-
cell origin include Burkitt’s lymphoma, diffuse large B-cell lymphoma, and primary 
mediastinal large B-cell lymphoma (Orkin, S. H. et al., 2009).  T-cell originating tumors 
include anaplastic large cell lymphoma and peripheral T-cell lymphoma. 
4.1.2 Ewing Sarcoma 
Ewing sarcomas are found predominantly in bone, though they can also be found 
in other soft tissues.  Histologically, the tumor cells often appear to be of neural origin 
(Cotran, R. S. et al., 1994) and show similar histology patterns to neuroblastoma, 
however the progenitor cells may actually be mesenchymal stem cells (Meltzer, P. S., 
2007). 
4.1.3 Rhabdomyosarcoma 
Rhabdomyosarcoma is the most common soft tissue tumor in children (Cotran, 
R. S. et al., 1994).  The progenitor cell is the rhabdomyoblast, which is a primitive 
muscle cell.  In the arms and legs, rhabdomyosarcoma is typically associated with 
skeletal muscle, however, in the rest of the body, it is typically found in areas with 
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minimal skeletal muscle, including the retroperitoneum, head and neck, and 
genitourinary track. 
Embryonal rhabdomyosarcoma, including botryoid type, is the most common 
subtype of rhabdomyosarcoma (Cotran, R. S. et al., 1994).  It is typically diagnosed in 
children less than 10 years old.  The rhabdomyoblasts mimic muscle cells at differing 
points of embryonic development, including both round cells and spindle cells.  
4.1.4 Existing Diagnostic Methods for Small Round Blue Cell Tumors 
There are several methods for differentiating specific types of small round blue 
cell tumors, including immunohistochemistry (Finegold, M. J. et al., 1983; Gregorio, A. 
et al., 2008), cytogenetics including fluorescence in situ hybridization (Taylor, C. et al., 
1993), and polymerase chain reactions (PCR) (Chen, Q.-R. et al., 2007), and 
complementary DNA microarrays (Khan, J. et al., 2001). 
One of the more common methods uses groups of antibodies which recognize 
markers within specific types of tumors (Gregorio, A. et al., 2008).  This is known as 
immunohistochemistry.  There is no single antibody or test, however, which can 
clinically differentiate all the sub-types of small round blue cell tumors.  Most research in 
developing diagnostic tests for small round blue cell tumors involves searching for new 
antibodies which can better identify tumor markers of the specific tumor types (Gregorio, 
A. et al., 2008).  The downside of immunohistochemical methods is that they can only 
examine one protein or tumor marker at a time (Chen, Q.-R. et al., 2007). 
Khan et al. used complementary DNA (cDNA) microarrays to identify 131 genes 
which have diagnostic capability for small round blue cell tumors (Khan, J. et al., 2001).  
They were able to predict disease classification using supervised clustering methods.  
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In 2007, the National Cancer Institute and Althea Technologies announced a 
methodology “capable of accurately differentiating the common forms of the disease: 
neuroblastoma, rhabdomyosarcoma, non-Hodgkin's lymphoma, and Ewing's family of 
tumors” ("Althea Technologies Announces the Development of a Diagnostic Capable of 
Differentiating Multiple Forms of Childhood Cancer," 2007).  It allows a diagnosis based 
on a single test, rather than a series of up to six immunohistochemistry tests.  The test 
was developed by using complementary DNA microarrays to identify genes which have 
diagnostic capabilities (Chen, Q.-R. et al., 2007).  39 total genes were selected for the 
final test, and neural networks were used to build a classification model.  Next, a 
reverse transcription polymerase chain reaction (PCR) assay was developed to 
measure the gene levels and make a tissue diagnosis (Chen, Q.-R. et al., 2007).      
The PCR test developed by Chen et al. is simpler and cheaper than the standard 
immunohistochemistry methods, and  the required sample size is much smaller (Chen, 
Q.-R. et al., 2007).  The turnaround time, however, is still 48 hours, and samples must 
be sent to an outside lab for the testing.  The test and laboratory were CLIA certified in 
2009 and began the FDA approval process.  The test is still not real time, however, and 
it requires a specialized lab and lab technician to perform the test.  The test began FDA 
testing in 2009 ("Childhood Cancer Panel," 2008). 
Raman spectroscopy offers several distinct advantages over this test, which is 
the current ‘state-of-the-art’.  A Raman diagnosis can be made in minutes, right from the 
operating room or pathology lab without the need for specialized laboratory equipment 
or technicians.  Sensitivity and specificity of previous work, including identification of 
neuroblastoma from other nervous system tumors are comparable to the sensitivity of 
58 
 
the Althea Technologies test.  Assuming similar results in identification of small round 
blue cell tumors, Raman spectroscopy could offer equally accurate results in a fraction 
of the time.   
4.2 Materials and Methods 
4.2.1 Sample Measurement 
Fresh and frozen samples of untreated neuroblastoma, Ewing sarcoma, 
rhabdomyosarcoma, and non-Hodgkin lymphoma were collected fresh from the 
operating room or frozen from our tumor bank.  Frozen tissues were included in the 
study without confirmatory analysis because our results from Chapter 2 suggested 
frozen tissues were comparable to their frozen counterparts. 
Half of each tumor sample was used for routine pathology, and half was used for 
Raman analysis using the same protocols described in Chapters 2 and 3.  Because the 
small round blue cell tumors display extremely similar histological characteristics, 
pathology techniques other than light microscopy were necessary for tumor diagnosis.  
Other techniques which were used to diagnose the control pathology tissue sample 
include conventional karotyping, FISH analysis, immunohistochemical staining, and 
electron microscopic examination as needed.   
After Raman measurement, a hematoxylin-eosin slide was created from the 
Raman sample to confirm tumor presence in that region of tissue.  Pathology diagnosis 
was not made based on microscopy review of the Raman sample, however, the 
pathologist did confirm that the Raman sample had similar histology to the gold 
standard pathology sample. In order to ensure the ‘purest’ samples, all treated tumors, 
tumors which displayed sparse malignant cells, and tumors with tissue damage such as 
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necrosis, freezing artifact, or trauma from surgery were excluded from the study.  This 
selection process was more rigorous than that used for identification of neural-derived 
tumors, but it ensured that all samples included were predominantly composed of viable 
tumor.  The goal of this study was to distinguish different types of tumors, rather than 
distinguish tumors from normal tissue.  This is the reason for exclusion of less than pure 
tumor samples. 
4.2.2 Data Processing 
Data was pre-processed, binned, and imported into SPSS as described in 
Chapter 2.  A mean spectrum was calculated for each type of tumor.  Confirmatory 
analysis using Principal Component Analysis and Discriminant Function Analysis was 
performed to ensure that the tissues could be separated.   
Once confirmatory analysis proved successful, a more detailed analysis was 
performed to identify specific peaks or regions of peaks which were diagnostically 
significant.  Preprocessed, unbinned data were entered into SPSS.  Unbinned data was 
used to obtain the most detailed possible information about the relevant peaks.  
Discriminant function analysis was performed on this data.  The table containing the 
standardized canonical discriminant functions was exported from SPSS.  This table 
contained a list of all peaks which were diagnostically significant in the analysis; 
however, one drawback of this table is that it tended to give higher significance to peaks 
with lower wavenumbers.  This is purely because they were entered into the analysis 
first.   
To combat this issue, the standardized canonical discriminant functions were 
further tested to reach the optimal combination of diagnostic peaks.  Some of the peaks 
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represent redundant variation that is already explained by other peaks, and others are 
due to artificial weighting at the lower wavenumbers.  An iterative process was followed 
to remove redundant peaks and come to as small of a peak set as possible.   
First, all the peaks from the standardized canonical discriminant functions table 
were entered into a discriminant function analysis.  A peak or a combination of peaks 
was then removed from the list and the discriminant function analysis was run again.  
Initially, a peak was be selected for removal if it had a low standardized canonical 
discriminant function value, or if it was very close to another peak(s) included in the 
standardized canonical discriminant functions (such as 745, 746, 748 cm-1). 
If the classification results improved, the peak could safely be removed from the 
analysis.  If the classification results got worse, the peak was again included in the 
analysis, and a new peak was selected for removal.  The process of peak removal 
continued in this manner until all peaks in the model were tested, and none could be 
removed without lowering classification results.  The peak selection process is 
illustrated in a flowchart in Figure 4.1. 
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Figure 4.1: Decision Tree for discriminant function analysis peak selection 
 
When the in-depth peak analysis was performed, a peak was excluded due to a 
low weighting value in the standardized canonical discriminant function table, or 
because it was a low wavenumber, or because there were two adjacent peaks which 
did not likely offer and more diagnostic ability than a single peak.  After several peaks 
were removed, it became more difficult to judge which peaks could be removed.  In this 
case, peaks were removed one-by-one until a peak which was not necessary for 
analysis was found. 
Once the maximal spectral classification was reached, each tissue was again 
assigned an overall diagnosis.  In the future, when an optimal classification model is 
determined, new tissues can be quickly diagnosed using the same model.  As the size 
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of the data set increases, however, the data model should be revisited for validation 
purposes. 
The combination of peaks which provided the highest diagnostic accuracy using 
discriminant function analysis was found.  Then, the minimum combination of peaks 
which was necessary to identify all tissues with 100% accuracy was found.  Data was 
analyzed at the individual spectra level, and then the tissue level results were calculated 
using the majority spectra rule. 
4.3 Results 
4.3.1 Tissues Studied 
Table 4.2 shows the data available for this study.  The data set included 179 
neuroblastoma spectra from 9 surgical cases, 37 Ewing sarcoma spectra from 3 
surgical cases, 100 non-Hodgkin lymphoma spectra from 6 surgical cases, and 164 
rhabdomyosarcoma spectra from 4 surgical cases.  Because some tumors had a large 
volume of viable tumor tissue, multiple samples were taken from some surgical cases.  
  
 Surgical Cases Samples Spectra 
Neuroblastoma 9 11 179 
Ewing Sarcoma 3 3 37 
non-Hodgkin Lymphoma 6 7 100 
Rhabdomyosarcoma 4 11 164 
TOTAL 22 32 480 
Table 4.2: Samples and spectra used for identification of neuroblastoma from other 
small round blue cell tumors. 
 
 
4.3.2 Visual Inspection of Raman Spectra 
The mean spectrum and a representative hematoxylin-eosin microscopy image 
for neuroblastoma, Ewing sarcoma, non-Hodgkin lymphoma, and rhabdomyosarcoma 
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are shown in Figure 4.2.  There were clear differences between each of the tissues.  
Some of the obvious changes are circled in Figure 4.2. 
Neuroblastoma lacked the shoulder region in the range 1230.5-1275.0 cm-1.  It 
had a distinct signature in the range of 1500-1659 cm-1, but it was not as predominant 
as the signature for Ewing sarcoma. 
753.7, 1230.5, and 1630.9 cm-1 are all associated with tryptophan.  Ewing 
sarcoma had the highest intensity at each of these peaks.  It also had the highest value 
at the diagnostic peaks 1540.6, 1567.2, 1571.5, 1608.9, 1630.9, 1653.7, and 1655.4 
cm-1, which were all within the range of 1500-1659 cm-1 where it had a strong signature.  
Finally, Ewing sarcoma had a significant valley at 793.5 cm-1 which was not present in 
the other tissues. 
The rhabdomyosarcoma and non-Hodgkin lymphoma spectra displayed only 
slight differences from each other.  They lacked the strong signature between 1500 and 
1659 cm-1 which was present in neuroblastoma and Ewing sarcoma.  
Rhabdomyosarcoma had a strong shoulder from 1230.5-1275.0 cm-1 while non-Hodgkin 
lymphoma had only a subtle shoulder.  Other characteristics which visually 
distinguished non-Hodgkin lymphoma from rhabdomyosarcoma were higher-intensity 
peaks at 1092.5 and 1446.1 cm-1 in non-Hodgkin lymphoma. 
4.3.3 Confirmatory Analysis 
Confirmatory analysis correctly classified 90.4% of spectra using principal 
component analysis and discriminant function analysis.  At the tissue level, all samples 
were correctly correlated with the pathology gold-standard as neuroblastoma, Ewing 
sarcoma, non-Hodgkin lymphoma, or rhabdomyosarcoma.  
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Figure 4.2: mean spectrum and histology images of neuroblastoma, Ewing sarcoma, 
rhabdomyosarcoma, and non-Hodgkin lymphoma with key diagnostic peaks marked. 
 
 
4.3.4 Peak-by-Peak Analysis 
Using, leave-one-out discriminant function analysis, 18 peaks identified 
neuroblastoma, Ewing sarcoma, non-Hodgkin lymphoma, and rhabdomyosarcoma with 
94% accuracy.  All sample-level diagnoses were correct.  The 18 peaks were 676.2, 
729.7, 753.7, 793.5, 980.7, 1005.5, 1092, 1127.1, 1230.5b 1275.0, 1446.1, 1540.6, 
1567.2, 1571.5, 1608.9, 1630.9, 1653.7, and 1655.4 cm-1.  They are marked on Figure 
4.2. 
When determining the minimum number of peaks necessary to classify all 
tissues with 100% accuracy, only the following 10 peaks were needed: 676.2, 729.7, 
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793.5, 980.7, 1092.5, 1230.5, 1275.0, 1571.5, 1608.9, and 1655.4 cm-1.  These peaks 
are marked in Figure 4.2.  With this combination of peaks, spectral classification was 
87.9% accurate. 
4.4 Conclusions 
This is the first study using Raman spectroscopy to distinguish between 
neuroblastoma, Ewing sarcoma, non-Hodgkin lymphoma, and rhabdomyosarcoma, a 
class of cancers known as small round blue cell tumors. 
Each of the small round blue cell tumors has a low incidence.  Each year in the 
United States, there are about 387 neuroblastoma cases (other sources suggest the 
number may be slightly higher: 400-650 annual cases ("What Are the Key Statistics 
About Neuroblastoma?," 2009; Young Jr, J. L. et al., 1986)), 112 Ewing sarcoma cases, 
191 rhabdomyosarcoma cases, and 386 non-Hodgkin lymphoma cases (Young Jr, J. L. 
et al., 1986), totaling less than 1100 diagnoses of the four most common small round 
blue cell tumors.  In contrast, there are more than 214,000 new cases of breast cancer 
and 234,000 new cases of prostate cancer diagnosed annually in the United States 
("Cancer Facts & Figures 2006," 2006).  Even though the small round blue cell tumors 
only represent a fraction of the total number of annual cancer diagnoses, their similar 
histologies make them a major diagnostic problem. 
Current clinical diagnostic methods to identify small round blue cell tumors in 
addition to traditional hematoxylin-eosin staining with light microscopy include 
immunohistochemistry, fluorescence in-situ hybridization, electron microscopy, and 
karotyping.  To get a definitive diagnosis might take several days.  The current state-of-
the-art test is being developed by Chen et al using polymerase chain reaction and 
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artificial neural networks to find unique genetic profiles for each type of small round blue 
cell tumors.  The drawback to this test, however, is that is still has a 48-hour turnaround 
time.  An existing, traditional Raman spectroscopy system stationed in a pathology 
laboratory could provide a diagnosis within hours of tumor resection.  Classification time 
could be further reduced by introduction of a portable Raman spectroscopy surgical tool 
directly into the operating room.  In that case, a surgeon could theoretically obtain a 
diagnosis even before the tumor is removed. 
Discriminant function analysis showed that only 10-18 peaks were necessary to 
accurately classify the small round blue cell tumors.  At the tissue level, small 
combinations of peaks classify data as well as the full range of peaks.  Spectral-level 
classification actually improved when only peaks which were diagnostically significant 
were used.  Identifying peaks which are diagnostically significant allows a simpler 
measurement and classification method than using the whole range of wavenumbers.   
While the process of peak selection is time consuming, it allows much greater 
understanding of the Raman spectra.  In the future, the selection process might be 
automated to reduce the time necessary for peak selection.  The automation process 
could also address other questions regarding this technique, including whether the 
order of peak removal matters.  In the data described here, peaks were removed from 
the analysis based on the standardized canonical discriminant functions, then based on 
the proximity of other diagnostic peaks, or on the magnitude of the wavenumber with 
lower wavenumbers selected for removal first.  It is unknown whether the results of 
peak selection (including which peaks are selected as diagnostically significant, and the 
overall classification results ) would change if peaks were removed from low-
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wavenumber to high-wavenumber, vice-versa, or through another technique such as 
attempting to remove peaks in order of lowest standardized canonical discriminant 
function. 
Peak-wise analysis was not performed on data prior to this point because the 
computing and software capability were not available.  A new software release of SPSS 
combined with a better processing system allowed in-depth data analysis and peak 
selection, rather than an overall analysis which provided little information regarding 
underlying biochemical significance.  In the future, other data included in this research 
can be reviewed and processed using similar techniques to improve classification 
results and draw conclusions about the biological significance of the diagnostic peaks. 
Using select peaks also allows derivation of biochemically significant information 
from the data.  Peaks which are diagnostically different correlate to varying 
concentrations of specific chemical bonds and biochemicals.  As an example, 
tryptophan had the highest concentration in Ewing sarcoma, according to the peak 
intensities at 753.7, and 1230.5, cm-1.  An experienced cancer biologist might then be 
able to correlate this finding with the biology of Ewing sarcoma.  One possible 
explanation is that tryptophan is over-expressed in Ewing sarcoma because it is key 
component in the CD99 protein and the EWS/FLI-1 gene.  This hypothesis could only 
be proven with careful testing and review by an experienced cancer biologist, however. 
Neuroblastoma had the sample size of each tumor group.  As the number of 
specimen examined increases for neuroblastoma and for the other small round blue cell 
tumors, more variability will be introduced into the database.  This will have several 
implications.   
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First, peaks which were originally thought to be diagnostically significant may not 
actually be significant.  As the mean and standard deviation are adjusted to truly 
represent the total population for a given tumor, some peaks will become less significant 
while others become more significant.  This means the data and classification models 
need to be adjusted over time to accommodate the fluid model. 
Another implication is a broader range of tumors will be identifiable over time.  As 
the significant peaks are fine-tuned, and more tumors are added to the database, 
classification ability should become more sensitive and specific over time. 
Some of the Raman ‘peaks’ which were mathematically selected in data analysis 
actually correlated to valleys on the Raman spectra.  This signifies the lack of a 
chemical or a region between two chemicals, or it may represent a horizontal peak shift.  
793.5 cm-1 was a strong valley for Ewing sarcoma, and 1571.5 and 1630 cm-1 were 
valleys for both neuroblastoma and Ewing sarcoma.  Another feature which was 
identified through mathematical peak selection was a shoulder at 1275 cm-1.  Re-
measuring samples with a higher-resolution optical system might point to a combination 
of individual peaks which amounted to a shoulder using our existing optical system.  
Examination of these spectral features by an experienced biochemist or biologist may 
provide further insight towards the cause of these features.  
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CHAPTER 5 CLASSIFICATION OF UNFAVORABLE, FAVORABLE, AND TREATED 
NEUROBLASTOMAS 
5.1 Introduction 
Treatment and prognosis of neuroblastoma are based on several factors.  The 
stage of the disease describes whether the tumor has metastasized, or spread to other 
locations.  Histology markers are used to determine the Shimada favorability of the 
tumor.  This allows doctors to identify the tumor’s aggressiveness.  Finally, the advent of 
genetic testing allows physicians to identify several genetic factors associated with a 
good or poor prognosis (Cohn, S. L. et al., 2009).  Several different stratification 
methodologies exist for determining neuroblastoma prognosis.  In general, the 
methodologies used depend on the geographic location of the hospital (North America, 
Europe, Asia, and Australia each have slightly different methodologies) and the 
pathologists’ personal preference. 
5.1.1 Shimada Classification Based on Histology Findings 
In 1999, Shimada proposed a method for determining the favorability of 
neuroblastoma as favorable or unfavorable (Shimada, H. et al., 1999a).  It considers the 
patient’s age, development of stroma, grade of differentiation, and Mitosis Karyorrhexis 
Index (MKI).  MKI is defined as the number of cells experiencing mitosis (process of 
separation of two sets of chromosomes in a splitting cell) or karyorrhexis (fragmentation 
of nucleus in the dying cell; measurable by the irregular distribution of chromatin in the 
cell) in a count of 5,000 total cells (Shimada, H. et al., 1999b).  The pathologist must 
sample between six and twenty areas on the sample to count a total of 5,000 cells.  Low 
MKI is defined as less than two percent of cells in mitosis or karyorrhexis, intermediate 
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is defined as two to four percent of cells, and high is defined as four percent of cells or 
more in mitosis or karyorrhexis. 
Stromal cells are connective tissue cells.  In stroma-poor neuroblastomas, there 
is little separation between neuroblast cells, and the stromal cells are poorly developed.  
In stroma-rich and stroma-dominant neuroblastoma, there are more stromal cells which 
are more developed (Shimada, H. et al., 1999b).  
In differentiating neuroblastomas, at least 5% of cells are matured to ganglion 
cells.  Poorly differentiating neuroblastomas have less than 5% of cells matured to 
ganglion cells.  Ganglioneuroblastoma subtype exhibits a mix of neuroblastoma-like 
tumor and ganglioneuroma-like tumor (mature stromal cells with scattered mature 
ganglion cells).  The undifferentiated subtype has small, unidentifiable undifferentiated 
cells.  Generally, pathologic methods other than histology (such as electron microscopy, 
genetic testing) are required to identify undifferentiated tumors (Shimada, H. et al., 
1999b). 
This system became a standard because it strongly correlated with event free 
survival rates, and there is typically high rate of consensus among pathologists.  
Agreement can vary, however, based on the region of the tissue which is tested.  Some 
areas display different characteristics than others.  Table 5.1 shows the decision 
processing for diagnosing neuroblastoma as favorable or unfavorable, as well as 
ganglioneuroblastoma. 
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Prognosis Age Differentiation MKI Stroma 
Favorable <18 months poorly differentiated low - 
<18 months poorly differentiated intermediate - 
18 mo - 5 yr differentiating low - 
ganglioneuroblastoma rich 
Unfavorable <18 months undifferentiated - - 
<18 months - high - 
18 mo - 5 yr undifferentiated - - 
18 mo - 5 yr poorly differentiated - - 
18 mo - 5 yr - intermediate - 
18 mo - 5 yr - high - 
> 5 years - - - 
- ganglioneuroblastoma - composite 
Table 5.1: Definition of the Shimada system of classifying favorable and unfavorable 
neuroblastoma, ganglioneuroblastoma, and ganglioneuroma.  (adapted from (Shimada, 
H. et al., 1999a)) 
 
5.1.2 International Neuroblastoma Staging System 
In 1988, the International Neuroblastoma Staging System was established for 
staging neuroblastoma and the International Neuroblastoma Response Criteria was 
established to track response to treatment (Brodeur, G. et al., 1988).  This was revised 
in 1993 (Brodeur, G. et al., 1993).  Howman-Giles et al. summarized the stages as 
follows: 
“Stage 1: Localized tumor without regional lymph node involvement. 
Stage 2: Unilateral tumor with either incomplete gross resection or ipsilateral nodal 
involvement. 
Stage 3: Tumor that crosses the midline or has contralateral nodal involvement. 
Stage 4: Tumor disseminated to distant lymph nodes, bone, bone marrow, liver, etc. 
Stage 4S: Special category: age <1 year, localized primary tumor, dissemination 
only to liver, skin, or bone marrow.”  
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5.1.3 Other Prognostic Factors 
While the two previous methodologies, Shimada classification and International 
Neuroblastoma Staging System, are widely accepted for neuroblastoma diagnosis, 
several other markers exist which are associated with a good or poor prognosis.  
Prognostic markers cover a variety of information, from age to tumor markers (VMA, 
HVA, dopamine, ferritin levels, etc.) to histology (degree of differentiation, MKI, 
presence of stroma, etc) and genetics (growth fraction, N-myc copy number, presence 
or absence of oncogenes and tumor suppressor genes, etc)  (Brodeur, G. et al., 1993).  
Several other key markers are described below: 
Age: While age is included in the Shimada classification, it stands alone as a 
significant prognostic marker.  Children who are diagnosed younger than 18 months are 
likely to have a good outcome ("How is Neuroblastoma Staged?," 2009).  However the 
exception to this rule is that children diagnosed with stage 4S disease at less than 4 
weeks old tend to have higher mortality rates due to complications from disease (van 
Noesel, M. et al., 1997). 
Ploidy:  Ploidy is the number of sets of chromosomes in a cell.  Normal human 
cells are diploid, meaning they have two pairs of chromosomes.  Cells expressing more 
sets of chromosomes are called hyperdiploid.  For very young children, hyperdiploidy is 
associated with better outcomes ("How is Neuroblastoma Staged?," 2009). 
MYCN Amplification: MYCN is a proto-oncogene.  It normally prevents cells 
from multiplying too quickly, and it is normally expressed within a cell.  When the level of 
MYCN is amplified, however, it turns into an oncogene, meaning it makes the cell 
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cancerous.  MYCN over expression is associated with a poor prognosis ("How is 
Neuroblastoma Staged?," 2009). 
Nerve growth factor (neutrophin) receptors: Neutrophin receptors are located 
on the surface of normal neural cells.  They receive extracellular signals which induce 
the cell to mature.  The presence of neutrophins such as TrkA are associated with a 
favorable prognosis ("How is Neuroblastoma Staged?," 2009). 
Serum Markers: Neuroblastoma cells may release chemicals such as ferritin, 
neuron-specific enolase, or lactate dehydrogenase into the blood, which are all 
associated with a poor prognosis ("How is Neuroblastoma Staged?," 2009).  These can 
all be tested with blood serum tests.  Another substance, ganglioside GD2 may be 
overabundant in neuroblastoma as well, but it’s correlation to prognosis is not known 
("How is Neuroblastoma Staged?," 2009). 
5.1.4 International Neuroblastoma Risk Group Classification System  
The stage of the neuroblastoma is based solely on the patient age, the tumor’s 
location and the spread of disease, while the Shimada classification is based strictly on 
the tumor histology and patient age.  Meanwhile, a variety of other markers also exist 
for predicting patient prognosis as described above, including VMA, HVA, dopamine, 
and ferritin levels, growth fraction, MYCN copy number and other genetic factors, and 
age.  All of this information combined gives a more accurate prediction about the 
patient’s prognosis and the best form of treatment.  Based on these prognostic factors, 
patients are placed into low, intermediate, or high risk groups.  In general, the 5-year 
survival rates for these groups are 90-95%, 85-90%, and ~30%, respectively ("How is 
Neuroblastoma Staged?," 2009).   
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From 2004 to 2006, researchers from all of the international neuroblastoma 
research groups met to establish a neuroblastoma prognostic and aggressiveness 
classification methodology based on statistical analysis of previous neuroblastoma 
prognostic factor, treatment, and outcome data in patients from 1990 through 2002 
(Cohn, S. L. et al., 2009).  Information was collected on 35 potential prognostic 
identifiers from 8,800 patients.  The significance of prognostic identifiers was judged 
based on event free survival (EFS) rates.  Because age was included as a factor, 
Shimada classification was split into tumor differentiation, MKI, and histology category. 
Factors which were found to be significant included stage of disease (INSS), 
patient age, histology category (neuroblastoma, ganglioneuroblastoma intermixed 
differentiated, or nodular), tumor differentiation, MYCN amplification, chromosome 11q 
abnormality, and ploidy (Cohn, S. L. et al., 2009).  From these seven factors, a decision 
tree was created for separating the different prognostic groups.  A total of sixteen 
different groups were created for pre-treatment classification.  The sixteen groups were 
further split into four risk groups: very low (>85% EFS), low (>75% - ≤85% EFS), 
intermediate (≥50% - ≤75% EFS), and high (<50% EFS).   
It was suggested that treatment protocols should be customized for each of the 
sixteen groups.  Generally, low risk patients are treated with surgery or no treatment, 
intermediate risk patients are treated with a moderate chemotherapy, and high risk 
patients are treated with aggressive chemotherapy and sometimes bone marrow 
transplants (Shimada, H. et al., 1999a).  The new 16-group prognostic model, however, 
may change the recommended protocol for some patient groups. 
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5.1.5 Effects of Treatment 
There are many variations in the effect of treatment on neuroblastoma.  If an 
ineffective method of treatment is used, there may be no effect on the tumor. Other 
changes include tissue necrosis, hemorrhage, calcification of the tissue, or maturation 
of the tumor.  When neuroblastomas mature, the neuroblast cells differentiate to 
ganglionic cells and the neurofibrillary stroma differentiate into collagenous 
Schwannian-type stroma.  The combination of these changes makes matured, treated 
neuroblastomas have histologies similar to ganglioneuroma or ganglioneuroblastoma. 
5.1.6 Previous Work in Identifying Specific Tumor Features 
While certain treatments can cause necrosis to a tumor and the surrounding 
tissue, the presence of a tumor, even untreated, can also cause necrosis.  A study of 
untreated glioblastoma tumors showed that it was possible to identify between tumor 
tissue and necrotic tissue with Raman spectroscopy using discriminant function analysis 
(Koljenovic, S. et al., 2002).  Peak analysis showed a higher contribution of cholesterol 
in necrotic tissue regions. 
Several studies have examined varying levels of dysplasia in different tissues, 
including cervix (Robichaux-Viehoever, A. et al., 2007), esophagus (Shetty, G. et al., 
2006a), epithelial tissues (Stone, N. et al., 2002), the larynx (Stone, N. et al., 2000), and 
the bladder (Crow, P. et al., 2004).  Dysplasia represents a shift from normal tissue 
towards cancer. It is often classified as high-grade or low-grade, or according to the 
types of cells present.  While this varies slightly from cancer grading, it represents a 
similar classification methodology based on the underlying biochemistry of the abnormal 
tissue. 
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 One Raman spectroscopy study was able to differentiate between three stages 
of bladder cancer, as well as identify them from other benign conditions and normal 
bladder tissue.  Also of note in this study, authors were able to predict the stage of the 
disease (how far it penetrated into other areas) based on the biochemical composition 
of the primary tumor site (Crow, P. et al., 2004).   
Prostate cancer represents another type of cancer where the designated 
aggressiveness of the disease (Gleason score) can vary between pathologists.  A study 
was performed which examined the three grades of prostate cancer (Gleason score 
less than 7, equal to 7, or more than 7) and benign prostatic hyperplasia using Raman 
spectroscopy.  Samples were only included if the two blinded pathologists studying the 
tissues came to the same Gleason score independently.  Analysis of the four tissue 
groups showed high sensitivity (81-94%) and specificity (92-100%) in identifying each 
grade of tumor and the benign condition (Crow, P. et al., 2003b). 
Rather than testing whole tissues, cell lines are sometimes used for Raman 
measurement.  This allows evaluation of only cancer cells, rather than inclusion of other 
extra-cellular components and other cell types.  One study was performed which looked 
at two aggressive prostate cancer cell lines (androgen insensitive, poorly differentiated) 
and two non-aggressive prostate cancer cell lines (androgen sensitive, well 
differentiated).  A combination of principal component analysis and discriminant function 
analysis was able to differentiate between the aggressive and non-aggressive cell lines.  
Furthermore, it could distinguish each cell line from the other three cell lines tested 
(Crow, P. et al., 2005a). 
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A similar study was performed to identify cells transformed to have an extended 
cell cycle and lifespan and cells exposed to asbestos for immortalization from normal 
bronchial epithelial cells.  Discriminant function analysis was able to identify the three 
groups of cells with 75-87% sensitivity and 85-96% specificity (Jess, P. et al., 2009).  
Other attempts to measure specific grades of tumors, including breast (Clare, S. 
E. et al., 2006) and thyroid cancer (Teixeira, C. et al., 2009) have been unsuccessful to 
date, with many studies concluding that a larger dataset of tumors of each grade would 
increase classification ability. 
5.1.7 Research Plan 
The goal of this chapter is to identify neuroblastomas as either favorable 
histology or unfavorable histology as designated by the Shimada classification, or to 
identify a neuroblastoma tumor as treated.  Raman spectroscopy should allow for easy 
and accurate evaluation of tumor histology, since it provides a biochemical fingerprint of 
the measurement area. 
5.2 Materials and Methods 
5.2.1 Data Collection 
The Raman spectra of neuroblastoma from Chapters 2 and 3 were used for this 
study.  At the time of pathology review, the pathologists assigned a favorable or 
unfavorable diagnosis to the untreated neuroblastomas according to the Shimada 
classification.  Neuroblastomas which received treatment were all assigned to a single 
group, regardless of the Shimada classification pre-treatment, or the histological effects 
of the treatment.  Following data analysis, slides were re-reviewed by pathologists when 
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there was a discrepancy between the Raman classification and the pathology 
classification. 
5.2.2 Data Processing 
Data was processed using the same methodology as described in section 1.2.4 
and Appendix B.   
5.3 Results 
5.3.1 Preliminary Fresh Tissue Analysis 
The initial data set consisted of 106 spectra from 6 unfavorable neuroblastomas, 
114 spectra from 5 favorable neuroblastomas, and 82 spectra from 5 treated 
neuroblastomas, as shown in Table 5.2.  Tissue favorability was determined by an 
experienced pediatric pathologist based on the Shimada classification. 
 
Histology Number of Tissues Number of Spectra 
Unfavorable Neuroblastoma 6 106 
Favorable Neuroblastoma 5 114 
Treated Neuroblastoma 5 82 
Table 5.2: Number of unfavorable, favorable, and treated neuroblastomas in preliminary 
fresh tissue analysis. 
 
Favorable and unfavorable tumors were classified with 95.3% sensitivity and 
93.8% specificity, as shown in Table 5.3.  Seven of 114 favorable spectra were 
misclassified, and five of 106 unfavorable spectra were misclassified.  Using the 
majority of individual spectra within a tissue to diagnose the whole tissue, favorable and 
unfavorable tumors were distinguished with 100% sensitivity and specificity. 
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Classification Resultsa 
  
Subgroup Predicted Group Membership 
Total   Unfavorable Favorable 
Original Count Unfavorable 101 5 106 
Favorable 7 107 114 
% Unfavorable 95.3 4.7 100.0 
Favorable 6.1 93.9 100.0 
a. 94.5% of original grouped cases correctly classified. 
Table 5.3: Classification of favorable and unfavorable neuroblastoma 
 
Figure 5.1 shows the mean spectrum for the preliminary favorable versus 
unfavorable neuroblastoma study.  Based on visual inspection of the mean spectrum, 
favorable histology tumors had higher protein levels based on the elevated peaks at 
1447, 1555, and 1660 cm-1 and the shoulder at 1264 cm-1.  Favorable tumors also 
seemed to exhibit increased amino acid peaks at 754, 938, 1004, 1034, 1210, and 1620 
cm-1.  These peaks are marked for visual clarity. 
 
 
Figure 5.1: Mean spectra of favorable and unfavorable neuroblastoma 
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When classifying between treated and untreated neuroblastoma, favorable and 
unfavorable neuroblastoma were combined into a single untreated group.  At the 
spectral level, treated and untreated tumors were separated with 93.2% sensitivity and 
70.7% specificity as shown in Table 5.4.  At the tissue level, all eleven untreated 
neuroblastoma were correctly identified, while three of the five treated neuroblastoma 
were correctly identified. 
 
Classification Resultsa 
  
Treated Predicted Group Membership 
Total   Untreated Treated 
Original Count Untreated 205 15 220 
Treated 24 58 82 
% Untreated 93.2 6.8 100.0 
Treated 29.3 70.7 100.0 
a. 87.1% of original grouped cases correctly classified. 
Table 5.4: Classification results comparing untreated and treated neuroblastoma 
 
 
One of the effects of treatment may be maturation from neuroblastoma to 
ganglioneuroma.  When treated neuroblastoma was compared with ganglioneuroma, 
they were differentiated with 90.2% sensitivity and 97.4% specificity, as shown in Table 
5.5.  Using the majority spectra rule, all ganglioneuroma spectra were correctly 
identified and four out of five treated neuroblastoma tissues were correctly identified. 
 
Classification Resultsa 
  
Subgroup Predicted Group Membership 
Total 
  
Ganglioneurom
a Treated 
Original Count Ganglioneuroma 184 5 189 
Treated 8 74 82 
% Ganglioneuroma 97.4 2.6 100.0 
Treated 9.8 90.2 100.0 
a. 95.2% of original grouped cases correctly classified. 
Table 5.5: Classification of ganglioneuroma and treated neuroblastoma 
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Finally, a combined data set of untreated neuroblastoma, treated neuroblastoma, 
and ganglioneuroma were compared.  Figure 5.2 shows the discriminant function 
analysis plot for this classificiation, and the mean spectrum for each type of tissue.  
Note that there seems to be a clear progression from untreated tumor towards 
ganglioneuroma as treatment is applied.  Classification results are shown in Table 5.6. 
 
Classification Resultsa 
  
Subgroup Predicted Group Membership 
Total   Unfavorable Favorable Treated 
Original Count Unfavorable 92 11 3 106 
Favorable 5 99 10 114 
Treated 13 16 53 82 
% Unfavorable 86.8 10.4 2.8 100.0 
Favorable 4.4 86.8 8.8 100.0 
Treated 15.9 19.5 64.6 100.0 
a. 80.8% of original grouped cases correctly classified. 
Table 5.6: Classification of unfavorable, favorable, and treated neuroblastoma 
 
Visual inspection of the mean spectra peaks showed that treated 
neuroblastomas displayed a strong shoulder near 1240 cm-1 differentiating it from 
untreated neuroblastoma and ganglioneuroma.  This might correlate to higher 
concentrations of collagenous stroma in treated neuroblastoma.  Treated 
neuroblastoma also appeared to differ from ganglioneuroma in the region 1516-1622 
cm-1.  This is a region rich in protein and amino acids (Socrates, G., 2001). 
Finally, a case study of three tumors from one patient was performed.  One 
sample was available from the time of diagnosis, one sample was available following 
tumor treatment, and one sample was resected from an extradural brain metastasis one 
year following diagnosis.  Figure 5.3 shows representative histology images from each 
tissue sample and the results of discriminant function analysis. 
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Figure 5.2: The mean spectra of untreated neuroblastoma, treated neuroblastoma, and 
ganglioneuroma with discriminant function analysis results shown. 
 
Discriminant function analysis separated the diagnosis and treated sample with 
100% sensitivity and specificity.  This is consistent with the maturation shown in the 
histology images.  The metastatic sample had two spectra which were diagnosed as the 
original tumor at the time of diagnosis.  On examination of the tumor histology, the 
metastatic tumor sample showed a mixture of ganglionic maturing cells and immature 
neuroblasts, which were prevalent in the original sample.  This likely explains the 
overlap between the two samples. 
 
83 
 
Figure 5.3: Discriminant function analysis and histology images of three tumors from 
one patient. 
 
 
 Once again, visual inspection of the Raman spectra for each sample showed that 
the treated sample had higher peaks at 719, 1000, 1031, 1093, 1152, 1444, 1547, 
1578, 1604, 1621,and 1659 cm-1, in addition to the characteristic shoulder around 1240 
cm-1.  Again, these peaks may all be associated with various protein components.  Also 
of note, there was a strong peak at 960 cm-1 in the Raman spectra of the metastatic 
sample.  The biochemical origin of that peak could not be determined. 
5.3.2 Preliminary Fresh and Frozen Tissue Analysis 
Analysis of the original fresh neuroblastoma tissues showed promising results for 
distinguishing unfavorable, favorable, and treated neuroblastoma, and in distinguishing 
treated neuroblastoma from ganglioneuroma.  Following this early analysis, frozen 
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tumors were included in the study to determine if they offered the same classification 
potential.  Table 5.7 shows the number of fresh and frozen tissues and spectra available 
for the preliminary fresh and frozen analysis. 
 
 Fresh Frozen 
 Tissues Spectra Tissues Spectra 
Untreated 16 257 5 63 
     Favorable 8 130 4 47 
     Unfavorable 8 127 1 16 
Treated 9 159 6 78 
Ganglioneuroma 14 206 2 22 
Table 5.7: Data collected for fresh versus frozen study 
 
The mean spectra of fresh and frozen favorable, unfavorable, and treated 
neuroblastoma are shown in Figure 5.4.  For each tissue type, the mean fresh and 
frozen spectra are extremely similar. 
When frozen treated and untreated neuroblastoma were classified using the 
fresh tissue model, 10 of 78 untreated neuroblastoma spectra and 12 of 63 treated 
neuroblastoma spectra were misclassified (Table 5.8).  As mentioned in Chapter 3, 
however, some of the frozen, treated neuroblastomas had nests of immature neuroblast 
cells although the majority of the tissue was composed of mature cells.  
Misclassifications of treated spectra may actually represent identification of immature 
cells within a sample which otherwise displays characteristics of a treated 
neuroblastoma. 
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Figure 5.4: fresh (solid black line) and frozen (dashed red line) mean spectra of 
unfavorable, favorable, and treated neuroblastoma 
 
 
Classification Resultsa,b 
   
Treated Predicted Group Membership 
Total    untreated treated 
Cases Selected Original Count untreated 231 26 257 
treated 43 116 159 
% untreated 89.9 10.1 100.0 
treated 27.0 73.0 100.0 
Cases Not Selected Original Count untreated 51 12 63 
treated 10 68 78 
% untreated 81.0 19.0 100.0 
treated 12.8 87.2 100.0 
a. 83.4% of selected original grouped cases correctly classified. 
b. 84.4% of unselected original grouped cases correctly classified. 
Table 5.8: Classification of treated and untreated frozen neuroblastoma (“cases not 
selected” row) based on classification model of fresh neuroblastoma (“cases selected 
row) 
 
Neuroblastoma morphology shifts to look more similar to ganglioneuroma when it 
is treated.  When frozen treated neuroblastoma and ganglioneuroma spectra were 
compared based on the model of fresh tissues, ganglioneuroma was identified 100% of 
the time, and only 4 of 78 treated neuroblastoma spectra were misclassified, as shown 
in Table 5.9. 
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Classification Resultsa,b 
   
Subgroup Predicted Group Membership 
Total    Gn tNB 
Cases Selected Original Count 
dimension3 
Gn 196 10 206 
tNB 24 135 159 
% 
dimension3 
Gn 95.1 4.9 100.0 
tNB 15.1 84.9 100.0 
Cases Not Selected Original Count 
dimension3 
Gn 22 0 22 
tNB 4 74 78 
% 
dimension3 
Gn 100.0 .0 100.0 
tNB 5.1 94.9 100.0 
a. 90.7% of selected original grouped cases correctly classified. 
b. 96.0% of unselected original grouped cases correctly classified. 
Table 5.9: Classification of treated and ganglioneuroma frozen spectra (“cases not 
selected” row) based on classification model of fresh spectra (“cases selected row) 
 
 Fresh tissues were not classified based on the frozen model because of the 
small size of the frozen data set.   
5.4 Conclusions 
This is the first study using Raman spectroscopy to identify histologic features of 
neuroblastoma tumors.  Untreated tumors were classified according to the gold 
standard Shimada classification, as assigned by experienced pediatric pathologists.  
Favorable and unfavorable were distinguished with 100% sensitivity and specificity at 
the tissue level.   
Unfavorable and favorable tumors were also combined into an untreated group 
and compared to treated tumors.  Effects of treatment can include maturation and 
necrosis.  When compared with untreated neuroblastoma and with untreated 
ganglioneuroma, untreated tumors were always differentiated from treated with 100% 
sensitivity at the tissue level.  Some treated tumors, however, were still misclassified as 
untreated.  This could be due to specific histologic features within the misclassified 
cases. 
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By visual examination, treated neuroblastomas exhibited a shoulder at 1240 cm-1 
and an increased signature in the range of 1516-1622 cm-1.  These may be due to 
increased protein and amino acid levels.  Consultation with an experienced biologist or 
biochemist may provide a more complete understanding of the underlying biochemical 
changes from tissue to tissue. 
Finally, frozen tissues were examined to gauge their similarity to the fresh 
tissues.  Very few frozen tissues were available, so it was not possible to build a frozen 
model and then test it on fresh tissues.  When the frozen tissue spectra which were 
available were tested based on the fresh model, there was high sensitivity in judging 
between untreated and treated neuroblastoma and between treated neuroblastoma and 
ganglioneuroma.  In the future, more frozen tissues will be tested, and a more in-depth 
comparison between fresh and frozen unfavorable, favorable, and treated 
neuroblastoma will be performed. 
This research opens a new door for both clinical and basic science cancer 
research using Raman spectroscopy.  Previous research used Raman spectroscopy to 
distinguish between normal tissue and cancerous tissue, or between two types of 
cancerous tissue, however, it did not identify specific subtypes or prognostic groups 
within a cancer.   
Rapid identification of aggressive and non-aggressive cancers through an 
objective methodology offers a great clinical advance.  Although classification 
methodologies such as the Shimada classification offer a somewhat objective approach 
with fixed parameters for each grouping, results can still vary based on the area of 
tissue sampled or the pathologist’s count of the specific features of the tumor.  Raman 
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spectroscopy can reduce the subjectiveness of this identification by measuring the 
specific biochemical constituents.  It can even reduce the error introduced by sampling 
different areas of the tissue if a scan is performed over several regions of the tissue. 
Raman spectroscopy also has potential to identify the effects of treatment on 
neuroblastoma.  Once a larger database is developed, it may have the sensitivity to 
identify exact changes due to drug treatment, including maturation or necrosis.  At a 
basic science level, this may allow researchers to better understand the effects of 
treatments on tumors of a known histology through analysis of the Raman spectra.  
Furthermore, periodic monitoring of patients throughout treatment can also be used to 
identify a tumor’s response to treatment.  This could allow clinicians to quickly evaluate 
the effects of a new treatment to determine if it is the optimal treatment or if another 
treatment should be used. 
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CHAPTER 6 BLINDED STUDY WITH CHILDREN’S ONCOLOGY GROUP TO 
IDENTIFY FAVORABLE, UNFAVORABLE, AND TREATED NEUROBLASTOMA 
6.1 Introduction 
In order to prove the diagnostic capability of Raman spectroscopy, it must be 
used in a truly blinded study, and then in prospective, blinded studies.  This chapter 
represents the first step towards proving diagnostic clinical capability in a blinded study 
performed in conjunction with the Children’s Oncology Group, a national tumor bank. 
Prior to this study, all human clinical studies were performed using the same 
Leica 20x objective.  This objective was damaged immediately before receiving the 
shipment of samples from the Children’s Oncology Group, and the new samples had to 
be measured with new lenses.  This introduced an additional layer of variability into the 
data.  In addition to describing the blinded study, this chapter also outlines the methods 
we used in an attempt to join our original data set with a blinded data set measured with 
another lens. 
6.2 Materials and Methods 
6.2.1 Sample Procurement 
In order to perform a truly blinded study, the Children’s Oncology Group agreed 
to share eight samples each of favorable, unfavorable, and treated neuroblastoma.  All 
24 samples could not be obtained because they do not allow depletion of any single 
tumor within their collection.  However, they did share 22 samples.  It is not known 
which diagnostic group the two unsent samples came from. 
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6.2.2 Sample Measurement 
This experiment consisted of a training set of data which was used to build a 
diagnostic model, and a testing set of data, which the model was tested on.  The 
training data consisted of all fresh and frozen specimens previously collected and 
described.  The testing data consisted of the Raman spectra of the samples provided by 
the Children’s Oncology Group. 
Samples were individually wrapped in foil and placed in tissue cassettes by COG 
employees, then shipped overnight on dry ice.  Upon arrival, samples were place in a -
80°C freezer until measurement time. 
When samples were ready for measurement, they were removed from their 
wrapping and placed in an eppindorf tube or cryovial which was then filled with room 
temperature saline.  Samples were allowed to defrost for 30 minutes, and then they 
were removed from the vial and place on a glass microscope slide.  Following 
measurement, samples were replaced in their foil wrapping and tissue cassette and 
placed in the -80°C freezer for storage. 
As mentioned in the introduction, the microscope objective which was originally 
used for measurement was damaged prior to receiving the Children’s Oncology Group 
samples.  All samples were originally measured with a replacement 20x Nikon Plan-
Flour microscope objective and replaced in the freezer.  On data analysis, however, this 
data was incompatible with the previous data set collected with a Leica-brand lens (see 
results).  After it was determined that data from the Nikon lens was incompatible, all 
samples were re-tested with a Leica 20x objective identical to the original objective.   
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6.2.3 Data Processing 
Data was preprocessed as previously described.  For classification, the original 
intent was to perform Principal Component Analysis on the training data and apply the 
results to the testing data, then perform discriminant function analysis on the training 
data and apply those results to the training data.  Because of the spectral differences 
from objective to objective, however, this method was not feasible.  The results section 
provides an in-depth description of the methods used throughout data analysis and the 
justification for each step of the analysis. 
The end result of the analysis was three methods of discriminant function 
analysis.  Because the study was blinded, there was no way to know which method was 
best without first consulting with the Children’s Oncology Group.   
A separate analysis was performed for treated vs untreated and for favorable vs 
unfavorable.  Because treated neuroblastoma can cover a broad range of histologies, 
all treated neuroblastomas were excluded from the training data set when analyzing 
tumor favorability.  That is why tumors marked as ‘treated’ also have a favorable or 
unfavorable diagnosis. 
6.3 Results 
6.3.1 Nikon Lens Results 
Figure 6.1 shows the mean spectrum of processed data from the favorable 
histology training group, the unfavorable histology training group, the treated histology 
training group, and the Nikon lens testing group, which was composed of the samples 
sent from the Children’s Oncology Group.  Visual examination shows a clear difference 
between the original training data and the new data measured with the Nikon lens. 
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Clearly, there is a difference in the underlying background signal measured 
between the two lenses, as exhibited by the varying signal intensities.  It is important to 
note, however, that most of the key peaks still align, just at different intensities.  The two 
types of lenses used allow varying amounts of light into the objective, which may cause 
the differences in the underlying backgrounds.  It may be possible to better align the 
peak intensities through software processing of the Raman spectra.   
 
 
Figure 6.1: mean spectra of favorable, unfavorable, and treated training data, and 
mean spectrum of unknown data measured with Nikon lens 
 
 
Further examination of the mean spectra shows that the mean spectra of the 
unfavorable, favorable, and treated histology training groups each have a maximum of 
about one, meaning that the data is relatively homogenous.  Examination of the testing 
data measured with the Nikon lens, however, showed a maximum value of only 
approximately .95.  This signifies a less homogenous data set, and likely signals 
multiple populations within the data set.  The data was examined more in-depth to 
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check for different populations based on the location of the maximum value for each 
individual spectrum.  The training data had very few spectra where the maximum value 
was outside the range of 1300-1350 cm-1.  However, the Nikon testing data displayed 
four distinct populations, as shown in Figure 6.2.  Note that the solid black line is the 
mean spectrum of the training data measured by the Leica lens and the red, blue, 
green, and yellow lines are the mean spectra from the four Nikon populations. 
  
 
Figure 6.2: Mean spectrum of all training data measured with Leica lens (black) and 
four distinct populations measured by the Nikon lens. 
 
 
Because the Raman spectra of the new tissue samples measured with the Nikon 
lens were so different from the Raman spectra of the training samples measured with 
the Leica lens, it was not possible to identify the histology of the new samples using 
existing processing and diagnostic methods.  Data collected using the Nikon lens was 
saved for future use, once processing procedures are adjusted to solve this problem.  In 
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the meantime, a replacement Leica lens identical to the original Leica lens was 
obtained, and samples were re-measured. 
6.3.2 Leica Lens Results 
Figure 6.3 shows the mean Raman spectra of the three training data groups 
measured with the original Leica lens and the Raman spectra of the unknown data 
measured with the replacement Leica lens.  There is much better agreement between 
the two Leica lenses than between the Leica and Nikon lens, however, minor 
differences still exist.  If the original Leica lens was damaged over time, this would 
slowly change the amount of light let in by the lens.  This could be part of the reason for 
the measurement differences between the two lenses.  Alternately, the lenses might 
simply provide slightly different signals due to small differences in the manufacturing 
process. 
 
 
Figure 6.3: Mean spectrum of unfavorable, favorable, and treated training data with 
unknown data measured using the replacement Leica lens 
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Data was reviewed to remove any spectra with the maximum value outside the 
range of 1300 to 1350 cm-1, and then the full spectral data was imported into SPSS.  
The spectra removed from this process will be referred to as ‘obvious outliers’.  Data 
review was also performed to remove any spectra with lower quality Raman spectra, 
potentially due to out of focus measurements, poor sample quality, or excess 
measurement noise.  These spectra will be referred to as ‘potential outliers’.  For each 
method, data analysis was performed twice: once using all data with only obvious 
outliers removed, and once using data with both obvious outliers and potential outliers 
removed.  The three classification methods which were used for data analysis are 
described below. 
6.3.3 Method 1: Key Peaks from 600-1800 cm-1 
Data classification was first attempted using principal component analysis 
followed by discriminant function analysis.  This did not work because the new data did 
not math closely enough with the old data to be compressed through principal 
component analysis then analyzed with discriminant function analysis.  Next, 
discriminant function analysis without principal component analysis using all peaks as 
input was attempted.  Again, this failed.   
Visual examination of the Raman spectra between the two lenses showed clear 
intensity differences in some regions.  It was hypothesized that classification difficulties 
might be partly caused by including those regions in data analysis.  To try to circumvent 
this problem, peak selection was performed using the method described in section 
4.2.2, based on the standardized canonical discriminant function results of discriminant 
function analysis using all peaks.   
96 
 
For classifying between treated and untreated neuroblastoma, the selected 
peaks of interest were 643.7, 655.9, 663.0, 666.1, 667.1, 699.5, 843.9, 855.6, and 
1402.9 cm-1.  Overall classification of the training data was 77.4%.  Table 6.1 shows the 
results excluding potential and obvious outliers, and Table 6.2 shows the classification 
results excluding only the obvious outliers. 
 
Classification Resultsa 
  
treatment Predicted Group Membership 
Total   untreated Treated 
Original Count untreated 215 50 265 
treated 43 103 146 
Ungrouped cases 116 103 219 
% untreated 81.1 18.9 100.0 
treated 29.5 70.5 100.0 
Ungrouped cases 53.0 47.0 100.0 
a. 77.4% of original grouped cases correctly classified. 
Table 6.1: Classification results of untreated versus treated tissue using select peaks in 
the range from 600-1800 and excluding potential and obvious outliers. 
 
 
Classification Resultsa 
  
treatment Predicted Group Membership 
Total   untreated treated 
Original Count untreated 215 50 265 
treated 43 103 146 
Ungrouped cases 134 120 254 
% untreated 81.1 18.9 100.0 
treated 29.5 70.5 100.0 
Ungrouped cases 52.8 47.2 100.0 
a. 77.4% of original grouped cases correctly classified. 
Table 6.2: Classification results of untreated versus treated tissue using select peaks in 
the range from 600-1800 cm-1 excluding only obvious outliers. 
 
 
For classifying between favorable and unfavorable neuroblastoma, the peaks of 
interest were 614.1, 621.8, 622.3, 626.3, 631.5, 637.6, 638.6, 725.7, 744.7, 768.7, 
797.5, 846.8, 825.2, 860.6, 917.1, 924.8, 951.8, 1152.2, 1158.7, 1173.5, and 1312.9  
cm-1.  This represents significantly more diagnostic peaks than were necessary for 
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discriminating between treated and untreated neuroblastoma, however, overall 
classification of the training data was 93.6%.  Table 6.3 shows the results excluding 
potential and obvious outliers, and Table 6.4 shows the classification results excluding 
only the obvious outliers. 
 
Classification Resultsa 
  
Subgroup Predicted Group Membership 
Total   UNb FNb 
Original Count UNb 123 12 135 
FNb 5 125 130 
Ungrouped cases 61 158 219 
% UNb 91.1 8.9 100.0 
FNb 3.8 96.2 100.0 
Ungrouped cases 27.9 72.1 100.0 
a. 93.6% of original grouped cases correctly classified. 
Table 6.3: Classification results of favorable versus unfavorable tissue using select 
peaks in the range from 600-1800 and excluding potential and obvious outliers. 
 
 
Classification Resultsa 
  
Subgroup Predicted Group Membership 
Total   UNb FNb 
Original Count UNb 123 12 135 
FNb 5 125 130 
Ungrouped cases 71 183 254 
% UNb 91.1 8.9 100.0 
FNb 3.8 96.2 100.0 
Ungrouped cases 28.0 72.0 100.0 
a. 93.6% of original grouped cases correctly classified. 
Table 6.4: Classification results of favorable versus unfavorable tissue using select 
peaks in the range from 600-1800 cm-1 excluding only obvious outliers. 
 
6.3.4 Method 2: Full Data Range from 600-1220 cm-1 
Upon in-depth examination of the mean spectra over the range of 600-1800 cm-1 
and examination of the key diagnostic peaks which were selected using the 
standardized canonical discriminant functions, it was determined that the mean 
spectrum of the replacement Leica lens closely matched the Raman fingerprint of the 
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training data measured with the original Leica lens below about 1250 cm-1.  Different 
cutoff points were iteratively tested to find the maximum classification within the training 
set.  This was done by performing discriminant function analysis over all the peaks from 
the range of 600 cm-1 to the cutoff points being tested.  Results of treated versus 
untreated analysis and favorable versus unfavorable analysis were recorded at each 
cutoff point.  Optimal results for both groups were reached using a cutoff point of 1220 
cm-1, so analysis was performed over the range of 600-1220 cm-1. 
Figure 6.4 shows the mean spectrum of the new lens and the three training 
groups over the full data range (left), and over the truncated data range (right).    Notice 
that the black line which signifies the new testing data matches much closer with the 
training data in the right hand image. 
Table 6.5 shows the classification results using all peaks in the range from 600-
1220 cm-1 to distinguish between treated and untreated neuroblastoma with obvious 
and potential outliers excluded, and Table 6.6 shows the same results excluding only 
obvious outliers.  Classification of the training data was 78.3%. 
 
Classification Resultsa 
  
Treatment Predicted Group Membership 
Total   untreated treated 
Original Count Untreated 223 42 265 
Treated 47 99 146 
Ungrouped cases 143 76 219 
% Untreated 84.2 15.8 100.0 
Treated 32.2 67.8 100.0 
Ungrouped cases 65.3 34.7 100.0 
a. 78.3% of original grouped cases correctly classified. 
Table 6.5: Classification results of untreated versus treated tissue using all peaks from 
600-1220 cm-1 and excluding potential and obvious outliers. 
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Figure 6.4: Mean Raman spectra of favorable, unfavorable, and treated spectra 
measured with original Leica lens and unknown spectra measured with replacement 
Leica lens before (top) and after (below) data truncation 
 
 
 
Classification Results 
  
treatment Predicted Group Membership 
Total   untreated treated 
Original Count untreated 223 42 265 
treated 47 99 146 
Ungrouped cases 164 90 254 
% untreated 84.2 15.8 100.0 
treated 32.2 67.8 100.0 
Ungrouped cases 64.6 35.4 100.0 
a. 78.3% of original grouped cases correctly classified. 
Table 6.6: Classification results of untreated versus treated tissue using all peaks from 
600-1220 cm-1 and excluding only obvious outliers. 
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Table 6.7 shows the classification results using all peaks in the range from 600-
1220 cm-1 to distinguish between favorable and unfavorable histology neuroblastoma 
with obvious and potential outliers excluded, and Table 6.8 shows the same results 
excluding only obvious outliers.  Classification of the training data was 84.5%. 
 
 
Classification Results 
  
Subgroup Predicted Group Membership 
Total   UNb FNb 
Original Count UNb 118 17 135 
FNb 24 106 130 
Ungrouped cases 119 100 219 
%UNb 87.4 12.6 100.0 
FNb 18.5 81.5 100.0 
Ungrouped cases 54.3 45.7 100.0 
a. 84.5% of original grouped cases correctly classified. 
Table 6.7: Classification results of unfavorable versus favorable tissue using all peaks 
from 600-1220 cm-1 and excluding potential and obvious outliers. 
 
 
 Classification Resultsa 
  
Subgroup Predicted Group Membership 
Total   UNb FNb 
Original Count UNb 118 17 135 
FNb 24 106 130 
Ungrouped cases 133 121 254 
%UNb 87.4 12.6 100.0 
FNb 18.5 81.5 100.0 
Ungrouped cases 52.4 47.6 100.0 
a. 84.5% of original grouped cases correctly classified. 
Table 6.8: Classification results of favorable versus unfavorable tissue using all peaks 
from 600-1220 cm-1 and excluding only obvious outliers. 
 
6.3.5 Method 3: Key Peaks from 600-1220 cm-1 
Since classification results were so promising using the full range of data from 
600-1220 cm-1, individual peak selection was performed within this specific range.  For 
classifying between treated and untreated neuroblastoma, the peaks of interest were 
614.1, 617.1, 618.2, 625.3, 704.5, 743.7, 854.6, 1015.0, 1041.6, 1051.1, 1052.2, 
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1155.9, and 1202.9 cm-1.  They provided 81.5% accurate classification of the training 
data.  Table 6.9 shows the classification results using these peaks to distinguish 
between treated and untreated neuroblastoma with obvious and potential outliers 
excluded, and Table 6.10 shows the same results excluding only obvious outliers.   
 
Classification Resultsa 
  
treatment Predicted Group Membership 
Total   untreated treated 
Original Count untreated 231 34 265 
treated 42 104 146 
Ungrouped cases 144 75 219 
%untreated 87.2 12.8 100.0 
treated 28.8 71.2 100.0 
Ungrouped cases 65.8 34.2 100.0 
a. 81.5% of original grouped cases correctly classified. 
Table 6.9: Classification results of untreated versus treated tissue using 13 select peaks 
from 600-1220 cm-1 and excluding potential and obvious outliers. 
 
 
Classification Resultsa 
  
treatment Predicted Group Membership 
Total   untreated treated 
Original Count untreated 231 34 265 
treated 42 104 146 
Ungrouped cases 165 89 254 
%untreated 87.2 12.8 100.0 
treated 28.8 71.2 100.0 
Ungrouped cases 65.0 35.0 100.0 
a. 81.5% of original grouped cases correctly classified. 
Table 6.10: Classification results of untreated versus treated tissue using 13 select 
peaks from 600-1220 cm-1 and excluding only obvious outliers. 
 
 
The number of peaks could be further reduced to 8 peaks while still maintaining 
80% classification of the training data.  These 8 peaks were 704.5, 743.7, 854.7, 
1015.1, 1041.7, 1051.1, 1052.0, and 1202.9 cm-1.  Table 6.11 shows the classification 
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results using these peaks with obvious and potential outliers excluded, and Table 6.12 
shows the same results excluding only obvious outliers.   
 
Classification Resultsa 
  
treatment Predicted Group Membership 
Total   untreated treated 
Original Count untreated 229 36 265 
treated 46 100 146 
Ungrouped cases 143 76 219 
%untreated 86.4 13.6 100.0 
treated 31.5 68.5 100.0 
Ungrouped cases 65.3 34.7 100.0 
a. 80.0% of original grouped cases correctly classified. 
Table 6.11: Classification results of untreated versus treated tissue using 8 select peaks 
from 600-1220 cm-1 and excluding potential and obvious outliers. 
 
Classification Resultsa 
  
treatment Predicted Group Membership 
Total   untreated treated 
Original Count untreated 229 36 265 
treated 46 100 146 
Ungrouped cases 163 91 254 
%untreated 86.4 13.6 100.0 
treated 31.5 68.5 100.0 
Ungrouped cases 64.2 35.8 100.0 
a. 80.0% of original grouped cases correctly classified. 
Table 6.12: Classification results of untreated versus treated tissue using 8 select peaks 
from 600-1220 cm-1 and excluding only obvious outliers. 
 
For classifying between favorable and unfavorable neuroblastoma, the selected 
peaks of interest were 614.1, 618.2, 622.3, 626.3, 631.5, 637.6, 680.3, 715.6, 744.7, 
768.7, 825.2, 846.8, 917.1, 924.8, 951.8, 1152.2, 1158.7, 1175.3, 1184.5, and cm-1.  
Table 6.13 shows the classification results using these peaks with obvious and potential 
outliers excluded to separate unfavorable and favorable neuroblastoma, and Table 6.14 
shows the same results excluding only obvious outliers.  The overall classification was 
86.4%. 
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Classification Resultsa 
  
Subgroup Predicted Group Membership 
Total   UNb FNb 
Original Count UNb 119 16 135 
FNb 20 110 130 
Ungrouped cases 111 108 219 
%UNb 88.1 11.9 100.0 
FNb 15.4 84.6 100.0 
Ungrouped cases 50.7 49.3 100.0 
a. 86.4% of original grouped cases correctly classified. 
Table 6.13: Classification results of unfavorable and favorable tissue using select peaks 
from 600-1220 cm-1 and excluding potential and obvious outliers. 
 
Classification Resultsa 
  
Subgroup Predicted Group Membership 
Total   UNb FNb 
Original Count UNb 119 16 135 
FNb 20 110 130 
Ungrouped cases 128 126 254 
%UNb 88.1 11.9 100.0 
FNb 15.4 84.6 100.0 
Ungrouped cases 50.4 49.6 100.0 
a. 86.4% of original grouped cases correctly classified. 
Table 6.14: Classification results of untreated versus treated tissue using 8 select peaks 
from 600-1220 cm-1 and excluding only obvious outliers. 
 
Peaks selected for treated versus untreated classification are marked in purple in 
Figure 6.5, and peaks selected for favorable versus unfavorable classification are 
marked in orange. 
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Figure 6.5: Key peaks in the range of 600-1220 cm-1 for classification of unfavorable, 
favorable, and treated neuroblastoma  
 
 
6.3.6 Comparison of Classification Methods 
The classification results for each method used to discriminate between treated 
and untreated neuroblastoma are shown in Table 6.15.  A diagnosis was only assigned 
to each sample if at least 60% of the individual spectra had the same diagnosis.  
Samples with 50-60% agreement were not given a diagnosis.  Results are shown for 
analyses excluding only obvious outliers and analyses excluding both obvious and 
potential outliers.  There is also an ‘overall diagnosis’ which was made based on the 
combination of the three methods, if they agreed.  The ‘value’ column represents the 
average diagnosis for each tissue, where 0 is unfavorable or untreated, and 1 is 
favorable or untreated.  Samples with a value of less than 0.4 were untreated (purple), 
and samples with a value of more than 0.6 were treated (yellow).   
Likewise, Table 6.16 shows the same results used to discriminate between 
favorable and unfavorable neuroblastoma.  Samples with a value of less than 0.4 were 
unfavorable (green), and samples with a value of more than 0.6 were favorable (red). 
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 TREATMENT  
 453 spectra 419 spectra  
 600- 
1800 
15pk  
600-
1200  
All  
600-
1200  
13 pk 
600-
1200  
8 pk  
600- 
1800 
15pk  
600-
1200  
All  
600-
1200  
13 pk 
600- 
1200 
8pk  treatment 
2001-07-P6020 0.86 1.00 1.00 1.00 0.86 1.00 1.00 1.00 treated 
2001-12-P8023 0.50 0.25 0.33 0.17 0.63 0.25 0.50 0.25 untreated 
2002-10-P8047 0.00 0.17 0.08 0.00 0.00 0.18 0.09 0.00 untreated 
2002-11-P8008 0.78 0.56 0.67 0.67 0.71 0.57 0.57 0.57 treated 
2002-12-P6025 0.73 0.18 0.09 0.18 0.78 0.22 0.11 0.22 untreated 
2003-01-P8006 0.42 0.67 0.83 0.75 0.50 0.70 0.90 0.80 treated 
2003-02-P8005 0.38 0.08 0.08 0.08 0.33 0.00 0.00 0.00 Untreated 
2003-06-P8029 0.15 0.38 0.15 0.08 0.15 0.38 0.15 0.08 Untreated 
2003-08-P8061 0.60 0.70 0.70 0.70 0.60 0.70 0.70 0.70 treated 
2003-10-P8055 0.67 0.58 0.33 0.33 0.67 0.58 0.33 0.33 Untreated 
2004-03-P0092 0.36 0.27 0.18 0.27 0.36 0.27 0.18 0.27 untreated 
2005-04-P0518 0.00 0.20 0.00 0.00 0.00 0.22 0.00 0.00 untreated 
2005-06-P0753 0.54 0.62 0.62 0.54 0.67 0.44 0.56 0.56 Treated 
2006-02-P0791 0.91 0.45 0.73 0.73 1.00 0.56 0.78 0.67 Treated 
2006-02-P0903 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Untreated 
2006-08-P0687 0.70 0.60 0.70 0.90 0.70 0.60 0.70 0.90 Treated 
2006-11-P0514 0.46 0.54 0.31 0.38 0.29 0.57 0.43 0.57 
2006-12-P0503 0.17 0.08 0.00 0.08 0.18 0.09 0.00 0.09 Untreated 
2007-01-P0160 0.25 0.17 0.00 0.00 0.25 0.17 0.00 0.00 Untreated 
2007-04-P0365 0.50 0.36 0.43 0.50 0.50 0.25 0.42 0.50 Untreated 
2007-05-P1011 0.85 0.23 0.31 0.31 0.85 0.23 0.31 0.31 Untreated 
2007-09-P0478 0.83 0.08 0.58 0.67 1.00 0.00 0.60 0.60 
Table 6.15: Comparison of tissue-level results using each classification method for 
treated versus untreated neuroblastoma.  453-spectra results represent analysis with 
obvious outliers removed, and 419-spectra results represent analysis with obvious and 
potential outliers removed. 
 
As shown in the Tables 6.15 and 6.16, there is fairly good agreement among 
classification methods for most tissues.  However, some tissues, such as 2007-09-
P0478 exhibited a shift from 83% treated to 92% untreated depending on the set of 
peaks used for diagnosis.  In some cases, such as 2006-11-P0514, the diagnosis of the 
tissue shifted from one group to another when low-quality spectra were removed.   
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The right hand side of the tables shows the overall classification results.  When 
there was fairly good agreement between the three methods, an overall diagnosis was 
made.  However, samples which were still unclear were left blank. 
 
FAVORABILITY  
453 SPECTRA 419 SPECTRA  Final DX 
Tissue ID 
600-1800  
21 pk 
600-1200  
All  
600-1200  
19pk 
600-1800  
21 pk 
600-1800  
All 
600-1200  
19pk 
  
2001-07-P6020 0.86 0.43 0.57 0.86 0.43 0.57   
2001-12-P8023 0.75 0.67 0.75 0.63 0.63 0.75  favorable 
2002-10-P8047 0.50 0.25 0.17 0.45 0.18 0.09  unfav 
2002-11-P8008 0.56 0.56 0.44 0.71 0.57 0.57   
2002-12-P6025 0.73 0.45 0.45 0.78 0.56 0.56   
2003-01-P8006 0.92 0.67 0.50 0.90 0.60 0.40   
2003-02-P8005 0.77 0.46 0.38 0.83 0.42 0.33  unfav 
2003-06-P8029 0.46 0.08 0.23 0.46 0.08 0.23  unfav 
2003-08-P8061 0.60 0.20 0.40 0.60 0.20 0.40  unfav 
2003-10-P8055 0.75 0.67 0.67 0.75 0.67 0.67  favorable 
2004-03-P0092 0.55 0.27 0.27 0.55 0.27 0.27  unfav 
2005-04-P0518 0.80 0.60 0.60 0.78 0.56 0.56  favorable 
2005-06-P0753 0.54 0.62 0.62 0.56 0.56 0.67  favorable 
2006-02-P0791 0.73 0.55 0.73 0.67 0.56 0.78   
2006-02-P0903 0.92 0.08 0.25 0.92 0.08 0.25  unfav 
2006-08-P0687 0.70 0.60 0.70 0.70 0.60 0.70  favorable 
2006-11-P0514 0.77 0.69 0.46 0.86 0.71 0.43   
2006-12-P0503 0.92 0.58 0.42 0.91 0.64 0.45   
2007-01-P0160 0.58 0.33 0.42 0.58 0.33 0.42  unfav 
2007-04-P0365 0.93 0.50 0.64 0.92 0.50 0.58  favorable 
2007-05-P1011 0.77 0.54 0.69 0.77 0.54 0.69  favorable 
2007-09-P0478 0.75 0.67 0.58 0.80 1.00 1.00  favorable 
Table 6.16: Comparison of tissue-level results using each classification method for 
favorable versus unfavorable neuroblastoma.  453-spectra results represent analysis 
with obvious outliers removed, and 419-spectra results represent analysis with obvious 
and potential outliers removed. 
 
 
107 
 
6.3.7 Comparison of Raman Diagnosis with COG Diagnosis 
Results from Children’s Oncology Group showed that Raman spectroscopy did 
not significantly distinguish between the blinded favorable, unfavorable, and treated 
samples.  Section 6.4 discusses several possible sources for classification error within 
this study, and suggests possible methods for improvement.  In the future, the data will 
be re-analyzed and results will be re-submitted to the Children’s Oncology Group. 
6.4 Conclusions 
Based on the results of the blinded study, the classification methodology must be 
further refined to improve classification.  Ideally, and ideal methodology will be 
established in the future, and the Children’s Oncology Group will share more of their 
samples for development of a complete pediatric cancer Raman spectroscopic 
database. 
At the time of preliminary analysis of unfavorable, favorable, and treated 
neuroblastoma, processing capability did not allow for in-depth peak wise analysis.  
Because SPSS now allows analysis of full spectral data, significant peak findings can 
be used to draw biochemical conclusions regarding the samples.  In the future, cancer 
biologists and biochemists will be consulted to correlate the significant peaks with 
biochemicals, which should allow conclusions to be drawn about the tumor biology. 
In the future, there are several ways to improve histologic classification.  A further 
refinement on the terms ‘favorable’, ‘unfavorable’, and ‘treated’ will improve diagnosis.  
Tumor favorability depends on age (a non-histologic factor); however, age is not related 
to the underlying tumor biochemistry.  Therefore, it should be removed as a factor from 
histologic diagnosis.  Instead, future Raman spectroscopic studies of in-house and 
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Children’s Oncology Group samples should examine the stromal index, MKI, and 
differentiation individually rather than favorability as a whole.   
Likewise, a quantification of treatment, such as maturation, necrosis, etc. should 
be used instead of simply defining treated and untreated neuroblastoma.  These 
specific descriptions have a concrete link to histology and tumor biochemistry and 
should allow more accurate Raman diagnosis.   
Finally, further development of the Raman tumor database with more samples 
will increase our classification ability.  Classification algorithms and processing 
techniques will also be continuously refined over time. 
Outside of classification of blinded tumor samples, this study raised concerns 
about the validity of processing and classification methodology when hardware 
components are changed on the Raman system.  The differences between the Leica 
brand lens and the Nikon brand lens were so pronounced that data from one could not 
be used to classify data from the other.  The differences between the two Leica brand 
lenses were not as pronounced, however, lens-to-lens classification still posed a 
significant problem.  Future work must be done to address this major problem.   
Lenses are not the only spectrometer with a limited shelf life.  Other components 
which may degrade over time include the laser excitation source, filters, and gratings.  
Furthermore, interchangeable hardware components may be changed over time for 
application of one Raman probe to different applications.  The final software package 
developed for clinical use must be robust enough to handle the periodic change of 
hardware components without invalidation of the existing spectroscopic database.  
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Enhanced background subtraction and calibration techniques, as well as modifications 
to the data cataloging system should address this problem. 
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CHAPTER 7 IDENTIFICATION OF MYCN AMPLIFICATION IN NEUROBLASTOMA 
CELLS 
7.1 Introduction 
7.1.1 Genetic Factors Associated with Neuroblastoma Prognosis 
Several genetic factors are associated with neuroblastoma prognosis.  Known 
factors include amplification of the MYCN gene (myc myelocytomatosis viral related 
oncogene, neuroblastoma derived), change in cell ploidy (number of sets of 
chromosomes), changes to the 11q chromosome (long arm of chromosome 11), 
changes to the 1p chromosome (short arm of chromosome 1), and increase of genetic 
material on the 17q chromosome (long arm of chromosome 17) (Cohn, S. L. et al., 
2009).  The International Neuroblastoma Risk Group found that the genetic factors most 
significantly associated with disease prognosis included MYCN amplification, 11q 
changes, and cell ploidy.  Of these genetic factors, MYCN was the most significant.  
Their study found that the 5-year overall survival rate dropped from 82% in non-
amplified MYCN tumors (n=5,947 patients) to just 34% in MYCN amplified tumors 
(n=1,155 patients) (Cohn, S. L. et al., 2009). 
The MYCN proto-oncogene is amplified (50-400 copies/cell) in 20-25% of 
neuroblastomas (Maris, J. M. Matthay, K. K., 1999).  When found at normal expression 
levels, it is not hazardous; however, when found at increased expression levels, it helps 
turn healthy cells into cancerous cells.  It produces the MYCN phosphoprotein, which 
interacts with MAX and MAD proteins and leads to changes in several downstream 
pathways.   
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It is unknown exactly how MYCN works beyond binding with MAX and MAD, but 
it is known that it can affect the expression of literally hundreds of other genes (Eilers, 
M. Eisenman, R. N., 2008).  In general, it up-regulates genes involved in protein 
synthesis, ribosome creation, metabolism, and increasing cell mass, while it tends to 
down-regulate genes involved in stopping the cell cycle, causing cell adhesion, and 
allowing cell-to-cell communication (Eilers, M. Eisenman, R. N., 2008). 
7.1.2 Regulation of MYCN Expression 
Previous reports have shown that retinoic acid (vitamin A) can be used to control 
N-myc expression, and even cause neuroblastoma tumor cells to differentiate into 
neuron-like cells (Thiele, C. J. et al., 1985).  However, retinoic may not be an ideal 
model because it can cause differentiation.  Differentiation would cause significant 
changes in the biochemical composition and likely change the Raman signature of the 
cells, so another model is necessary. 
The MYCN gene is particularly difficult to test in cell cultures because it cannot 
be transfected into animal models (Lutz, W. et al., 1996).  This is a similar problem 
across many types of cells and many genes.  To address this general problem, Gossen 
and colleagues developed a methodology to create cell lines with controllable gene 
expression (Baron, U. et al., 1995; Gossen, M. Bujard, H., 1992; Gossen, M. et al., 
1995). 
Using this method, there are two series of transfections into the cell.  The first 
transfection contains the tTa and a plasmid for neomycin resistance.  Many cells are 
transfected in the first step.  Of those cells, only cells which exhibit tet-controlled 
luciferase expression are selected for the second round of transfection.  The second 
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transfection contains tetracycline-controlled cDNA for the gene of interest (NMYC in the 
case of this research), and another plasmid for hygromycin-resistance.    Finally, the 
selected cells must exhibit resistance to neomycin and hygromycin, and exhibit 
tetracycline-control of the gene.   
Clearly, creation of a tetracycline-inducible cell line is quite complicated and 
outside the scope of this research.  The following sections describe two cell lines 
previously developed by outside researchers which were considered for use in this 
study. 
7.1.2.1 TET21 Cell Line 
Lutz et al. created the first tetracycline-controlled cell line for neuroblastoma in 
1996 (Lutz, W. et al., 1996).  The original cell line used was SH-EP which is a sub clone 
of SK-N-SH.  They used the transfection method described by Gossen and Bujard 
(1992) to develop their cell line.  This cell line is an example of a TET-off system, 
because MYCN expression is highest when no tetracycline is present in the cell media.  
In this cell line, MYCN gene expression was increased 10-fold, and mRNA was 
increased at least 15-fold.  Also of note, light microscopy showed no morphological 
differences between the induced and non-induced cells.  
They found that increased MYCN expression increased the levels of ornithine 
decarboxylase and the level of α-prothymosin approximately three-fold.  It also caused 
an increase in DNA synthesis and reduced the cell cycle from 16.5 hours in control cells 
to 11.5 hours in MYCN-amplified cells.  Part of this was caused by a quicker transition 
(about 4 hours) from G0 to S phase in the MYCN-amplified cells.  The time to reach the 
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G2 phase was the same in both cell lines.  The MYCN-amplified cells also grew to 
higher confluence. 
Tests on the transfected cells led to several conclusions which can be applied to 
this experiment.  First immunofluorescence showed that all of the cells in the population 
responded to the MYCN induction.  This means that there should not be cell-to-cell 
variation in MYCN expression within a batch of treated of untreated cells.  Furthermore, 
both the control cell and tetracycline-induced cell MYCN proteins were able to bind with 
the MAX protein, so the pathway of the gene should be the same between the treated 
and untreated cell lines. 
When treated to amplify MYCN expression, MYCN protein was detectable in 4.5 
hours, and MAX protein was detectable after 5 hours.  Conversely, when amplified cells 
were treated to stop MYCN expression, the MYCN protein levels returned to normal 
after 4.5 hours. 
7.1.2.2 MYCN-3 Cell Line 
In 2005, Slack et al. described creation of a second neuroblastoma cell line, in 
which MYCN amplification could be controlled by tetracycline (Slack, A. et al., 2005).  
This cell line differs from the previous cell line because it displays MYCN amplification 
when treated with tetracycline, and it displays normal low-level MYCN when not treated 
with tetracycline.  This is an example of a TET-on gene expression system. 
They found the MYCN controls MDM2.  That stops p-53 apoptosis.  This cancels 
out the increased apoptosis caused my plain MYCN amplification.  MDM2 was 
increased 1.5-2.5x after NMYC amplification.  After induction, MYCN protein levels peak 
12-16 hours.  MDM2 was increased 2.8-3x after 24 hours MYCN induction. 
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7.1.3 Research Goal 
The goal of this chapter is to determine whether Raman spectroscopy can 
distinguish between cells with normal levels of MYCN expression and cells with 
increased MYCN expression.  It is unknown whether any changes detected would be 
due to increased MYCN protein expression or due to other downstream changes 
caused by increased MYCN expression. 
7.2 Materials and Methods 
7.2.1 Cell Culture 
All cell culturing was performed in a clean room under a negative-pressure hood.  
The Tet-on MYCN-3 cell line was provided by Dr. Jason Shohet (Texas Children’s 
Cancer Center, Houston, TX).  Cells were grown in RPMI 1640 media (Invitrogen) with 
10% tetracycline-free Fetal Bovine Serum (Invitrogen) and 1% penicillin/streptomycin 
(Invitrogen) supplementation.  MYCN was induced by adding 1 µg/mL doxycycline 
(Sigma Aldrich) to the media. 
For the preliminary study, we started with a T75 flask at 100% confluence 
(~5,000,000 cells).  Of those cells, 1/3 were re-plated into 3 T-25 flasks (totaling 1/9 of 
cells per T25).  The other 2/3 of the cells were discarded.  The following day, cells from 
one T-25 flask were isolated for Raman testing and PCR.  These cells were called the 
time=24 hour control sample.  At the same time, the media was changed in both of the 
other flasks, with one receiving plain media and the other receiving media with 
tetracycline supplementation.  24 hours later, cells from each flask were isolated for 
testing with Raman spectroscopy and PCR.  These cells were called the time=48 hour 
control and time=48 hour tet-on samples.  This experiment was repeated twice. 
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7.2.2 Cell Isolation 
Following trypsinization, cells were centrifuged for 5 minutes at 1200 RPM.  The 
supernate was removed, and cells were resuspended in phosphate buffered saline 
(PBS).  Cells were split between two centrifuge tubes so that three quarters of the cells 
were reserved for PCR and one quarter of the cells were used for Raman spectroscopy.  
Both tubes were centrifuged again at 1200 RPM for 5 minutes, and the supernate was 
removed.  The cells for Raman testing were resuspended in 1 mL of PBS.  Cells 
earmarked for PCR testing were either resuspended in lysing buffer and placed on ice 
until RNA isolation or placed in RNAlater for future RNA isolation. 
7.2.3 Raman Spectroscopy 
Following isolation, cells were moved from the clean room to a negative-pressure 
laboratory hood.   Cells were mixed with a micropipetter, and then a 200 µL drop was 
place on the end of a spectral grade UV-quartz slide.  UV-quartz was selected because 
it has a relatively low contribution to the Raman spectrum as shown in Figure 7.1.   
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Figure 7.1: Representative Raman spectra of a MYCN-3 cell (top) and UV quartz slide 
(below) 
 
 
Raman spectroscopy was performed using a Renishaw InVia Raman microscope 
with 785nm excitation wavelength and 1200 lines/mm grating identical to the system 
used in tissue studies.  The slide was placed on the microscope objective with the drop 
end hanging over the edge, as shown in Figure 7.2.  Because the cells in suspension 
and the UV-quartz slide are relatively invisible at 785 nm, the penetration depth of the 
laser is long enough to also excite the chemical bonds in the microscope stage.  
Therefore, the cells are hung over the edge of the stage to ensure there is no 
measurement error due to Raman signal from the microscope stage. 
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Figure 7.2: Schematic showing cell measurement setup 
 
A 60x Nikon dipping objective was used for all cell experiments.  The objective 
was lowered until it formed a bubble with the cell droplet, and then adjusted to focus on 
a single cell using the bright field microscope setting.  Healthy-appearing, round, single 
cells were selected for measurement, as shown in Figure 7.3.  The focus was adjusted 
so that cells were surrounded by a white ‘halo’ as shown in Figure 7.3.  Consistent 
measurement parameters of 10 accumulations of 10 seconds each at 50% power over 
the range 900-1800 cm-1 were used for all cells. We could not measure the Raman 
spectrum over the entire Raman range because UV quartz is not entirely invisible at 
785nm.  We found that the UV quartz caused significant interference below 900 cm-1. 
 
a b c  
Figure 7.3: a) shows an ideal cell for measurement.  The cell is clearly separated from 
surrounding cells and displays a white ‘halo’.  b) and c) show examples of cells which 
would not be measured because they are out of focus and too close to each other. 
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  When the drop of cells dried up or cells started exhibiting visible changes, a 
new 200 µL drop was placed on the slide.  To ensure cells were as close to their true 
normal state as possible, measurements were only performed within two hours of cell 
isolation.  This time constraint allowed us to measure 12-16 cells per batch. 
7.2.4 Confirmation of MYCN Amplification Using PCR 
Polymerase chain reaction (PCR) was used to verify the results of tetracycline 
treatment and amplification of MYCN.  Specific details and results can be found in 
Appendix D. 
7.3 Results 
PCR results for trial 2 were inconclusive so it was excluded from further analysis.  
For trial 1, PCR showed that tetracycline-treated cells exhibited about 11.8 times more 
MYCN cDNA than the non-treated control cells.  The time = 24 hour control cells 
displayed approximately 3 times more MYCN cDNA than the time=48 hour control cells.  
These results are shown in detail in Appendix D. 
Following elimination of Raman spectra with measurement error, the resulting 
data set for this trial included 8 spectra from the t = 24 hour control cells, 6 spectra from 
the time = 48 h control cells, and 12 spectra from the time = 48h tet-on cells.  The mean 
spectrum of each group is shown in Figure 7.4.  As shown, the mean spectra for each 
group are extremely similar and display only subtle differences. 
Preliminary confirmatory analysis was performed on the data using all peaks over 
the range of 924-1800 cm-1.  924 cm-1 was selected as the minimum value because 
some variables had values of zero below 924 cm-1 which adversely affected 
discrimination results.  The three groups were separated with 100% accuracy as shown 
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by the SPSS output in Table 7.1.  Because the data set used was so small (26 spectra), 
in-depth peak analysis was not performed. 
 
 
Figure 7.4: Mean spectrum of each group in the 3-flask experiment.   
 
Classification Resultsa 
 
Group Predicted Group Membership 
Total  1 2 3 
Original Count 1 8 0 0 8 
2 0 6 0 6 
3 0 0 12 12 
imensi on2 
1 100.0 .0 .0 00.0 
2 .0 100.0 .0 00.0 
3 .0 .0 100.0 00.0 
a. 100.0% of original grouped cases correctly classified. 
Table 7.1: Classification results using all peaks from 924-1800 cm-1.  Group 1is the 
control group at t=24h, Group 2 is the control 
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7.4 Conclusions 
This is the first study to examine the changing Raman spectra in a tetracycline-
controlled cell line.  Tetracycline was used to increase the level of MYCN RNA within 
the cells.  While it is not known if Raman spectroscopy is sensitive enough to measure 
the minor RNA changes in the cell, it should be sensitive enough to measure the effect 
of increased RNA and effects of other downstream regulatory changes, such as 
changes to the cell wall and receptors.   
A tetracycline-inducible cell line model was chosen for preliminary testing for 
several reasons.  First, the changes to the cell line caused by altered genetic 
expression are expected to be very subtle.  Testing a tissue model might obstruct the 
subtle changes of MYCN amplification due to the other extra-cellular components. 
Second, using a tetracycline-controlled cell lines allows isolation of all other 
experimental factors.  MYCN is associated with other poor prognostic factors, including 
tissue histology.  Testing MYCN amplification in a tissue model would inherently include 
histologic and other factors in the analysis, confounding the results.  Likewise, 
confounding variables would be hard to eliminate when testing several cell lines with 
and without MYCN amplification.  Tetracycline-inducible cell lines offer the most control 
over all other outside variables. 
An extensive study is needed to confirm the results found here.  A potential study 
design is described in Chapter 9, Future Work.  Hopefully, that research will further 
pinpoint which peaks are diagnostically useful in measuring MYCN amplification.  Once 
diagnostic peaks are selected, other neuroblastoma cell lines can be examined for 
MYCN amplification.  Catalogues exist which identify the MYCN genetic status of 
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various neuroblastoma cell lines (Thiele, C. J., 1998).  Finally, once MYCN amplification 
measurement is firmly established in cell lines, it can confidently be applied to tissue 
models.  MYCN amplification is routinely tested during pathology workup, so existing 
measurements could be used by simply correlating patient records to current Raman 
spectroscopic data (with proper Institutional Review Board approval). 
Some cells with MYCN deficiency still over express the MYCN protein (Cohn, S. 
et al., 1990; Wada, R. K. et al., 1993), but ALL cells with MYCN amplification have 
MYCN overexpression.  While it might not be possible to guarantee the presence of the 
MYCN gene amplification, Raman spectroscopy could definitely act as a screening tool 
for detecting tumors at risk for MYCN gene amplification.  If Raman could rule out 2/3 of 
cases which definitely do not have MYCN amplification and genetic tests were run only 
on the remaining 1/3 with MYCN protein, this would still offer a significant clinical 
improvement. 
In performing this study, other incidental findings were made (not mentioned in 
text) which may have scientific significance.  The Raman spectra of the MYCN3 cells 
exhibited changes when the CO2 level of the cell incubator was low, and when the cells 
changed from low- to high-confluence.  Further testing of these findings may show that 
Raman spectroscopy might have capability to act as a monitoring tool for cell viability. 
While the results of this experiment are promising, they can only be counted as 
preliminary.  Only 26 spectra were included in the data analysis.  In order to validate 
these findings, the experiment must be repeated.  Acquisition of more spectral data will 
also allow for identification of diagnostically significant peaks, which can provide 
122 
 
information about the underlying biochemical changes caused by increased MYCN 
gene expression levels.   
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CHAPTER 8 CONCLUSIONS 
8.1 Summary of Findings 
Neuroblastoma was successfully distinguished from other peripheral nervous 
system tumors, including ganglioneuroma, nerve sheath tumor, and 
pheochromocytoma.  It was also distinguished from healthy adrenal gland.  This is 
significant because it is the most common site of incidence for neuroblastoma.  Likewise 
it was successfully distinguished from tumors with similar histology, including 
rhabdomyosarcoma, non-Hodgkin lymphoma, and Ewing sarcoma.  Improved 
processing techniques allowed identification of specific peaks which were diagnostically 
significant.   
Frozen tissues were evaluated to see if they could be used within a diagnostic 
database.  Fresh tissue data classified frozen tissue data with 100% sensitivity and 
specificity.  Frozen tissue data could classify fresh tissue data with high sensitivity and 
specificity as well, although the inclusion of more data should further improve results. 
In-depth examinations of some prognostic markers of neuroblastoma were also 
performed.  Raman spectroscopy was able to identify favorable and unfavorable 
histology neuroblastomas, as judged by the Shimada classification in fresh and frozen 
tissues.  A blinded study of frozen tissues supplied by the Children’s Oncology Group 
was performed to further gauge classification ability. 
Finally, the tetracycline-controlled MYCN-3 cell line was used to identify the 
specific changes due to increased MYCN gene expression in a cell line.  These results 
can later be validated with additional testing.  It may be possible to extrapolate these 
findings to whole tissue samples. 
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8.2 Novelty and Significance 
This is the first research using Raman spectroscopy to identify cancer in a 
human pediatric model, specifically, neuroblastoma.  While many other types of cancer 
with higher incidence rates have been examined, tumors with lower incidence have 
largely been ignored.  Neuroblastoma was identified from other tumors of the peripheral 
nervous system, and from tumors which had very similar histologies.   
Identification of neuroblastoma from other small round blue cell tumors is 
especially significant, because current state of the art tests take two days or more.  
Rapid identification of neuroblastoma and other small round blue cell tumors offers a 
considerable improvement in patient care, and allows immediate treatment planning. 
This is the first study using Raman spectroscopy to identify the favorability of a 
tumor.  The histologic Shimada classification is an important factor in determining the 
prognosis of a neuroblastoma tumor.  Using Raman spectroscopy could offer a more 
objective evaluation of tumor histology (and underlying biochemistry) and remove inter-
observer bias.   
Evaluation of frozen tissues provided by the Children’s Oncology Group led to 
several questions which must be addressed in the future.  Specifically, better methods 
for classifying tumor histology were proposed, removing age from an otherwise 
biochemical-based histologic classification, and judging effect of treatment by specific 
histologic changes which occur in the tissue.  Additionally, future studies must also be 
performed to better understand the changes caused by switching components in the 
Raman spectrometer, and to address these issues, possibly through enhanced data 
processing techniques. 
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Finally, this is the first study which measures changes in genetic expression 
within cells using Raman spectroscopy.  Genetic testing takes several days to reach a 
definitive diagnosis, whereas Raman spectroscopy can provide an immediate answer.  
Again, this offers a major benefit over the accepted testing method.   
If each of these individual testing components is combined into a single model, 
Raman spectroscopy could provide an immediate, complete diagnosis of 
neuroblastoma, including an objective measure of tumor aggressiveness.  If Raman 
spectroscopy is used in the operating room, physicians can begin development of a 
treatment plan before the surgery is complete.  Increased accuracy in diagnosis may 
improve development of treatment plans, leading to better outcomes, just as shorter 
time to treatment may improve outcomes. 
Improved diagnostic models may also allow for real-time scanning of tumor 
margins during tumor resection surgeries.  Normally in tumor resection, the area 
surrounding the tumor (margin) is sent to the pathology laboratory while the surgery is in 
progress.  An experienced pathologist examines the tissue for any remaining tumor 
cells.  If cells are found near the excision border, more tissue is removed and again sent 
for pathologic testing.  This process is expensive and time consuming.  It may be 
possible, instead, to scan the tumor margins intra-operatively for remaining tumor cells.  
It could offer quicker and more accurate results than frozen section analysis. 
Since this research was extremely successful in identifying neuroblastoma and 
its prognostic markers, another logical next step is to expand the research to other 
tumors.  Raman spectroscopy has strong potential to dramatically impact the field of 
cancer diagnosis if other tumors can be identified as well as neuroblastoma. 
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CHAPTER 9 FUTURE WORK 
While this work represents a great advance in clinical applications for Raman 
spectroscopy, specifically for advanced diagnosis of neuroblastoma, it naturally leads to 
many more questions and problems which must be addressed. 
9.1 Data Processing to Account for Changing Hardware Components 
Before Raman spectroscopy can be used clinically as a diagnostic tool, there 
must be a system developed which can account for changes in the Raman spectra due 
to switching out hardware components within the system.  For example, Chapter 6 
discusses the differences in the Raman spectra between two Leica-brand lenses and 
one Nikon-brand lens.  Each lens had different underlying background signals, even 
when measured on the same tissue.   
When Raman spectroscopy is used clinically, the system will have even more 
components which can impact the Raman spectra.  Parts such as filters, grating, and 
even laser light sources vary slightly from piece to piece, and they each have a limited 
shelf life.  This means system components may change throughout the lifespan of a 
product.  As a specific component begins to fail, the Raman spectroscopy may exhibit 
subtle changes over time.  Furthermore, an ideal Raman spectrometer would have 
interchangeable parts so it could be customized for specific applications.   
These needs require a method for normalizing variations in Raman spectra due 
to changing equipment.  Since software methods already exist for background 
subtraction, they may be the best avenue for addressing these needs in the future. 
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9.2 Clinical Testing for FDA Approval and Obtaining Reimbursement Codes 
Before moving into the truly clinical realm, Raman spectroscopy must go through 
a series of validation steps, including FDA approval.  This includes approval of the 
instrument to be used as well as the diagnostic algorithms and databases used.  As a 
starting point, the FDA safety requirements and procedures must be examined.  Once 
the process is understood, the application process can begin.   
Simultaneously, investigation should begin towards establishing a standardized 
reimbursement code (CPT) for hospitals to use in procedural billing (Association, A. M.).  
The technology may fall under an existing code, or it may require development of a new 
code.  If that is the case, a Category III (experimental) code can be obtained during FDA 
testing (Association, A. M.).  Within five years, it can be changed to a Category I 
(procedural) code once requirements for a Category I code are met (Association, A. M.). 
9.3 Study Expansion to Other Pathologies 
Neuroblastoma represents just one of dozens of diseases which pose significant 
diagnostic problems.  Since Raman spectroscopy displays great promise in diagnosing 
neuroblastoma from similar tumors and great promise in diagnosing specific parameters 
of neuroblastoma aggressiveness, it is logical that it be applied to other diseases and 
disease processes.  It can also be used to track the effects of drug treatment, either 
through tissue testing, or ex-vivo testing on cells.    
When higher incidence tumors are studied, there is also a possible business 
opportunity for developing commercial laboratory and surgical biopsy tools.  A brief 
market analysis of high-incidence tumors is shown in Appendix E. 
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9.4 Biochemical Correlation to Raman Spectroscopic Peaks 
The studies described in this dissertation go as far as to identify peaks which are 
diagnostically significant.  However, there is not yet an attempt made to correlate these 
peaks to their biochemical correlates.  Some of the Raman peaks which were 
diagnostically significant were actually valleys or slopes between peaks.  An in-depth 
study is needed to determine why these Raman features were significant and to 
determine what they represent.  Once the identity of the Raman features is established, 
they can be traced back to the underlying cancer biology, and conclusions can be 
drawn regarding underlying biological processes in the disease progression. 
9.5 Development of a Cell-Line Database 
Raman spectroscopy was highly sensitive and specific at detecting even the most 
subtle genetic changes in the MYCN-3 cell line.  This suggests that Raman 
spectroscopy could easily detect less-subtle changes within cells, and it should easily 
be able to distinguish from cell line to cell line.  Building a database of existing cell lines 
would provide a valuable tool to basic science researchers.  Once a database is 
created, further subtleties can be cataloged, including changes in the Raman signature 
due to genetic alteration, drug treatment, etc. 
An incidental finding in this work was that Raman spectroscopy could detect 
changes in the Raman signal of cells due to changes in their environment.  Changes 
which appeared to be measurable using Raman include cell confluence, CO2 levels in 
incubation, and quality of cell media being used.  While monitoring these changes does 
not relate to cancer diagnostics, it opens up another avenue for Raman spectroscopic 
research.   
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9.6 In-Depth Measurement of MYCN Gene Amplification 
The research performed measuring MYCN amplification was only a preliminary 
study.  Further testing is necessary to confirm these results.  A detailed follow-up study 
is outlined which measures MYCN amplification at several time points and compares it 
to untreated control samples at every time point.  If there are measurable changes due 
to cell confluence, this experiment will also find those changes. 
First, determine a growth curve for the cell line to determine the ideal plating 
densities.  Grow cells to confluence in a T-75 flask.  Trypsinize the flask and split the 
cells equally into 7 groups.  Isolate 1/7 of the cells for immediate Raman testing.  
Replate the remaining six groups into six T-25 flasks.  They should be plated at 
approximately 20% confluence.  Treat three of the flasks with doxycycline to induce 
MYCN amplification.  Harvest the cells and measure the Raman signatures from one 
control and one MYCN-amplified flask at the time points of 6 hours, 24 hours, and 48 
hours.  Figure 9.1 graphically depicts the experimental design.  
 
 
Figure 9.1: Experimental design.  Control cells were tested at time = 0 hours.  Control 
and MYCN-amplified cells were tested at time = 6 hours, 24 hours, and 48 hours. 
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1 APPENDIX A INTERNAL REVIEW BOARD DOCUMENTATION  
1. COPY OF CURRENT PROTOCOL 
Raman Spectroscopy for Diagnosis of Pediatric Neoplasms 
Objectives: 
This project seeks to evaluate the Raman spectroscopic signals associated with 
normal and malignant variations of different pediatric tissues.  The specific objectives of 
this project are: 
1. Use variations in spectra to differentiate between normal, benign, and malignant 
tissue. 
2. Examine various tumor grades of the same tissue type in order to allow 
development of a new grading scale for tumor differentiation based on molecular 
composition. 
3. Build a database of frozen tissues, which are more easily accessible.  Frozen 
tissues can be correlated to similar fresh tissues.  
4. Develop a Raman spectroscopy database of various tissue types. 
5. Finally, our goal is to use the identified wavelengths for tissue diagnosis and 
condense the laser mechanism to incorporate laser emission and signal 
detection into a fiber optic probe.  This will allow intra-operative use in tumor 
diagnosis and scanning tumor beds for residual malignant cells.* 
Background Information: 
Currently, gross and histopathologic diagnosis is routinely performed for resected 
tissue in cases of neoplastic growth. These diagnoses are often times delayed, 
inaccurate on frozen section and provide limited prognostic value. The state of genetic 
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testing and prognostication are not fully developed and are mainly utilized in academic 
investigation. 
Various alterations occur during the degeneration of normal tissue to neoplastic 
tissue. As a result of this process, the cellular makeup of this tissue can be significantly 
different. For example, changes in protein to lipid ratios, protein and DNA modifications 
and or changes in DNA content have been reported to occur in association with 
neoplastic change.  These tissue changes can be precisely detected by Raman 
spectroscopy. 
The Raman Effect occurs when light incident on a sample is scattered at a new 
wavelength due to donation of energy to the sample’s vibrational bonds.  A photon of a 
new wavelength is emitted, and the change in wavelength is proportional to the change 
in vibrational energy in the sample.  These changes in wavelength can be correlated 
with specific chemical constituents, yielding a “molecular fingerprint” that is unique to 
each sample. 
 In the past decade, Raman spectroscopy has been applied for identification of 
human normal and malignant tissues, including breast (Haka, A. S. et al., 2006b), skin 
(Nijssen, A. et al., 2007), colon (Chowdary, M. V. et al., 2007), esophagus (Shetty, G. et 
al., 2006b), neuroblastoma(Rabah, R. et al., 2008; Wills, H. et al., February 2008), and 
Wilms’ Tumor (Wills, H. et al., (Submitted)) with high sensitivity and specificity.  
Specifically, our group has published reports on breast cancer (in mice) (Kast, R. E. et 
al., 2008; Thakur, J. S. et al., 2007), pancreatic ductal carcinoma (in mice) (Pandya, A. 
et al., 2008), neuroblastoma and related nerve tumors in children (Rabah, R. et al., 
2008; Wills, H. et al., February 2008), and Wilms tumor in children (submitted) (Wills, H. 
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et al., (Submitted)).  We have also examined smaller samples of many pediatric 
cancers, including brain, bone, lymph node, testicular and soft tissue cancers.  To date, 
we believe we are the only group which focuses specifically on pediatric neoplasms. 
Our long-term goal is to develop a fiber-optic probe which can be used to 
evaluate tissue disease status in near-real time.  This will have applications from basic 
science to margin assessment in tumor resection. 
Aims: 
The aims of the study are to evaluate all tissue resections or biopsies obtained 
by various surgical specialists at Children's Hospital of Michigan, and Detroit Receiving 
Hospital. Such methods will reveal spectral correlates of normal and abnormal tissue in 
children compared to pathologic readings to determine validity of this new technique. 
This technique will be utilized on fresh tissue and archived tissue from pathology. 
This data will be used in developing microprobes that will allow in vivo detection 
of tissue in a less invasive and more accurate manner. This will also serve as an 
important diagnostic tool in evaluating the tumor bed after resection. 
Materials and Methods: 
Patient Selection-Inclusion/Exclusion Criteria: 
All patients at Children's Hospital of Michigan and Detroit Receiving Hospital that 
undergo resection or biopsy will be eligible for the study. The study will encompass all 
surgical fields and will attempt to evaluate all tissue regardless of site of origin. Only 
patients who do not have sufficient tissue to evaluate by both histopathology and by 
Raman spectroscopy will be excluded. Pathology will have the priority in evaluating 
tissue for diagnosis. 
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The study will involve a minimum of 600 subjects with the aim of developing a 
Raman database of various tissue types.  Hepatoblastoma, neuroblastoma, Wilms 
tumor, Ewing sarcoma, lymphoma and intracranial neural tumors are some of the 
malignancies that will be evaluated, but we will also evaluate normal tissue from many 
organs. Subjects will be enrolled regardless of gender, race, or ethnicity. All patients 
identified as having tissue submitted for pathologic diagnosis will be enrolled.  Normal 
control samples will be obtained from autopsy cases.  A copy of the autopsy consent 
form is attached. 
There will be no additional risk to the patients as a result of conducting this study. 
All samples will have undergone resection or biopsy as a matter of diagnostic and 
therapeutic intervention. This study will only utilize tissue samples already removed 
from the patient. 
No consents will be obtained, but patient confidentiality will be maintained. The 
study coordinator (RK) will be responsible for maintaining all medical information.  Any 
identifying patient information will be removed from records before being accessed by 
the rest of the group.  Patients will be assigned a unique identifier which is not 
associated with a patient record number.  The link to patient information will be stored 
on a computer in the department of surgery office. 
Apparatus 
A Raman spectroscopy unit consists of an Argon pumped Titanium: Sapphire 
laser, collection optics and spectrometer with a silicon based charge-coupled device 
(CCD). Selected wavelengths (514.5 nm & 785 nm) with detectable reflected intensities 
will be studied. These wavelengths were selected due to their use in previous studies 
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and existing knowledge of Raman effect on biologic tissue at varying wavelengths while 
limiting background fluorescence.  
A Verax InPhotonics portable Raman spectrometer is also available with a 785 
nm, 350 mW class III excitation laser.  There is a short fiber optic coupling probe, and a 
long, skinny attachment.  The probe will be used to interrogate pathology samples and 
will not be used for in-vivo testing. 
Background spectra of samples will be obtained for the glass slide, cover slip, 
Acrytol mounting media, formalin and paraffin.  This background spectral data is 
important in studying tissue because these chemical signatures may be included in the 
spectral findings. Once background information is collected, archived tissue slides of 
hepatoblastoma, neuroblastoma and Wilms tumor along with normal tissue from the 
same patients will be analyzed. 
Raman Measurement  
The Raman technician will cut the tissue into smaller specimens if necessary, 
and measure the Raman spectrum of the tissue using a Raman spectrometer.  Raman 
spectroscopy is performed by mounting the tissue sample on a microscope stage 
(translational stage) with x, y and z coordinates. No sample pre-treatment of any kind 
will be performed on the tissue prior to spectroscopic examination. The laser light is 
focused on the tissue and the Raman spectra will be measured using a 10 second 
exposure time. Two exposures will be obtained to get an average reading for better 
signal-to-noise ratio. At least 12 spectra will be obtained from each tissue for each 
wavelength of light, unless quality spectra cannot be obtained from the sample.  Spectra 
will be collected at random locations for each sample. 
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Following measurement, samples will be placed in a cryovial, labeled with a 
unique pathology code, and stored in a -80°C freezer .  At a later date, tissues will be 
removed from the freezer, placed in saline, thawed for 20-60 minutes, and tested again 
according to the same procedure.  Following testing, the samples will be replaced in the 
cryovial and put back in the freezer. 
 Periodically (depending on the rate of accrual), study pathologists (RR or JP) will 
again remove the frozen samples to cut a frozen H&E section; the remainder of the 
tissue will again be stored in the freezer.  Frozen sections will be examined by light 
microscopy to determine the ‘gold standard’ diagnosis, which will be used to create a 
model of the tissues. 
 Tissues will be stored in the freezer for up to 10 years, in case there is question 
about the diagnosis of the sample.  In the event of a disagreement between histology 
and Raman spectroscopy, a second frozen H&E section will be cut to re-examine the 
tissue with light microscopy.  If a Raman spectrometer is obtained which uses a 
different excitation wavelength, tissues may be re-examined at the new excitation 
wavelength to help construct a database at the new wavelength. 
COG Samples 
 Additional samples will be shipped frozen to Children’s Hospital of Michigan from 
the Children’s Oncology Group.   
Data Management 
 The study coordinator will be in charge of the data management. She will be 
primarily responsible for arranging sample delivery from the operating room, arranging 
testing schedules for researchers, doing the data processing, and downloading the data 
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to a secure server. She will record diagnostic information provided by pathologists and 
store patient records in a locked drawer in the Harper Hospital surgery offices.  Data will 
be stored on a secure online server.  Parameters for each tissue, including the tissue 
code, date collected, and type of disease will be stored on a secure online SQL 
database, with links to the data files on the secure server.  Only the study coordinator 
will have access to patient-identifying information. 
Conflict of Interest and Funding 
 There are no conflicts of interest to report for any of the investigators.  The study 
will be funded by Children’s Hospital of Michigan. 
Statistical Analysis: 
10-20 spectra will be collected from each tissue sample.  Each spectrum will be 
pre-processed by an algorithm to remove cosmic rays, noise and fluorescence 
background from the Raman spectra (Cao, A. et al., 2007).  Spectra will be evaluated 
with all peaks, in order to get the full biochemical understanding of the sample, 
however, spectra will also be compressed using Principal Component Analysis to 
minimize file size for diagnostic testing.  Variations in peak spectra for patient to patient 
variability as well as variability between archived and fresh tissue of similar tumors will 
be analyzed. 
Box plots will be used to remove outliers from the data.  Relevant peaks for 
biochemical analysis can be chosen using four approaches: (1) Subjective observation 
of the spectra by an experienced Raman investigator, (2) A Matlab program will be 
created which will extract the N highest peaks, (3) Relevant literature will be consulted 
which lists the Raman peaks for specific chemicals, (4) Principal component analysis 
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(PCA) will be used to reduce the data into a smaller number of variables. We will retain 
the first N principal components that account for >90% of the variance. 
Discriminant Function Analysis and Neural Networks will be used to build 
diagnostic models of the tissues for classification.  The ‘gold-standard’ diagnosis 
provided by the pathologists will serve as the training mechanism.  Two approaches will 
be used for testing and training, as both have benefits and drawbacks: (1) data sets will 
be randomly split in half, with one half being used for ‘training the  model’ and the other 
half being used for ‘testing the model’.  After classification, the groups will be reversed 
to get a classification picture of the whole dataset.  (2) Leave-one-out analysis will 
create a model of the tissues based on all the spectra except one.  The single spectrum 
will then be tested with the model.  After testing, that spectrum will be replaced in the 
dataset and another spectrum will be removed.  Again, a new model will be created, 
and the spectrum will be tested on that model.  The process repeats until all the spectra 
have been tested in this manner. 
When the data and histological diagnosis permits, we will breakdown the tumors 
according to the grade, treatment, or other parameters and repeat the procedure to 
determine the sensitivity and specificity for different grades of tumors.  Analysis will also 
be done to examine the effects of freezing on Raman spectra.  If frozen spectra  
Significance: 
This work has potential significance in tumor diagnostics. It can serve in a 
minimally invasive fashion and allow optical diagnosis of abnormal tissues. It may also 
lead to developing better prognostication data and serve to yield a molecular analysis of 
gross tissue. These molecular signals may allow for further classification of tumor 
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variants and allow for more precise grading.  It also holds potential for tumor bed 
scanning and obtaining a molecular scan o surface tissue to detect abnormal areas. 
Budget Justification: 
The College of Engineering has been working on issues relating to the 
automotive industry and has started to become more interested in biomedical 
engineering. The School has acquired many expensive fabrications and measurement 
instruments over the years and will fully utilize them in this project. 
The requested items under supplies are specific for this project due to the 
necessary adaptation to the equipment to perform these readings. An example is the 
translation stage and mounting posts kit required for measurements on slides or tissue 
cassettes. Other items such as sapphire substrates are consumable items utilized over 
the course of the project. The other major items are two notch filters required 
specifically for the wavelength utilized for biologic tissues. All of the major equipment is 
already on site and will not be paid for in any manner by this grant. No items are being 
requested for this study, as they are already available on-site. 
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2. 2009 PROGRESS REPORT SUBMITTED TO IRB 
Our hypothesis is that an imaging technique called Raman spectroscopy can 
distinguish between normal and cancerous tissue. The goal of the study is to develop a 
Raman database of various tissue types.  Building a database of ‘normal’ versus 
neoplastic tissues will aid in the development of a surgical tool for near real-time cancer 
detection. 
We collect normal and tumor tissues from resections and biopsies obtained from 
the operating room.  We also collect tissue samples from autopsies.  Most tumors have 
some normal tissue at its surroundings.  When possible, the pathologist takes two 
samples from the tissue: one tumor and one normal. We collect Raman signals from 
both samples. Then the samples are sent to histopathology, or frozen for future testing. 
The Raman signals are statistically analyzed to see if there are any differences between 
normal and cancerous tissue.  We also see if we can predict what kind of sample it is 
from the Raman signal. This prediction is compared to the histopathological findings.   
We recently began collaboration with the Children’s Oncology group, where they 
sent us frozen samples of neuroblastoma (cancer of the adrenal gland or nerves) and 
similar tissues.  This blinded study will support our hypothesis and aid us in collecting 
this rare type of tumor. 
We have collected 350 tissues from 30 different tissue types.  This year, two of 
our papers were published (submitted last year, titled: Raman Spectroscopy Detects 
and Distinguishes Neuroblastoma and Related Tissues in Fresh and (Banked) Frozen 
Specimens, and Diagnosis of Wilms Tumor Using Raman Spectroscopy), and we 
submitted a new paper to the journal of pediatric surgery titled “Differentiation of Small 
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Round Blue Cell Tumors Using Raman Spectroscopy”.  Instead of comparing normal vs. 
cancerous, this paper compared tumors which look the same using traditional pathology 
methods.  Our findings showed that Raman spectroscopy can quickly and accurately 
distinguish these types of tumors which are otherwise hard to tell apart.  We will also 
present this paper at the American Academy of Pediatrics National Conference and 
Exhibition October 17-20, 2009 in Washington DC. 
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APPENDIX B RAMAN SPECTROSCOPY DATA PROCESSING 
Preprocessing Data (may apply to cancer data only) 
1. Put all the data files in the same folder. 
2. Put a copy of adaptminmax######.m, combinespectra######.m, and 
meanspectraplot.m into the same folder 
3. Open Matlab 
4. Click […] button next to the ‘current directory’ field and browse to select the folder 
your data is in 
5. Type ‘dir’ into the command window to get a list of all the files in the folder 
6. Highlight the filelist and press ctrl+c to copy the list (See Rachel for the secret trick if 
your filelist is longer than the command window in Matlab) 
7. Open the notepad program and press ctrl+v to paste the list 
8. Go through the list and delete any items which are not file names.  If non-spectral 
files are included, you will get an error when you try to process the data 
9. Save the file as ‘filelist.txt’ 
10. In the Matlab command window, type ‘adaptminmax######’ and press enter to run 
the preprocessing program 
11. You will be asked if you want to see the graphs.  Type ‘1’ for yes and press enter 
12. The processing program will begin preprocessing.  For each file, a new graph will 
open which shows the original data and background subtraction on the top, and the 
processed spectrum on the top.   
13. Relax for 10 minutes or so while the computer processes.  The program is setup to 
pause after it processes 100 files.  Sit back until you get to a pause.   
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14. One-by-one, look at each spectrum to see if it looks decent, and then close each 
window.  Write down a list of all the files which look bad as you do this.  Possible 
reasons for exclusion include: spectrum of glass or stainless steel, cosmic rays 
which were not removed, measurement which was stopped mid-way, etc 
15. Save this list for later.   
16. Once you’ve gone through all the files, you will be back at the Matlab command 
window.  It will say ‘Press any key to continue’.   
17. Press any key to continue (pretty self explanatory, I know) 
18. Repeat steps l-q until all your files are preprocessed 
19. Once a file is preprocessed, the code ‘amm-‘ is appended to the file.  That is how 
you can identify processed data.  You will also notice that map files which had many 
points are now separated into individual processed files. 
Combine all the individual files into one mega-file 
20. Open windows explorer and navigate to the folder where your data is stored 
21. Copy all of your original data into a new subfolder (I suggest naming the folder 
‘Original’ or ‘Original Data’ or something similar, for easy identification if you need it 
later).  You won’t need it anymore for data processing 
22. Remember that list you made with all the bad files?  It’s time to get rid of them so 
they aren’t included in the analysis.  Go through and delete all of those bad boys.  
Make sure you’re deleting the processed files (with ‘amm-') and not the original files 
23. Go back to Matlab and type ‘dir’ into the command window to get a list of all the files 
in the folder 
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24. Highlight the filelist and press ctrl+c to copy the list (See Rachel for the secret trick if 
your filelist is longer than the command window in Matalb) 
25. Open the notepad program and press ctrl+v to paste the list 
26. Go through the list and delete any items which are not file names.  If non-spectral 
files are included, you will get an error when you try to combine the data into one file.  
Make sure that you are looking only at processed files.  You don’t want any original 
files included in the filelist. 
27. Save the file as ‘filelist.txt’ 
28. Go back to Matlab again (we’re almost done in Matlab, I promise!) and type in 
‘combinespectra######’ 
29. You will be asked if you want to create separate files or one big file.  For now, we 
want to make one big file so we can import all the data into SPSS at once.  Type ‘b’ 
and press enter. 
30. The command window will say ‘filelist.txt has ### files’, then it will work for a couple 
minutes to create the file.  It is done when you get a message which says 
‘allspectra.txt being created’. 
Import Data Into SPSS and Setup your data 
31. Open SPSS. 
32. If the intro window pops up, press Cancel. 
33. Select File/Read Text Data 
34. In the browser that pops up, navigate to your data folder, and select ‘allspectra.txt’, 
then press ‘open’ 
35. You will then go through a wizard system to help you import the data.   
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a. In Step 1, select ‘No’, then press the Next button 
b. In step 2, select ‘yes’ for ‘Are variable names included at the top of your file?’ 
c. In step 3, press the Next button – the defaults are all ok here 
d. In step 4, un-select ‘Space’ as a delimiter and press Next 
e. In step 5, you will get an error that the file names are not an appropriate 
format.   Press ok, then next 
f. In step 6, press finish to complete the import process 
36. If you are trying to append new data to an existing SPSS file, there are many more 
steps.  For now, see Rachel.  Full notes will be written later 
37. SPSS has 2 views you can look at.  You switch between the views by choosing the 
‘Data View’ tab or the ‘Variable View’ tab at the bottom.  The data view tab is just like 
an Excel spreadsheet.  Each row represents a single case, and each column 
represents a variable.  The variable view tab is where you can add variables, change 
their format, etc.  In this view, each row represents a variable, and the different 
columns represent different parameters for those variables.  We need to add in more 
variables such as the filename, diagnosis, etc before we can classify data. Right now 
the only variables in SPSS are the peak intensities at each wavenumber.   
38. To add variables, go to the variable view tab.  Right click on row 1 and select “Insert 
Variable”. 
a. Create a filename variable.  Double click in the name column to change the 
variable name to ‘filename’.  Click on the ‘Type’ for the variable and a […] 
button will appear.  Click on that.  In the ‘Variable Type’ window that pops up, 
select ‘String’.  In the ‘Characters’ tab, delete the 8 and put a more 
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reasonable number – think about how long your filenames would be – I 
recommend a nice large number like 100. 
b. Create a variable for tissue/cell/bacteria/etc type.  Again, right click on row 1 
and select “insert variable”.  Double click in the name column to change the 
variable name to whatever is suitable for your data.    This time, we will leave 
the variable type as ‘numeric’.  Change the ‘decimals’ field for the variable to 
‘0’.  This just makes your data look prettier.  Click on the field in the ‘values’ 
tab, then click the […] button.  This lets you make a key so that your numeric 
variable correlates to a text value.  The text values will appear in the analysis 
output in your results.  The value field will be a number (use consecutive 
numbers) and the label field will be the string value.  For example, 
1 neuroblastoma 
2 ganglioneuroma 
3 normal adrenal gland 
c. Create any other variables that are necessary for your analysis. 
39. Now you have to enter in the information about each of your files!   
40. Open notepad, and open the filelist.txt file.  Use ctrl+a to select the whole filelist, 
then ctrl+c to copy it 
41. Go to the data view tab in SPSS 
42. Highlight the filelist column and press ctrl+v to paste the filelist.  Now you don’t have 
to enter all the filenames manually! 
43. Go through the rest of your columns/variables and fill in the information.  (Hint: copy 
& paste speed this process up a lot) 
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Process Data 
When you open SPSS, there are 2 windows.  The first window is your data 
window (which has the data view tab and your variable view tab).  The second window 
is the output tab.  When you do analysis, the results will be shown in the output window. 
For analysis in SPSS, there are approximately 1.3 gazillion ways you can 
analyze your data.  I will explain how to do 2 essential methods: Principal Component 
Analysis (PCA) and Discriminant Function Analysis (DFA).  PCA compresses the 
variability of your data set from many hundred variables to 5-20 really essential ones.  It 
is up to you whether you want to perform PCA before doing DFA.  If you want to look at 
the significance of your actual peaks, it’s better to just run DFA.  If you want to 
compress your data into a smaller set and then perform analysis, use PCA.  DFA is the 
classification method.  You have 3 methods for training: (1) do the classification based 
on all the data.  This method has no validation and is not recommended.  (2) Perform a 
leave-one-out analysis.  In this method, a single spectrum is removed from the data set.  
DFA is performed on the remaining (n-1) files, and then the classification is applied to 
the single point.  Then, another single spectrum is removed from the dataset and 
classification is performed again.  This process repeats over and over until it has been 
performed for each point.  If you have a reasonably sized data set, the changes to the 
PCA structure are so minimal that you do not need to do leave-one-out analysis on the 
PCA.  (3)Test/Train grouping.  In this method, you split your data in half into a testing 
group and a training group.  You would create a placeholder variable (as described 
earlier) – for instance, ‘1’ could represent training group, and ‘0’ could represent the 
testing group.  You would perform PCA (if desired) and DFA on the training group to 
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build your model, and then test it with the training group.  You could then switch, and 
make the training group the test group and vice versa. 
Selecting Cases for Analysis 
Let’s say that you have three groups in your data set, but only want to compare 
groups 2 & 3.  In that case, we need to temporarily eliminate group 1 from the data set.   
44. Select Data/Select Cases from the menu 
45. In the Select area, choose “if condition is satisfied”, then press the “if” button 
46. In the pop up window, you will put in logic code to choose the cases you want to 
KEEP.  You can automatically move variable names from the left window, or you can 
manually type them in.  The logic buttons are below.  The & means ‘and’.  The | 
means ‘or’.  Make sure to use proper parenthesis if you are using complicated logic. 
47. For example, if you wanted to select groups 2 & 3 as described above, you could 
type either of the following: 
(Group=2) | (Group = 3)    Group = (2 | 3) 
48. For a more complicated example, suppose you want to look at 2 groups, where 
group a is fresh, untreated tumors and group b is frozen, treated, normal tissues.  
You might use the following code: 
((Treatment = 1) & (Temp = 1) & (Tumor = 1)) | ((Treatment = 0) & (Temp = 0) & 
(Tumor = 0)) 
49. When you are satisfied with your selection press the ‘continue’ button, and then 
press the ‘ok’ button. 
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50. You should check your data before proceeding to make sure you selected the 
correct cases.  All of the cases which are temporarily excluded will have a diagonal 
line through their case number on the left hand side of the data window. 
Performing Principal Component Analysis 
51. From the data window or the output window, select Analyze/Dimension 
Reduction/Factor 
52. In the left hand column, select all of the Raman peak variables (you can hold down 
the shift key and use the mouse to quickly scroll through the list).  Press the right-
facing arrow button to move them to the variables column.  These are the variables 
which will be used for analysis.  If you don’t want to use all the variables, only select 
the ones you want. 
53. If you only want to do PCA on a specific group such as a training group, (it will be 
applied to everything else automatically) select the variable for the desired group, 
and use the bottom right-facing arrow to move it to the selection variable field.  Click 
on the value button.  In the pop-up box, enter the value you wish to use for the 
training group. 
54. Press the extraction button.  In the ‘analyze’ area, select ‘covariance matrix’ (instead 
of correlation matrix) then press continue. 
55. Press the ‘scores’ button and select ‘save as variables’.  Then press continue. 
56. Press ‘ok’ to run the analysis 
Reviewing Principal Component Analysis Results 
57. The results will show in the output window. 
58. Principal components with an eigenvalue >1*the mean eigenvalue are saved.   
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59. The ‘Total Variance Explained Table’ shows you how many Principal components 
were saved.  The 2 right hand columns are the important ones.  They show how 
much variance is explained by each principal component individually and 
cumulatively.   
60. The ‘Component Matrix’ table shows the weighting factors of each variable for each 
component.  This would be important if you wanted to determine which chemicals 
are represented in each PC.  For instance, you could do further testing to examine 
how diagnostic each PC is, then determine which chemicals are diagnostic.  You’re 
probably better off just doing this with DFA results though. 
Discriminant Function Analysis 
61. From the data window or the output window, select Analyze/Classify/Discriminant 
62. In the left hand column, select the variable which you are classifying, and use the 
top blue arrow to move it to the ‘grouping variable’ field.  Press the ‘define range’ 
button and enter the minimum and maximum values for your classification variable.  
If you have 2 groups, this might be 1, 2; three groups would be 1, 3, etc 
63. In the left hand column, select all of the Raman peak variables (you can hold down 
the shift key and use the mouse to quickly scroll through the list).  Press the middle 
arrow button to move them to the ‘independents’ column.  These are the variables 
which will be used for analysis.  If you don’t want to use all the variables, only select 
the ones you want. 
64. Press the ‘Classify’ button.  In the ‘display window, select the following 
a. ‘casewise results’: this will show you case-by-case results in a huge table.  If 
you want to examine misclassified cases, you will need this table 
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b. ‘summary table’: this will give you overall classification percentages.  If you 
have 2 groups (cancer/normal), it is like sensitivity and specificity.  If you do 
leave-one-out analysis or test/train analysis, the table will be twice as long, 
with original classification (no special training) on top, and the leave one out 
or test/train analysis on the bottom.  Make sure you are careful which half you 
look at when writing your results. 
65. If you think you might want to access your results later or make a pretty plot, press 
the save button and check the ‘discriminant scores’ box.  Then press continue. 
66. Setup the specific training parameters you wish to use 
a. If you don’t want to do any special training, no extra steps are necessary. 
b. If you are doing train/test analysis, select the associated variable in the left 
hand column, and use the bottom blue area to move that variable to the 
‘Selection Variable’ field. 
c. If you are doing leave-one-out analysis, press the ‘classify’ button.  In the 
‘display’ area, check ‘leave one out classification’ then press continue.  Click 
on the value button.  In the pop-up box, enter the value you wish to use for 
the training group. 
67. Press ‘ok’ to run the analysis 
Reviewing Discriminant Function Analysis Results 
68. The results will show in the output window. 
69. The number of discriminant functions/standardized canonical discriminant functions 
will be 1 less than the number of classification groups.  (if you have normal/cancer 
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there will be 2-1=1 group, if you have normal/benign/cancer, there will be 3-1=2 
groups).   
70. The ‘standardized canonical discriminant functions’ and ‘structure matrix’ tables can 
show which Raman peaks are significant for each discriminant function.  Use these if 
you want to determine which peaks have diagnostic capability. 
71. The casewise statistics table shows you all of your misclassifications.  Cases 
marked with * were misclassified.  The actual group column shows how you entered 
the classification in SPSS (this would be the gold standard).  The predicted group 
column shows the group that the data is placed into based on DFA (not the gold 
standard).  If you look at the case number, you can go to that row in the data table to 
see which file is misclassified. 
72. The classification results table shows how many cases were diagnosed to each 
group with actual number of cases classified and percentage classified.  Special 
training methods (test/train or leave-one-out) are shown below the overall results 
(even if you don’t want overall results, SPSS gives them to you anyway).  Make sure 
you are careful which half you look at when writing your results. 
73. Lots of other really cool statistics can be done with DFA, but we’ll leave it at that for 
now.  If you want to learn more, take PSY8150. 
74. To create a plot of the DFA results, select Graphs/Legacy Dialouges/Scatter/Dot.  
Select the simple scatter or the 3-D scatter option.  Scroll down to the bottom of your 
left hand list until you see the saved discriminant function scores (I hope you 
remembered to save them when you ran the analysis).  Choose the variables you 
want, and move them to the x, y, and z (if applicable) –axis fields.  At the top of the 
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left hand field list, select the classification variable, and move it to the ‘Set markers 
by’ field.  This will make it so each case is labeled by its ‘gold standard’ diagnosis 
and you can easily see how well you classification separated the data.  You can also 
do this with PCA values.  I’ll let you try to figure this out if you want. 
a. Note – remember the number of discriminant functions created is 1 less than 
the number of classification groups.  Therefore, if you only have 2 
classification groups, you’ll only have 1 discriminant function.  Therefore, you 
can only make a 1-D scatter plot. 
Excluding/changing data points 
75. Once misclassified cases are identified, go back to the raw data to look for reasons 
why.  Review the raw data text file to see if there is anything unusual.  If it seems ok, 
go back to your original sample (if possible).   Review the slide or other available 
information to look for explanations for the misclassification. 
76. If you find that you have to delete a case or change its diagnosis, you must update 
the SPSS data table, then re-do your analysis, starting with PCA if applicable. 
Creating mean spectra figure files (In Matlab) 
77. If you didn’t already do step 1, make sure all the data files are in the same folder, 
with a copy of MeanSpectraPlot.m. 
78. Open Matlab 
79. Click […] button next to the ‘current directory’ field and browse to select the folder 
your data is in 
80. Open SPSS or excel to get a list of your files and their classifications. 
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81. Copy the list of filenames for the group whose mean spectrum you would like to 
calculate 
82. Paste the list into WordPad or similar program and save the file as graphfilelist.txt 
83. In the Matlab command window, type meanspectraplot then press the enter key to 
run the program. 
84. At the prompt, type 2 (All the files) and press enter 
85. The program will work for awhile and you’ll be prompted to select the type of plot you 
want to see.  To see the mean spectrum plot, select 5. 
86. Repeat the same steps (75-80) for each group you’d like to calculate a mean 
spectrum plot for. 
87. To edit a plot, click on the arrow button of the toolbar icon menu in the plot window.  
Then, if you double click on plot characteristics, a pop-up edit window will appear, or 
you can edit the text as well.  If you don’t like this way, you can programmatically 
change plot options as well, but we won’t get into that here. 
88. This program, as you can see, has lots of other options that you can utilize.  If you 
want to calculate a difference spectrum (between 2 groups only) or plot multiple 
mean spectra on the same plot (no limit on how many groups allowed), your text file 
must also include group assignments.  To make the group assignments, you need to 
copy 2 columns into the graphfilelist.txt file.  The left column should be the filename 
and the right column should be the group number.  It’s easier to arrange your 
columns this way in Excel or SPSS, then copy to WordPad. 
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APPENDIX C CELL CULTURING SOP 
Materials 
• Trypsin (see specific cell line notes for exact type) 
• Medium (see specific cell line notes for exact type) 
• Dulbecco’s Phosphate Buffered Saline (PBS)  
• Flasks 
• Pipetter and pipettes (1cc, 2cc, 5cc, 10cc, 25cc) 
• Alcohol and kimwipes/clean room paper  
• Bleach in a beaker 
• Centrifuge tubes (when splitting adherent cells or testing cells with Raman) 
• UV-quartz slide (when testing with Raman) 
 
General Cell Culture Notes 
• Media is added to flask containing trypsin because the media neutralizes the trypsin 
• Generally cells are split every other day 
o Fast growers are generally split  1:3 (1 initial flask + 2 new flask) 
o Slow growers are generally split  1:2 (1 initial flask + 1 new flask) 
o It’s important to passage to prevent overgrowth, nutrient depletion, & 
contamination. 
• Generally with trypsin one wants to use as little as possible & allow to sit on cells for 
as little time as possible.  The time varies by cell line.  See cell line specific notes for 
more information. 
• Avoid touching the neck of the flask and the back (cell side) of the flask with the 
pipetter.  This will avoid contamination and prevent you from damaging the cells 
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• When pipetting, pay close attention to both the flask and the pipetter.  Make sure not 
to suck liquids to the level of the cotton in the flask.  This keeps the pipetter from 
being contaminated. 
• Media and trypsin can become bad if they are old or are over-heated/heated too 
long in the incubator 
• Once a pipette has been in the flask or other contaminated either, it should not go in 
the sterile fluid containers (media, PBS, trypsin, etc) 
• Wear gloves, and avoid touching any exposed skin while wearing gloves 
• Wash hands after working with cells 
• Complete medium should not be left in the fridge >3 weeks.   
Mixing Cell Media 
Start with a 500 mL bottle of cell medium.  Then add: 
• 50 mL fetal bovine/calf serum 
• 5 mL L glutamine 
• 5 mL antibiotic (we used a mix of 2 antibiotics and 1 antifungal) 
Place the lid back on the medium and shake by hand to mix.  Label the container 
with initials, date, and what you added.  With the above additions to the media the 
media is referred to as complete media. 
Defrosting Cells 
1. Move cells from the -150C freezer to the -80 freezer (all our cells are currently in the 
-80C freezer) 
2. Prep the hood area by spraying with 75% alcohol 
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3. Start with a new flask (spray flask or flask bag with alcohol before bringing under 
hood) 
4. Label the flask with your initials, the date, the cell line, and any other pertinent 
information 
5. Add 11 mL of complete medium to the flask 
6. Prepare the area for transferring the cells. 
a. Leave the flask lid loose 
b. Place a 2mL pipette on the pipetter (leave the paper wrapping on) 
7. Move the cells from the -80 freezer to the 37 bath. 
8. Wait about 90 seconds or until there is a small, pea-sized ice still remaining.  For 
most cell lines, you want to spin the flask between your fingers while defrosting, 
without letting the neck of the flask touch the water.  See specific cell-line notes for 
more instructions. 
9. Spray the cell vial and your hands with 75% alcohol and wipe down with a 
Kimwipe/clean room paper. 
10. Open the cell cryovial (place the lid face-up in the hood if necessary) 
11. Use the 1cc pipette to suck out the cells from the flask 
12. Empty the pipette into the flask (put the pipette tip all the way into the medium fluid 
and then empty) 
13. Mix a couple of times to rinse out the pipette 
14. Suck out about 0.5 mL of the cell/medium mixture 
15. Use this to rinse out the cryovial a couple of times 
16. Suck the 0.5 mL out of the vial and replace it in the flask. 
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17. Mix a couple more times. 
18. Replace the lid on the flask (tightly) 
19. Discard the pipette  
20. Place the flask under the microscope and double-check your cells 
21. Place the flask in the 37C incubator 
22. Put some bleach in the vial to kill the cells (since we are working with human cells).  
Allow the bleach mixture to sit for at least 5 minutes, then you can pour the bleach 
mixture down the drain (dilute with running water) 
23. Clean the working area by spraying with 75% alcohol 
Cell Passage (Splitting): Adherent Cells 
1. Remove complete media and trypsin from refrigerator & warm (RT – 37 °C, takes 20 
– 30 minutes) 
While complete media & trypsin are warming, steps 2-5 may be performed 
2. Prep the hood area by spraying with 75% alcohol and wiping down.  Put the other 
necessary supplies under the hood too (pipetter, pipettes, PBS, bleach, etc) and put 
the biohazard bag close to your work area 
3. Start with a new flask (spray flask or flask bag with alcohol before bringing under 
hood) 
4. Label T-75 flask w/cell line (i.e. 2774), date, initials, and split ratio (i.e. 1:3).  Label 
both the front and the bottom of the flask. 
5. While media warming, check cell growth under the microscope to determine its 
confluence. 
a. Generally, cells should be split ~ 70% confluence. 
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b. If media is not ready, place cells back into the incubator 
When complete media & trypsin are warmed, continue below 
6. Use a 10 cc pipette to suck out the media, and discard in the bleach container 
7. Add 5 – 8 ml Dulbecco’s PBS to flask. (Add to front wall, side of flask w/o attached 
cells.)  
8. Re-cap & then rock/roll flask side-to-side w/fluid touching attached cells. (Don’t let 
fluid enter cap.) 
9. Remove PBS and discard in bleach container 
10. Some cell lines need to be rinsed with PBS 2-3 times (generally cancer cells).  See 
cell-line specific notes. 
11. Add ~3 ml trypsin to the attached cells and then rock side-to-side.  Generally, cancer 
cells need to be placed in the 37C incubator for ~5min for the trypsin to act, whereas 
normal cells can sit under the hood 2-3 min.  See cell-line specific notes.   
12. You can look at the back wall of the flask or look under the microscope to verify that 
the cells are detaching.  
13. Add 7 ml of media to back wall of flask to deactivate the trypsin & continue to wash 
back of wall (power wash) until cells come off. 
14. Break up cell clumps.  You can suck up all the media into the pipette, place it against 
the bottom of flask and push out the cells, or you can release the cells against the 
corner of the flask to break clumps.  Check with microscope if desired. 
15. When splitting cells in the T-75 flask, 12 ml of fluid need to be in each flask.  There 
should be 10cc of liquid in the flask currently (3 trypsin, 7 media).  Determine the 
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amount of fluid you need to add to get to the right concentration (add 14 cc media to 
make 2 flasks/24 cc, 26 cc media to make 3 flasks/36 cc, etc). 
16. Add the proper amount of media you just figured out and mix.  (Go up and down with 
the pipette several times) 
17. Place 12 ccs of media/cells in each flask and cap your flasks.  Check with 
microscope if desired. 
18. Place flasks in incubator 
19. Clean hood and everything left in hood with the 75% alcohol.  After cells have been 
in bleach for at least 5 min, they can be poured down the sink (dilute with running 
water) 
Freezing Cells 
Cells Should be split ~1 day prior to freezing.  They should be at approximately 
80-90% confluence when splitting. 
1. Warm up media and trypsin 
2. Sterilize hood with 70% EtOH 
3. Prepare all necessary materials, wipe everything with 70% ethanol 
4. Check cells for confluence & contamination 
5. Remove media from flask 
6. Rinse with 5-7 cc PBS (add to front wall) 
7. Remove PBS 
8. Add 3 mL trypsin (see cell notes for which type) to back wall, cover bottom, incubate 
as described in cell-specific notes 
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9. Add 7cc fresh media to resuspend.  Power wash back wall to detach all cells, break 
up any clumps 
10. Put media/trypsin/cell into centrifuge tube and spin at 700 RPM for 5 min 
11. Bleach flask while waiting 
12. Warm up freezing media and prepare cryovials with labels 
13. Use 1mL or 2mL pipette to remove media from centrifuge tube.  Near the bottom, tilt 
the tube to remove fluid rather than putting the pipette near the cell pellet. 
14. Resuspend in PBS to wash away any remaining medium.  Break up any clumps. 
15. Centrifuge at 1200 RPM for 5 min 
16. Remove PBS from centrifuge tube (remember to tilt the tube) 
17. Add 1 mL of freezing media for each flask you wish to make. 
18. Put 1 mL of media in each cryovial.  Do not put bubbles in.  It is ok to have slightly 
less than 1 mL. 
19. Place in Mr. Frosty in -80. 
20. Remove from Mr. Frosty the next day and place in -150 freezer if available 
Testing Cells with Raman Spectroscopy 
In the clean room: 
1. Remove cells from flask (trypsinize if necessary) and place in centrifuge tube 
2. Spin down at 700 RPM for 5 min 
3. Remove media with 1mL or 2mL pipette and discard in bleach container.  Tilt 
tube when you get to the bottom rather than putting pipette near the cell pellet. 
4. Resuspend cells in PBS and re-spin at 700 RPM for 5 min (this will make sure 
the cells are thoroughly rinsed) 
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5. Remove media with 1mL or 2mL pipette and discard in bleach container.  Tilt 
tube when you get to the bottom rather than putting pipette near the cell pellet. 
6. Resuspend in 1-2 mL of PBS and place cells in a cryovial 
In 3322: 
1. Turn on the live-cell chamber and place the cryovial in the chamber so it stays 
warm. 
2. Turn on and calibrate the Raman if it isn’t already ready 
3. Put the Nikon 60x dipping objective on the microscope 
4. When the Raman is ready, move the cells under the hood, and place 150 uL on 
the end of a clean UV-quartz slide. 
5. Carefully bring the slide over to the Raman.  Put the remaining cells back in the 
live cell chamber. 
6. Place the slide on the stage, with the cell end hanging over the edge. 
7. Raise the stage until the objective contacts the liquid 
8. Adjust the stage to focus on a cell 
9. *Carefully close the door to the Raman and switch the laser on. 
10. Ensure the laser is properly focused and begin the measurement 
11. The parameters we use are: 
a. 10 accumulations 
b. 10 seconds each 
c. 50% power 
d. Check cosmic ray removal 
e. Check ‘close shutter after measurement’ 
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f. 600-1800 cm-1 
The filename should include this information, as well as the cell type (note if 
suspended in PBS), the date, and which measurements came from each cell (A1, A2, 
B1, B2, etc) 
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APPENDIX D PCR PROCEDURES AND RESULTS 
RNA Isolation 
Total RNA was isolated using the RNeasy Protect Mini Kit (Qiagen), adding the 
optional step to perform DNase I digestion.  Briefly, cells were stored at 4°C in PBS until 
RNA isolation.  Cells were lysed using Buffer RLT, then homogenized using a 
QIAshredder spin column.  The RNA was bound to the RNA column, treated with 
DNaseI to remove genomic DNA, washed, eluted with RNAase-free water, and stored 
at -80°C.   
cDNA Generation 
Prior to cDNA generation, the concentration of total RNA in each sample was 
measured using the NanoDrop spectrometer (Thermo Fisher Scientific, Wilmington, 
DE).  1 µL of sample was pipetted onto the measurement surface, and the arm was 
closed, creating a bubble between the arm and measurement surface.  The height of 
the bubble was automatically adjusted for the wavelength of light, and the quantity of 
RNA in the sample was determined.  The NanoDrop was cleaned with lens paper 
between each sample measurement. 
NanoDrop also provided information about the quality of RNA, and whether it had 
protein contamination.  Protein is generally more absorbent at 280 nm whereas nucleic 
acids have higher absorbance at 260 nm.  In general, a 260/280 absorbance ratio of 2.0 
represents a pure RNA sample.  Lower values mean the sample may be contaminated 
by protein or other chemicals ("NanoDrop Technical Support Bulletin T009," 2007).  
Table D.1 shows the RNA concentrations and 260/280 ratio for each sample. 
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Sample Number RNA concentration (ng/uL) 260/280 ratio 
MYCN3-B-120809 236.28 2.13 
MYCN3-L-120909 585.29 2.12 
MYCN3-K-120909 297.78 2.07 
MCYN3-M-121009 34.40 2.6 
MYCN3-Q-121109 1641.42 2.08 
MYCN3-P-121109 1388.21 2.11 
Table D.1: Relative concentration of RNA and 260/280 ratio for each sample. 
 
As Table D.1 shows, sample M had an exceptionally low concentration of RNA.  
It was removed from the study. 
cDNA was created following RNA quantification.  Ready-To-Go You-Prime First-
Strand Beads (GE Healthcare) with random hexamers (Integrated DNA Technologies, 
Coralville, IA) were used to create the cDNA.  RNA was added to the You-Prime First-
Strand Bead tubes at a concentration of 2 µg/ 30 µL.  The initial concentration of RNA 
detected using the NanoDrop was converted to µg/µL, and then entered into the formula  
volume sample RNA = (2 µg * 1 µL) / concentration 
to determine the volume of sample necessary to reach 2 µg.  Then, the volume of water 
necessary to reach the 30 µL volume was calculated using the formula 
volume water = 30 µL – volume sample RNA. 
Table D.2 shows the volumes of sample RNA and water used for each sample. 
 
Sample ID Initial RNA (ng/ 
µL) Concentration 
Convert to 
µg/µL 
µL RNA to get 
2 µg RNA 
µL water to 
reach 30 µL 
MYCN3-B-120809 236.28 0.2363 8.4638 21.5362 
MYCN3-L-120909 213.43 0.5853 3.4171 26.5829 
MYCN3-K-120909 297.78 0.2978 6.7159 23.2841 
MCYN3-M-121009 34.40 Excluded Excluded Excluded 
MYCN3-Q-121109 1641.42 1.6414 1.2185 28.7815 
MYCN3-P-121109 1388.21 1.3882 1.4407 28.5593 
Table D.2: Calculations for each sample to determine the concentration of RNA and 
water needed to initiate cDNA generation 
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Next, 2 µg of random hexamer diluted in 3 µL RNA-free water was added to each 
tube.  We started with 10 nm (nanomoles) of dry random hexamer at a molar 
concentration of 5581.3 pm (picomoles) / 10 µg and calculated that our total weight of 
hexamer of 18.18 µg.  We diluted the dry random hexamer in 90.9 µL of RNA-free water 
to get a final concentration of 0.2 µg/ µL water ((18.18 µg*1 µL)/0.2 µg).  Using this 
dilution, we can be sure that each 1 µL of water contains exactly 0.2 µg of random 
hexamers.  A large quantity of random hexamer equal to the volume necessary for 13 
samples was mixed using 13 µL of random hexamer and 26 µL of RNA-free water.  
Then, 3 µL volumes were pipetted from this mixture to each sample tube.  One extra 
sample was made in case of pipette errors.   
Once the sample tubes were all prepared, they were gently vortexed and briefly 
centrifuged to mix the sample and move it to the bottom of the tube.  Tubes were 
incubated at 37°C for 60 minutes while the cDNA reacti on occurred.  After the reaction, 
cDNA samples were stored at -20C until PCR measurement. 
PCR 
PCR was performed using a MYCN TaqMan gene expression assay with a FAM 
marker (Applied Biosystems) to quantitate the level of MYCN in our cells.  We also used 
a probe to measure the GAPDH housekeeping gene marked with a JOE tag as a 
control (Applied Biosystems).  Housekeeping genes are found at the same expression 
level in all cells; therefore, they should provide a constant expression value in all 
samples. 
The MYCN probe was supplied at an 18µM concentration for primers and 5µM 
concentration for the probes, totaling a 20X concentration.  The GAPDH probe was 
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supplied with a 10µM forward primer, a 10 µM reverse primer, and a 5 µM probe.  
TaqMan ® Universal PCR Master Mix at a 2x concentration (Invitrogen) was used for 
the reaction. 
The MYCN gene expression assay was specially designed to simplify the PCR 
chemistry.  Each 20 µL reaction was composed of 10 µL of master mix, 1 µL of primer 
(at 20x concentration), and 9 µL of water containing the cDNA.   
The GAPDH gene expression assay was designed such that each 20 µL reaction 
was composed of 10 µL of master mix, 2 µL of forward primer, 2 µL of reverse primer, 2 
µL of the probe, and 4 µL of water containing the cDNA. 
Each sample was tested in duplicate for each gene (MYCN and GAPDH) at two 
different concentrations (100 ng/reaction and 10 ng/reaction).  A negative control (NTC) 
containing no DNA was also tested for each gene of interest in duplicate.  Tests were 
performed in duplicate to ensure there was no sample contamination.  Singleplex PCR 
was used because it requires less setup and calibration than multiplex PCR. 
In order to minimize the number of pipetting steps, the following procedure was 
followed: 
• Determine the number of reactions necessary (5 samples * 2 genes * 2 replications * 
2 concentrations) + (1 NTC * 2 genes * 2 replications) = 44 reactions; for each gene, 
this are 22 reactions.  
• Allow for a 10% pipette error, and adjust the number of reactions mixed accordingly.  
For each gene, allow for 22 reactions + 2 pipette error reactions = 24 total reactions. 
• Determine which combination of reaction components for each gene can be 
combined to pipette in one step 
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o All ingredients are the same for each gene tested except the cDNA plus water 
ingredients – the cDNA material must be pipette individually for each sample 
o The smallest amount of water needed in a reaction is 4 µL using the GAPDH 
probe.  
 The GAPDH reaction mix should contain 10 µL of master mix, 2 µL of 
forward primer, 2 µL of reverse primer, and 2 µL of probe for each 
reaction 
 The MYCN reaction mix should contain 10 µL of master mix, 1 µL of 
primer, and (9 µL – 4 µL) 5  µL of water for each reaction 
• Combine the ingredients determined in the previous step, making enough material 
for all reactions for each gene 
o For GAPDH, combine in a single tube 
 10 µL * 24 reactions = 240 µL of master mix 
 2 µL * 24 reactions = 48 µL of forward primer 
 2 µL * 24 reactions = 48 µL of reverse primer 
 2 µL * 24 reactions = 48 µL of GAPDH probe 
o For MYCN, combine in a single tube 
 10 µL * 24 reactions = 240 µL of master mix 
 1 µL * 24 reactions = 24 µL of primer 
 5 µL * 24 reactions = 120 µL of water 
• Pipette 16 µL of the GAPDH mixture into each well designated for GAPDH testing.  
The same pipette tip can be used for the entire process, as long as it does not get 
contaminated.   
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• Pipette 16 µL of the MYCN mixture into each well designated for MYCN testing.  The 
same pipette tip can be used for the entire process, as long as it does not get 
contaminated. 
• Determine the volume of water and cDNA necessary to reach concentrations of 
100ng cDNA / 4 µL water. 
o cDNA was created at a concentration of 2 µg / 33 µL.  This is equivalent to 
60.6 ng / µL. 
o Prepare enough material to have 1 extra reaction.  Therefore, there should be 
at least 5 reactions made for each sample (2 reactions for MYCN, 2 reactions 
for GAPDH, and 1 extra for each sample) 
o The volume of cDNA necessary for 500 ng is 500 ng / (60.6 ng / µL) = 8.25 µL 
o The volume of water required to reach the final volume of 20 µL is 20 µL – 
8.25 µL = 11.75 µL. 
• Determine the volume of water and cDNA necessary to reach concentrations of 
10ng cDNA / 4 µL water. 
o The smallest reliable pipette volume is 1 µL, or 60.6 ng.  Therefore, make 
enough material for 6 reactions.  (60 ng / 6 reactions = 10 ng / reaction) 
o The remaining volume of water necessary to reach the volume of 24 µL (6 
reactions * 4 µL) is 24 µL – 1 µL = 23 µL. 
• Create a 100 ng / reaction mixture and a 10 ng / reaction mixture for every sample 
using the volumes listed above. 
• For each sample, pipette 4 µL of the appropriate mix into the appropriate well.  To 
avoid contamination, use a new pipette tip for each well. 
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• Add 4 µL of water to the NTC wells of the plate.  Since these are control wells, there 
should be no genetic material in the well.  
 
The end result is a well plate where every test well is filled to the same volume of 
20 µL.  The layout of the 96-well plate is shown below in Figure D.1. 
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Figure D.1: Layout of 96-well plate for PCR 
 
 Once the well plate was set up, it was sealed with parafilm, making sure 
each well was individually sealed.  The tray was vortexed to ensure there were no air 
bubbles, and to ensure that the whole sample volume was at the bottom of the well 
plate.  Next, the plate was centrifuged for 2 minutes at 400 rpm. 
Real-time PCR was performed using a 7900HT Real-Time PCR system (Applied 
Biosystems).  The well plate was placed in the robot, and the software was setup to 
identify the detector (gene target: MYCN or GAPDH) and reporter (dye: JOE or FAM) in 
each well plate.  Wells with no sample included were also identified.  Finally, the 
standard thermal cycle protocol was selected and PCR was initiated. 
179 
 
PCR Results 
Figure D.2 shows the amplification curves for samples B, K, and L at 100 ng 
cDNA concentration.  Note that within each sample, the lines run very close to each 
other and in parallel.  This signals consistent results within each sample. 
Table D.3 shows the output quantitative PCR results for the experiment.  The 
MYCN Ct value of each sample was correlated to the GAPDH Ct value of the same 
sample.  This ensured that even if the concentration of sample within the well is off, the 
data analysis results will still be conclusive.  In the table below, results are shown 
relative to the PCR concentration of 100ng of sample K.   
 
#   Sample Avg Ct 
Avg 
∆Ct 
∆Ct 
SE 
Delta 
Delta 
Ct SD RQ RQ Min RQ Max 
1 100ng B 22.522 5.141 0.236 -1.554 2.937 0.579 14.901 
2 100ng K 22.836 6.695 0.185 0 1 0.281 3.562 
3 100ng L 20.891 3.126 0.167 -3.569 11.868 3.773 37.333 
4 100ng P 23.891 5.214 0.937 -1.481 2.791 0.004 1757.162 
5 100ng Q 25.396 5.868 -0.827 1.774 
6 10ng B 25.692 2.905 1.446 -3.79 13.828 0.001 288934.5 
7 10ng K 27.376 6.168 3.693 -0.527 1.441 0 1.55E+11 
8 10ng L 24.087 -0.909 2.781 -7.604 194.524 0 3.96E+10 
9 10ng P 24.774 -0.472 1.62 -7.167 143.667 0.002 9922547 
10 10ng Q 29.264 5.019 3.659 -1.676 3.196 0 2.73E+11 
11 
NTC 
MYCN 
Table D.3: Relative quantification PCR results, calibrated to 100ng sample K and the 
GAPDH housekeeping gene. 
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Figure D.2: PCR amplification curves for sample B (top), K (middle), and L (bottom). 
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 The RQ min and RQ max columns show the top and bottom values of the 
expected error bars for each sample.  Note that the error bars for the 10ng sample 
range from 0 to ~270 billion times amplification.  These results were excluded from the 
remainder of the experiment.  The 100 ng concentration P and Q samples of trial 
number 2 were also excluded for similar reasons.  This is not totally unexpected.  Since 
the ideal concentrations of cDNA for running PCR were unknown, multiple 
concentrations were tested. 
Also, note that the NTC row of Table X contains no data.  This is expected, since 
that sample was used purely as a control, with no cDNA placed in the well.  If that row 
had data, it would signal a flaw in the experimental setup. 
Finally, examine the 100 ng B, K, and L rows of Table D.3, which are highlighted 
in blue.  The Ct value is the number of times the material was doubled before it reached 
a threshold value.  Therefore each increase in Ct represents a doubling.  The delta delta 
Ct value represents the difference in cycles to get to the threshold when normalized to 
the GAPDH control and the 100ng K MYCN sample.  The RQ value is 2^(delta delta Ct) 
and it represents how much more MYCN cDNA was in samples B and L.  RQ min and 
RQ max represent the error bars for the RQ calculation.  Figure D.3 graphically depicts 
the RQ values. 
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Figure D.3: Relative quantitative PCR results with sample K as the control 
 
As shown, sample L, which was treated with tetracycline has 11.9 times more 
MYCN cDNA than the control sample K counterpart.  This is a significant change 
because the error bars do not overlap.  Sample B had approximately 2.9 times more 
MYCN cDNA than sample K; however, this difference was not significant, as exhibited 
by the overlapping error bars.  These results suggest that treatment by tetracycline did 
increase the level of MYCN cDNA within the experimental cells. 
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APPENDIX E MARKET ANALYSIS FOR RAMAN BIOPSY TOOL 
U.S. Cancer Incidence 
It was estimated that there would be 1,399,790 new cases of cancer diagnosed 
in 2006 in the United States, including the following high-incidence cancers ("Cancer 
Facts & Figures 2006," 2006): 
• Prostate Cancer (234,460) 
• Breast Cancer (214,640) 
• Lung Cancer (174,470) 
• Colon Cancer (106,680) 
• Melanoma (62,190) 
• Bladder Cancer (61,420) 
These numbers exclude new cases of basal and squamous cell carcinomas, as 
well as in situ carcinomas.  Within Michigan, it was predicted there would be 48,250 
new cancer cases diagnosed in 2006.  As the average age of the American population 
continues to rise, it is expected that cancer incidence will rise accordingly.  The 
incidence of invasive cancer developing at any site between birth and 39 years of age is 
1 in 70 for men and 1 in 50 for women.  By age 69, the odds of developing cancer 
increase to 1 in 6 for men and 1 in 9 for women ("Cancer Facts & Figures 2006," 2006). 
Market Plan: Surgical Instrument 
Preliminary data suggests a surgical spectrometer could be priced as low as 
$10,000; however, the market may support a price much higher than this if the device is 
truly useful to the surgical user.  For example, the newest daVinci robot sells for 
approximately $1.5 million. 
We propose selling our equipment for a fixed price, and then charging a per-use 
diagnostic fee for each biopsy performed.  Initially, we will focus on the three highest-
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incidence cancers in the United States (prostate, breast, and colon cancer), which 
account for over one third of total U.S. cancer cases annually, as shown in Table E.1.  
Lung cancer was excluded from preliminary marketing because it may require slightly 
different instrumentation (i.e. Raman measurement through and endoscope instead of 
through a probe). 
 
 Annual US incidence Annual MI incidence 
Prostate Cancer 234,460 7,370 
Breast Cancer 214,640 7,070 
Colon Cancer 106,680 4,930* 
TOTAL 555,780 19,370 
*includes colon and rectal cancer 
Table E.1: Annual incidence of the most common types of cancer 
 
In the first year, we expect to sell 5 units to our collaborating hospitals.  One 
hospital, Karmanos Cancer Institute sees 6,000 new patients per year.  We assume that 
each of the other hospitals will see approximately the same amount of patients annually.  
Since prostate, breast, and colon cancer make up approximately 1/3 of cancer cases, 
we can assume approximately one third of cancer patients at each hospital will be seen 
with these conditions.  Of the 2,000 patients per hospital, we will assume that one third 
undergo surgery using our diagnostic Raman probe for margin mapping.  This allows for 
some patients who do not receive surgery, and it also accounts for surgical time of the 
instrument.  With (52 weeks * 4 working days) 208 working days annually for elective 
surgeries, 667 cases per hospital equates to approximately three uses per day.  This is 
in agreement with the average scheduling time necessary for a tumor resection surgery. 
6000 cases * (1/3 of cases are prostate/breast/colon) * (1/3 of those cases) * 5 hospitals 
= 3,333 uses   (See Table E.2) 
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Item Cost Number Revenue 
Laboratory systems $10,000 5 $50,000 
General biopsy diagnosis $10 3335 $33,350 
Total   $83,350 
Table E.2: Projected Year 1 revenue 
Since no technology currently exists like this product, it is impossible to predict 
the product life cycle, or how quickly other users will adopt our technology.  The 
following model is based on our best guess. 
Following the first year, we expect our collaborating hospitals to adopt more 
systems in order to fully address their case load.  We expect both surgeon and patient 
word of mouth in addition to our marketing to increase interest among outside 
institutions.  In 2005, there were 4,936 community hospitals, including 2,927 urban 
hospitals and 2,009 rural hospitals (Association, B. C. a. B. S., 2008), however, we 
expect that the early adopters of the Raman probe technology will be the same users 
who are early adopters of similar high tech devices, such as the daVinci robot.  Of the 
daVinci systems, 358 systems are placed in 290 Tier 1 hospitals (>325 beds), and  64 
are located in Tier 2 hospitals (200-325 beds) ("U.S. Image Guided and Robot 
Assisted Surgery Markets N14C-54," 2008).  Sixty one hospitals have two or more 
daVinci systems. 
In year two, we predict that two thirds of the sixty one hospitals using multiple 
daVinci systems would be early adopters of our technology.  We also predict that four of 
our original collaborating hospitals will invest in a second device, in order to increase 
the case load of Raman-diagnosed tumor resection surgeries.  We predict that each 
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device will be used in approximately 667 cases annually, or about 3 cases per working 
day. 
In year three, we predict selling 50 units, and we predict selling 75 units annually 
in years four and 5.  By year 5, we expect to be involved in approximately 166,000 
cases of breast, colon, and prostate cancer annually (Table E.3), or about 30% of 
cases.  This still allows room for future growth.  Expansion into other types of cancer or 
diagnosis of other diseases allows for further growth. 
 
 Year 1 Year 2 Year 3 Year 4 Year 5 
Units Sold 5 45 50 75 75 
Total Units in the Market 5 50 100 175 250 
Procedures Performed  
667 cases / unit / year 
3,335 33,350 66,700 116,725 166,750 
      
Unit Revenue $50,000 $440,000 $500,000 $750,000 $750,000 
Diagnostic Revenue $33,350 $333,500 $667,000 $1,167,250 $1,667,500 
Total Annual Revenue $83,350  $773,500  $1,167,000  $1,917,250  $2,417,500  
Cumulative Revenue $83,350  $856,850  $2,023,850  $3,941,100  $6,358,600  
Table E.3: Predicted five year revenue of surgical instrument 
 
9.6.1 Surgical Biopsies 
Non-cancer diagnosis must also be included in market analysis.  While most 
breast biopsies are performed through a needle, sometimes an open surgery is required 
to access the tissue in question.  1.6 million breast biopsies are performed annually in 
the U.S.  Of those, approximately 5% (80,000) require an open biopsy (Shockney, L., 
2009). 
We do not anticipate selling any new devices for this market.  Current customers 
would use their existing surgical systems to perform surgical biopsies.  One local 
collaborator, Henry Ford Hospital, performs 48,000 breast procedures annually ("Breast 
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Cancer," 2010).  Assuming each of our collaborators performs approximately the same 
amount of procedures, and 3% of those are surgical biopsies, we predict (48,000 
procedures * 5 systems * .03 of cases) 7,200 biopsies performed in year one at $10 
diagnostic fee per case, for an additional revenue of $120,000 in breast biopsy cases 
alone.  As long as a breast biopsy database exists, there would be minimal overhead 
cost in this market, as users would be paying for database lookup only. 
9.6.2 Laboratory-Based In-Vitro Diagnostics 
The global in-vitro market is expected to grow to $8 billion annually in 2012, with 
11% annual growth ("Global cancer diagnostics market to reach $8B by 2012 ", 2008).  
The market increase is partially due to increased emphasis on cancer screening and 
early detection, as well as improved treatment methodologies, allowing cancer to be 
treated more like a chronic disease.   
Design of a laboratory-use Raman spectrometer is actually much simpler than 
design of a handheld surgical system.  Theoretically, the current probe design could be 
adapted for laboratory use, and sold at the same price of $10,000.  We would sell per-
use diagnostic software, with a detailed diagnosis including tumor aggressiveness (etc) 
for an additional $10. 
If only breast biopsy samples are included in the analysis, there are 1.6 million 
annual cases.  Assuming only growth with known collaborators in the first year 
(DMC/Karmanos, Henry Ford, U of M, U of Chicago, etc) in the first year, we can expect 
to sell 5 systems in year one, with growth growing exponentially after that.  One local 
collaborator, Henry Ford Hospital, performs 48,000 breast procedures annually ("Breast 
Cancer," 2010).  Assuming each of our collaborators performs approximately the same 
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amount of procedures, and assuming 10% of biopsy samples are tested with Raman 
spectroscopy, this equates to (48,000*.10*5)  24,000 biopsies in year one.  We assume 
that 30% (7200) of those samples would be positive for breast cancer and would require 
in depth Raman diagnosis.  The total revenue, then, in the first year would be 
 
Item Cost Number Revenue 
Laboratory systems $10,000 5 $50,000 
General biopsy diagnosis $10 24,000 $240,000 
In-depth Raman Diagnosis $10 7,200 $72,000 
Total   $362,000 
Table E.4: Potential first-year revenue from pathology laboratory-based systems for 
breast cancer 
 
 
This model poses minimal overhead costs.  Development of laboratory systems 
should be simpler and quicker than development of portable systems.  Conversely, a 
portable surgical system could be sold with a stationary mounting system and used as-
is.  The only other cost involved would be development and maintenance of diagnostic 
database systems.  Furthermore, this laboratory system could easily be expanded to 
other types of cancer simply through sample testing and database development. 
This model assumes about 4,800 biopsies per year per institution, which may be 
a slight over-estimation for what a normal hospital would see.  Assuming (50 weeks * 5 
working days) 250 working days per year for biopsies (overnight hospitalization is not 
normally required, so procedures are more commonly performed on Fridays), this 
equates to 19 biopsies per day.   
Our 5 year model will assume a more reasonable 5 biopsies per day per 
institution, or 1,250 cases annually per institution.  Since the biopsy market is actually 
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larger than the tumor resection market, we can estimate that the same number of units 
or more will be adopted for lab use as for surgical use. 
 
 Year 1 Year 2 Year 3 Year 4 Year 5 
Units Sold 5 45 50 75 75 
Total Units in the Market 5 50 100 175 250 
Procedures Performed  
1250 cases / unit / year 
6,250 62,500 125,000 218,750 312,500 
           
Unit Revenue $50,000  $440,000  $500,000  $750,000  $750,000  
Diagnostic Revenue $62,500  $625,000  $1,250,000  $2,187,500  $3,125,000  
Total Annual Revenue $112,500  $1,065,000  $1,750,000  $2,937,500  $3,875,000  
Cumulative Revenue $112,500  $1,177,500  $2,927,500  $5,865,000  $9,740,000  
      
Annual Surgical Revenue* $83,350  $773,500  $1,167,000  $1,917,250  $2,417,500  
Cumulative Surgical Revenue* $83,350  $856,850  $2,023,850  $3,941,100  $6,358,600  
      
Total Annual Revenue $195,850  $1,838,500  $2,917,000  $4,854,750  $6,292,500  
Total Cumulative Revenue $195,850  $2,034,350  $4,951,350  $9,806,100  $16,098,600  
* Taken from Table E.3 
Table E.5: Five-year revenues for laboratory-based diagnostics and surgical diagnostics 
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ABSTRACT 
 
IDENTIFICATION OF NEUROBLASTOMA AND ITS PROGNOSTIC MARKERS 
USING RAMAN SPECTROSCOPY 
 
by 
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Major: Biomedical Engineering 
Degree: Doctor of Philosophy 
Introduction: Neuroblastoma is the most common cancer of infancy.  It is one of 
several peripheral nervous system tumors, including ganglioneuroma, peripheral nerve 
sheath tumor, and pheochromocytoma.  It is commonly situated on the adrenal gland.  It 
displays similar histology to other small round blue cell tumors, including non-Hodgkin 
lymphoma, rhabdomyosarcoma, and Ewing sarcoma.  One method of judging 
neuroblastoma aggressiveness uses tumor histology factors, including mitosis-
karyorrhexis index, Schwannian stromal development, degree of differentiation, and 
patient age.  Tumor aggressiveness can also be judged based on the amplification of 
certain genes, including MYCN.  Raman spectroscopy is a physics-based method which 
identifies the biochemical fingerprint of a sample.  It has recently been applied to 
disease classification, specifically in adult cancers. 
Methods:  To identify neuroblastoma from adrenal gland, peripheral nervous 
system tumors, and small round blue cell tumors, and to identify tumor histology, fresh 
and frozen samples were collected from the operating room and tested with Raman 
spectroscopy.  Tissues were assigned a ‘gold standard’ diagnosis by experienced 
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pediatric pathologists.  Tumor histology was further evaluated with blinded tissues 
provided by the Children’s Oncology Group.  To test identification of gene amplification, 
the tet-on MYCN-3 cell line was cultured in the presence and absence of tetracycline to 
induce or repress MYCN gene expression.  Cells were harvested and tested with 
Raman spectroscopy and polymerase chain reaction.  All Raman spectra were 
preprocessed and classified with discriminant function analysis. 
Results:  Raman spectroscopy identified neuroblastoma from healthy adrenal 
gland, peripheral nervous system tumors, and small round blue cell tumors with 100% 
sensitivity and specificity.  It identified favorable, unfavorable, and treated 
neuroblastoma with high accuracy.  Neuroblastoma cells with and without MYCN 
amplification were identified with 100% sensitivity and specificity. 
Conclusions:  This is the first study applying Raman spectroscopy to identify 
pediatric tumors, and the first blinded Raman spectroscopy study performed in 
collaboration with the Children’s Oncology Group, a national tumor bank.  It provides the 
first in-depth examination of specific markers of aggressiveness, including tumor 
favorability and MYCN gene amplification.  Raman spectroscopy has the potential to 
revolutionize the field of cancer diagnostics.  It can provide a detailed, accurate 
diagnosis in minutes instead of days. 
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